# MIMER MEDICAL COLLEGE, TALEGAON (D)

# 6.5.5.1.

# **Other Relevant Information**

Sr. No	Particular	Page No
01	Foundation Course	2-12
02	Bio ethics curriculum	13-23
	implementation Centre	
03	Students Securing Distinction	24-41
04	Mentorship	42-46
05	MEU Training Sessions	47
06	Dept of Clinical Research &	48-54
	Incubation Centers	
07	ICT Tools	55
08	ICMR & MUHS Projects	56
09	Central Research Lab	57-81
10	Intellectual Property Rights (IPR)	82-91
11	Good Clinical Practices	92-115
12	Value-added Courses	116
13	Add on Courses	117
14	SOPs in clinical practice	118-129
15	Pharmacovigilance Committee	130-155
16	Introspective Morbidity And	156
	Mortality Meetings, CPCs, Tumor	
	Board Meetings	

# **1. FIRST MBBS FOUNDATION COURSE**

## Time table of the Foundation Course 1<sup>st</sup> Year MBBS 2020-2021

Date	Time	Topic	Teacher
Mon 18/01/2021	10.00 am to 11.00 am	Introduction	Dr. Swati Belsare
	11.30 am to 12.45 pm	Principal's Address	
	2.00 pm to 4.00 pm	Introduction to Anatomy department Hospital Visit - OPD / wards visit	Dr. Swati Belsare Dr. Ashwini Bhele Mr Sandeep khalkar
Tue	9.00 am to 11.00 am	Medical ethics, attitudes & professionalism	Dr. Derek D'souza
19/01/2021	11.00 am to 1.00 pm	Health care system & its delivery	Dr. S. V. Chincholikar
	2.00 pm to 4.00 pm	Introduction to Physiology & Alternate health systems in the country Visit to Herbal Garden, Hospital Visit and OT complex visit	Dr. Deepa Nair Dept. of Physiology
Wed 20/01/2021	9.00 am to 11.00 am	National health priorities & policies	Dr. Aastha Pandey
20/01/2021	11.00 am to 1.00 pm	Introduction to Biochemistry. Patient Safety, Biohazard Safety	Dr. S. A. Pratinidhi
	2.00 pm to 4.00 pm	History of medicine and UG lab, Blood bank, CCL visit	Dept. of Biochemistry
Thu 1/01/2021	9.00 am to 11.00 am	Universal precautions & vaccinations	Dr. Madura Ashturkar
	11.00 am to 1.00 pm	Principles of primary care (general & community based care)	Dr. S.J.Kulkarni
ſ	2.00 pm to 4.00 pm	Extra curricula activity – Movie "Shwas"	Dept. of Anatomy

Date	Time	Topic	Teacher
	9.00 am to 11.00 am	Physician's role in the Society	Dr Sudam Khedkar
Fri 22/01/2021	11.00 am to 1.00 pm	Movie – Patch Adams	Dept of Anatomy
	2.00 pm to 4.00 pm	E. C.A –Debate/ speech "Why I want to become a Doctor"	Dept of Physiology
Mon 25/01/2021	9.00 am to 12.00 am	Yoga	Dr. Sonali Khake Dr. Rupali Baburdikar Dr.Vaishali Lunawat
	12.00 am to 1.00 pm	"Euthanasia" short film "Baluta" short film	Dept. of Anatomy
	2.00 pm to 4.00 pm	Language (Student Questionnaires)	Dept of Physiology
Tue 26/01/2021	9.00 am to 10.30 am	Flag hoisting ceremony	
	9.00 am to 11.00 am	Interpersonal relationships	Derek Dsouza
Wed 27/01/2021	11.00 am to 1.00 pm	UGC film- Anti-ragging documentary	Dept of Anatomy
27/01/2021	2.00 pm to 4.00 pm	Community Visit – 1	Dept. of Community Medicine
	9.00 am to 11.00am	Communication Skills	Smita Watve
Thu	11.00 am to 1.00	Universal Precautions in Laboratory	Dr Sandhya Kulkarni
28/01/2021	pm	Introduction to Computer	Dr Shashank Vedpathak
	2.00 pm to 4.00 pm	Community Visit-2	Dept of Community Medicine

.

Fri 29/01/2021	9.00 am to 11.00 am	Time management	Dr. Ashish Ubale		
	11.00 am to 1.00 pm	Reflection writing	Dr Sushama Chavan		
	11.00 am to 1.00 pm	Review of Movie Shwas, Euthenesia and Baluta Interactive session	Dr. Sonali Khake Dr. Sushama Chavan Dr Ashwini Bhele		
	2.00 pm to 4.00 pm	First Aid	Dr. Ajit Jadhav		
Sat 30/01/2021	Medical Health Check up				

12

you

7

Dr.S.M.Belsare Prof & Head Dept of Anatomy

Prof. & Head Dept. of Anatomy MIMER Medical College Talegaon Dabhade

n

# MIMER MEDICAL COLLEGE, TALEGAON (D)

# 1<sup>ST</sup> MBBS BATCH 2019-2020

# Programme Schedule for Inaugural Principal's Address

# Ist MBBS (2019-20) Batch

VENUE: Lecture Hall No. 4, 3rd Floor, MIMER Medical College Building DATE: 1st August 2019 TIME: 11.00am - Onwards 1. Arrival of Dignitaries on the Dias 11.00 am 2. Opening remarks 11.01 am 3. World Peace Prayer 11.05 am 4. Principal's Address 11.10 am 5. Speech by Student 11.25 am 6. Speech by Director-PG Programme 11.35 am 7. Film on biggest dome in the world, 11.45 pm Rajbaug campus, Loni 8. Speech by Student 12.05 pm 9. Speech by Alumnus 12.15 am 10. Speech by Executive Director 12.35 pm 11. Vote of Thanks 12.45 pm 12. Pasaydan 12.50 pm 12.55 pm 13.1 1145

Date: 29/08/2018

### MIMER MEDICAL COLLEGE, TALEGAON (D) 1<sup>ST</sup> MBBS batch 2018-2019 Programme schedule for Principal's Address

Date: 1st Sept. 2018

Time: 11.00 am onward

Venue: Lecture Hall No. 4, 3rd Floor, MIMER Medical College Building

- 1) Welcome to new batch
- 2) World Peace Prayer
- 3) Principal's Address
- 4) Speech by: -
  - Dr. Suchitra Nagare [Executive Director (P & D)]
  - Dr. Arun Jamkar [Director PG programme]
  - Dr. Sonali Khake [Alumnus]
  - Students

5) Pasayadan

Followed by Tea

C. C. To:

- 1. Medical Director
- 2. Executive Director (P & D)
- 3. Executive Director (HA)
- 4. Director- PG programme R & D
- 5. Principal
- 6. Principal- College of Physiotherapy
- 7. Director NBCIC
- 8. All HOD's- Pre/ Para/ Clinical
- 9. Medical Superintendent
- 10 Dy. Registrar
- 11. Warden- Girls & Boys hostel



# **MIMER MEDICAL COLLEGE, TALEGAON (D)**

# Programme schedule for Indoctrination 1<sup>st</sup> MBBS (2018-2019) Batch

**VENUE:** Lecture hall No. 4, 3<sup>rd</sup> Floor, MIMER Medical College building

DATE: 1st September 2018

TIME: 11 am onwards

- 1. Arrival of Dignitaries on the Dais
- 2. Opening remarks
- 3. World Peace Prayer
- 4. Principal's Address
- 5. Speech by Student
- 6. Speech by Director PG programme
- 7. Speech by Student
- 8. Speech by Alumnus
- 9. Speech by Executive Director
- 10. Vote of Thanks
- 11. Pasaydan

Теа

### MIMER MEDICAL COLLEGE, TALEGAON (D)

## **1<sup>ST</sup> MBBS ACADEMIC YEAR 2018 – 2019**

TERM	FROM	ТО
FIRST TERM	1 <sup>st</sup> August 2018	31 <sup>st</sup> December 2018
WINTER BREAK	28 <sup>th</sup> October 2018	11 <sup>h</sup> November 2018
SECOND TERM	1 <sup>st</sup> January 2019	5 <sup>th</sup> May 2019
	EXAMINATIONS	
TERMINAL	3 <sup>rd</sup> week of Dec. 2018	
PRELIMINARY	2 <sup>nd</sup> week of April 2019	Tentative dates

#### TERM AND EXAMINATION SCHEDULE

- ANNUAL SOCIAL GATHERING (Tentative days) 4 (four) days only in second or third week of February 2019
- TENTATIVE DATES OF UNIVERSITY EXAMINATION FIRST WEEK OF JUNE 2019

Prof. & Head Dept. of Physiology Prof. & Head Dept. of Anatomy Prof. & Head Dept. of Biochemistry

#### Principal MIMER Medical College

### **GENERAL INSTRUCTIONS 2018-2019**

 Satisfactory attendance and performance is crucial for the student to be eligible to appear for university examination. Mandatory requirement for the attendance is as follows

Theory classes ---- 75 % attendance Practicals ---- 80 % attendance

- 2. Attendance and performance status of the ward will be notified to the parents AFTER THE TERMINAL EXAMINATION (Approx second week of January 2019) Response and counselling thereafter from the parents is highly appreciated
- 3. Scoring Maximum marks in INTERNAL EXAMINATIONS is always beneficial to reduce the pressure during University Examinations.
- Students should NOT leave the college premises after preliminary examination without signing the FINAL INTERNAL ASSESSMENT MARKSHEETS. Tentative date: 1<sup>st</sup> week of May 2019

Prof. & Head Dept. of Physiology Prof. & Head Dept. of Anatomy

Prof. & Head Dept. of Biochemistry

#### Principal MIMER Medical College



# MIMER MEDICAL COLLEGE, TALEGAON (D) 1<sup>ST</sup> MBBS BATCH 2017-2018

VENUE: Anatomy Lecture Hall No. 1– Gr.Floor, MIMER Medical College building.

DATE: 4th August 2017.

TIME: 11 A.M.

# ORIENTATION PROGRAMME I - M. B. B. S.

1) 11A.M. To 12 Noon
 Introduction by HODs - Anatomy
 Physiology
 Biochemistry
 Community medicine

2) 12 Noon To 1 P.M.

Introduction to individual departments

# Regular teaching schedule will start on

5<sup>th</sup> August 2017

## MIMER MEDICAL COLLEGE, TALEGAON (D) 1<sup>ST</sup> MBBS BATCH 2016-2017

## **Programme Schedule for Principal Address**

<u>VENUE</u>: Lecture Hall no.4 – 3<sup>rd</sup> Floor, <u>DATE:</u> 6<sup>th</sup> October 2016.

MIMER Medical College building. <u>TIME:</u> 11 a.m. onwards

11 am to 12 pm :

Welcome to new batch.

World Peace Prayer.

Principal's Address.

Director / ED Speech.

\* Director PG Students.

Preclinical HOD's –

- HOD Biochemistry: General Instructions.
- > HOD Physiology: Attendance
- HOD Anatomy: Internal Assessment.
- HOD Community Medicine: Communication skills & medical ethics
- ✤ Students Speech

✤ Police inspector speech.

\* Announcement regarding orientation batches.

Pasaydan

12.00 pm to 12.30 pm : Tea Break
12.30 to 2.00 pm : Orientation to Preclinical Departments & Hospital in batches.

Batches for orientation shall be as follows:

ds

A	:	01 - 40
В		41 - 80
С		81 - 120
D	. t	120 onwar
	1	

#### MAEER MIT PUNE'S MAHARASHTRA INSTITUTE OF MEDICAL EDUCATION AND RESEARCH , (MEDICAL COLLEGE) DR. BHAUSAHEB SARDESAI TALEGAON RURAL HOSPITAL Accredited by NAAC with 'A' Grade P.O.Talegaon General Hospital, Talegaon Dabhade, Pune – 410 507, Maharashtra, India. Tel. (02114) 308300, 808799040/41/42/43 "Fax : 02114- 223916 "Website : www.mitmimer.com "Email :-info@mitmimer.com"

### MIMER MEDICAL COLLEGE – TALEGAON DABHADE

### **Activities of National Bioethics Curriculum Implementation Centre-2017**

- The National Bioethics Curriculum Implementation Centre (NBCIC) was inaugurated on 4<sup>th</sup> Oct 2017 at MIMER Medical College, Talegaon Pune. Dr Russell DSouza, Head Asia Pacific Division, UNESCO Chair in Bioethics Haifa, Melbourne Australia handed over the writ of establishment on behalf of Prof Amnon Carmi, Chair UNESCO Chair in Bioethics Haifa to Dr Suchitra Nagare, Executive Director to mark this momentous occasion. The solemn function was presided over by Dr V D Karad, Founder and Director General, MAEER'sMIT Pune. Dr S Geethalakshmi, Honourable Vice Chancellor TN Government Dr MGR Medical University also graced the occasion. Dr ArunJamkar was bestowed with the writ of appointment as the Chair and Dr Derek D'Souza as Director of the NBCIC.
- 2. Dr Suchitra Nagare, Executive Director was invited as Guest of Honour at the Inauguration of the Bioethics Unit of Maharaja Agrasen Hospital at Punjabi Bagh Delhi on 18<sup>th</sup> Nov 2017. This is the first hospital based Bioethics unit in the country and it was a matter of great pride for MIMER Medical College to be associated with this programme.
- 3. Dr Derek DSouza, Director NBCIC was invited as guest faculty at the1<sup>st</sup> National Training Faculty Quality Assurance Camp under the UNESCO Bioethics India Programme held at Hotel Ocean Pearl, Mangalore on 20<sup>th</sup> November 2017. He presented two papers at the campon 'Learning from teaching – The 3T IBHScExperience'and'Use of Standardised patients in Bioethics Education'which were well appreciated.
- 4. The 1<sup>st</sup> National Bioethics Conference was held at the historic Fr Muller's Medical College and Hospital on 21<sup>st</sup> and 22<sup>nd</sup> Nov 2017. Dr Suchitra Nagare, our Executive Director was the Chief Guest at this grand event and spoke of the need for implementation of Bioethics into all spheres of the medical education system. She quoted from Swami Vivekananda and the Rig Veda to emphasize the need to revamp the teaching and practice of health sciences in India. Dr Derek DSouza also attended

the conference as invited guest speaker and presented a paper on 'Ethics of Artificial Intelligence'.

## MIMER MEDICAL COLLEGE TALEGAON DABHADE INAUGURATION OF THE NATIONAL BIOETHICS

## CURRICULUM IMPLEMENTATION CENTRE OF UNESCO CHAIR IN BIOETHICS 4<sup>TH</sup> OCTOBER 2017

The National Bioethics Curriculum Implementation Centre under the Indian programme of the UNESCO Bioethics Chair (Haifa) was inaugurated at a glittering function presided over by the revered Founder and Director General of the MAEER's Group of Institutions, Dr VishwananthKarad held at MIMER Medical College on 4<sup>th</sup> Oct 2017.

TheIndian programme of the UNESCO Chair in Bioethics has played a pioneering role in the establishment of the Bioethics curriculum into the health sciences syllabus. Under the leadership of Dr Amnon Carmi, Chair UNESCO Bioethics (Haifa), and Dr Russell DSouza, faculty training courses have been organised all across India to setup a network of Bioethics units with trained faculty to carry this programme forward.

The rapid spread of the network in India had necessitated the need to establish a National Bioethics Curriculum Implementation Centre. The vision and foresight of Dr VishwananthKarad and the whole-hearted support of Executive Director, Dr Suchitra Nagare had resulted in MIMER Medical College, Talegaon, Pune being bestowed upon the unique honour to host such a centre. Dr ArunJamkar has been installed as the Head and Dr Derek DSouza as the Director of this prestigious centre. This centre is the first of its kind in the entire Asia Pacific region under the UNESCO Chair in Haifa. The centre will be the National Co-ordination Centre for planning and implementation of the integrated Bioethics programme for the entire country.

Dr Russell DSouza, Head Asia Pacific Region UNESCO Bioethics Programme handed over the writs of establishment on the 4<sup>th</sup> October at a special function organised at MIMER Medical College. He said that he was confident that the faculty and students of the college would live up to the responsibility bestowed upon them. Speaking on the occasion, Dr S Geethalakshmi, Vice Chancellor Tamil Nadu MGR Medical University congratulated Executive Director and all faculty of MIMER Medical College and said that she was looking forward to working closely with the faculty in taking this programme further. Dr V. D. Karad, in his Presidential address expressed his satisfaction at the establishment of such a centre at MIMER Medical College. He emphasised that this special occasion should inspire all faculty and students to abide by the teachings of Swami Vivekananda and Saint ShriDnyaneshwara that the "Union of science and Relgion/Spirituality alone will bring harmony and peace to the humanity" and also of the guiding principle of "VasudhaivaKutumbakam – that the World is One Family"

A separate Bioethics unit has also been established at MAEER's College of Physiotherapy and the Writ of establishment was handed over at the same function. This is the first time that an independent Bioethics unit has been set-up in a college of physiotherapy in India. Separate Writs of establishment of the Student Wings at both MIMER Medical College and MAEER's Physiotherapy college were also presented to the students.

### PROGRAMME FOR INAUGURATION OF NBCIC 04 OCT 2017

Ne	Time	Dreading manage
No	Time	Programme
1.	11:00 - 11:20	Address by Dr OP Kalra
2.	11:20 - 11:40	Address by Dr S Geetalakshmi
3.	11:40 - 11:55	Interaction with students
		INAUGURATION
4.	12:00 - 12:02	Arrival of Guests on the dais
5.	12:02 - 12:05	Introductory remarks by DrVaishaliKorde
6.	12:05 - 12:10	World Peace Prayer
7.	12:10 - 12:15	Welcome Address by Dr Suchitra Nagare
8.	12:15 - 12:25	Address by DrArunJamkar
9.	12:25 - 12:35	Address by Chief Guest Dr Russell DSouza
10.	12:35 - 12:38	Presentation of Writ of Establishment of NBCIC
		Writ of Establishment presented to Dr Suchitra Nagare
		Writ of Chair, NBCIC to DrArunJamkar
		Writ of Director, NBCIC to Dr Derek DSouza
11.	12:38 - 12:40	Presentation of Writ of Establishment of Bioethics Unit
		MAEER's Physiotherapy College
		Writ of establishment of Bioethics Unit to Principal
		Writ of Steering Committee Head
		Writ of Head of Students Wing
12.	12:40 - 12:55	Presidential Address by DrVishwanath D. Karad
13.	12:55 - 13:00	Vote of Thanks by Dr Derek DSouza
14.	13:00 onwards	Lunch

The National Bioethics Curriculum Implementation Centre (NBCIC) was inaugurated on 4<sup>th</sup> Oct 2017 at MIMER Medical College, Talegaon Pune









Dr Suchitra Nagare, Executive Director MIMER Medical College was invited as Guest of Honour at the Inauguration of the Bioethics Unit of Maharaja Agrasen Hospital at Punjabi Bagh Delhi on 18<sup>th</sup> Nov 2017



1<sup>st</sup> National Bioethics Conference Father Muller's Medical College and Hospital, Mangalore. 21<sup>st</sup> and 22<sup>nd</sup> Nov 2017 Dr Suchitra Nagare, Executive Director MIMER Medical College was invited as Chief Guest



4<sup>th</sup> October 2017

Dr. Suchitra Nagare, Executive Director MIMER Medical College Talegaon Dabhade

On establishing that the requirements of the UNESCO Chair in Bioethics (Haifa) have been met, I hereby on the Fourth Day of October in the year Two Thousand and Seventeen, issue this writ confirming and approving the establishment of the

### National Bioethics Curriculum Implementation Centre

of the Indian Program of the UNESCO Chair and of the International Bioethics Network of the UNESCO Chair in

Bioethics at:

MIMER Medícal College Talegaon Dabhade

Ammon Calmi

**Professor Amnon Carmi,** Head, & Chair Holder UNESCO Chair in Bioethics (Haifa)



# The UNESCO Chair in Bioethics Haifa

# Certifies that

# Dr Arun Jamkar

Has been appointed

## Chair

# National Bioethics Curriculum Implementation Centre MIMER Medical College

### Talegaon Dabhade

to fulfil the objectives of stimulating Teaching, Training and Research in Bioethics in Medical and Health Science Education

Annon Calmi

Prof. Amnon Carmi, Head, UNESCO Chair in Bioethics University of Haifa

Prof Russell D'Souza MD Head Asia Pacific Division UNESCO Chair in Bioethics

4<sup>\*</sup> October 2017



# The UNESCO Chair in Bioethics Haifa

## Certifies that

# Col (Dr) Derek SJ DSouza

#### Has been appointed

#### Director

National Bioethics Curriculum Implementation Centre MIMER Medical College

### Talegaon Dabhade

to fulfil the objectives of stimulating Teaching, Training and Research in Bioethics in Medical and Health Science Education.

Annon Calmi

Prof. Amnon Carmi, Head, UNESCO Chair in Bioethics University of Haifa

Prof Russell D'Souza MD Head Asia Pacific Division UNESCO Chair in Bioethics

4<sup>th</sup> October 2017



# The UNESCO Chair in Bioethics Haifa

Certífies that

The Student Wing of

## MIMER Medical College

of the UNESCO Chair in Bioethics is established

In proclamation of the establishment of the **Bioethics Unit at MIMER Medical College** 

on the 4<sup>th</sup> October 2017

to fulfil the objectives of stimulating Teaching, Training and Research in Bioethics in Medical & Health Science Education.

Ammon Calvi

Prof. Amnon Carmi, Head, UNESCO Chair in Bioethics University of Haifa

u Turz

Prof Russell D'Souza MD Head Asia Pacific Division UNESCO Chair in Bioethics

## MIMER MEDICAL COLLEGE, TALEGAON DABHADE

### DISTINCTION HOLDERS NAMES OF MUHS EXAMINATION Winter 2020

II MBBS :

II MBBS : RANK	COLLEGE	NAME OF THE STUDENT	MARKS	REMARKS		
I		NUPUR MUKESH CHATURVEDI	433	DISTINCTION		
	RANK	PURVA SANJAY KUKDE	431	DISTINCTION		
		PATIL MAHI ANAND	429	DISTINCTION		
		NISHANT JAYAWANT	421	DISTINCTION		
		SHINGTE SUPRAJ CHANDRAKANT	420	DISTINCTION		
		DADIA DHVANI MANOJ	419	DISTINCTION		
		GUPTA AMIT CHANDRAKANT	418	DISTINCTION		
		KANANI DARSHAN DAMJIBHAI	418	DISTINCTION		
		PUROHIT JANHAVI VIVEK	416	DISTINCTION		
		PATEL SHUBHAM RAJKISHOR	415	DISTINCTION		
		BHALGAT SIDDHI SANTOSH	414	DISTINCTION		
		DISTINCTIONS - 11				
RANK	SUBJECT	NAME OF THE STUDENT	MARKS	REMARKS		
I	PHARMA	PATIL MAHI ANAND	123	DISTINCTION		
Ш	COLOGY	SAVLA HAIT JAYANTILAL	121	DISTINCTION		
		SUDNYA VINOD MALODE	120	DISTINCTION		
		NUPUR MUKESH CHATURVEDI	119	DISTINCTION		
		NISHANT JAYAWANT	118	DISTINCTION		
		GUPTA AMIT CHANDRAKANT	118	DISTINCTION		
		KANANI DARSHAN DAMJIBHAI	118	DISTINCTION		
		PATEL SHUBHAM RAJKISHOR	118	DISTINCTION		
		SAVLA BHAKTI NILESH	118	DISTINCTION		
		KOTHARI CHAKSHU DILIP	118	DISTINCTION		
		THAKKAR SHIVAM SHAILESH	118	DISTINCTION		
		PURVA SANJAY KUKDE	117	DISTINCTION		
		SHINGTE SUPRAJ CHANDRAKANT	117	DISTINCTION		
		BHALGAT SIDDHI SANTOSH	117	DISTINCTION		
		MANCHKAR SHRUTI SHASHIKANT	117	DISTINCTION		
		MANE MANASI RAMAKANT	117	DISTINCTION		
		SANGAMNERKAR SAYEE MUKUND	117	DISTINCTION		
		SINGH SAACHI UDAI	117	DISTINCTION		
		DUGAD VINIT MILIND	117	DISTINCTION		
		DADIA DHVANI MANOJ	116	DISTINCTION		
		PAWAR YADNI PRATAP	116	DISTINCTION		
		DESHMANE RITUJA RAJESH	116	DISTINCTION		
		PINATE ABHILASHA DNYANOBA	116	DISTINCTION		
		PARAM KADAM	116	DISTINCTION		
		RAO JAYRAJ AMITKUMAR	116	DISTINCTION		

	PUROHIT JANHAVI VIVEK	115	DISTINCTION	
	KAWADE RIDDHI MAHESH	114	DISTINCTION	
	PEMARE VARSHA SUDAM	115	DISTINCTION	
	MAJITHIA YASH KAMLESH	113	DISTINCTION	
	GOVALKAR SHREYA MANGESH	113	DISTINCTION	
	SHETH VIDHI DEEPAK	113	DISTINCTION	
	GHOSH RIYA DEEPAK	113	DISTINCTION	
	ANKIT PAL	115	DISTINCTION	
	GHORPADE ARYA SACHIN	115	DISTINCTION	
DISTINCTIONS - 34				

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	REMARKS
	ATHOLOG	NUPUR MUKESH CHATURVEDI	117	DISTINCTION
I		PATIL MAHI ANAND	117	DISTINCTION
		PURVA SANJAY KUKDE	114	DISTINCTION
н 1		SHINGTE SUPRAJ CHANDRAKANT	114	DISTINCTION
		MANE MANASI RAMAKANT	114	DISTINCTION
		TILOKCHANDANI MOHAK ANIL	114	DISTINCTION
DISTINCTIONS - 06				

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	REMARKS		
I	MICROBI	PURVA SANJAY KUKDE	128	DISTINCTION		
Ш	OLOGY	PATEL SHUBHAM RAJKISHOR	122	DISTINCTION		
		PAWAR YADNI PRATAP	121	DISTINCTION		
		NUPUR MUKESH CHATURVEDI	120	DISTINCTION		
		DADIA DHVANI MANOJ	119	DISTINCTION		
		PATIL MAHI ANAND	118	DISTINCTION		
		DESHMANE RITUJA RAJESH	118	DISTINCTION		
		SUDNYA VINOD MALODE	117	DISTINCTION		
		KHEBUDKAR SIDDHI RAVINDRA	117	DISTINCTION		
		KANANI DARSHAN DAMJIBHAI	116	DISTINCTION		
		BHALGAT SIDDHI SANTOSH	115	DISTINCTION		
		SANGAMNERKAR SAYEE MUKUND	115	DISTINCTION		
		PARAM KADAM	115	DISTINCTION		
		MANCHKAR SHRUTI SHASHIKANT	114	DISTINCTION		
		NARAYAN CHAUBEY	114	DISTINCTION		
		SHINGTE SUPRAJ CHANDRAKANT	113	DISTINCTION		
		GUPTA AMIT CHANDRAKANT	113	DISTINCTION		
		SAVLA BHAKTI NILESH	113	DISTINCTION		
		KAWADE RIDDHI MAHESH	113	DISTINCTION		
	DISTINCTIONS - 19					

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	REMARKS		
I	FMT	PUROHIT JANHAVI VIVEK	81	DISTINCTION		
II		NISHANT JAYAWANT	80	DISTINCTION		
		KANASE PARINEETA BHARAT	78	DISTINCTION		
		NUPUR MUKESH CHATURVEDI	77	DISTINCTION		
		SANE DEVANSHI HEMANT	77	DISTINCTION		
		KHEBUDKAR SIDDHI RAVINDRA	77	DISTINCTION		
		SHINGTE SUPRAJ CHANDRAKANT	76	DISTINCTION		
		DADIA DHVANI MANOJ	76	DISTINCTION		
		KANANI DARSHAN DAMJIBHAI	76	DISTINCTION		
		GANATRA SHEFALI DEEPAK	76	DISTINCTION		
		GUPTA AMIT CHANDRAKANT	75	DISTINCTION		
		BHALGAT SIDDHI SANTOSH	75	DISTINCTION		
		SAVLA BHAKTI NILESH	75	DISTINCTION		
		PEMARE VARSHA SUDAM	75	DISTINCTION		
		BHUJBAL CHAITANYA RANGNATH	75	DISTINCTION		
		INAMDAR GARGI ANAND	75	DISTINCTION		
		SHAIKH NAZISH FATIMA NASER	75	DISTINCTION		
		SAHOO MADHUMITA DEBASIS	75	DISTINCTION		
		VAIDYA SANEEKA RAJESH	75	DISTINCTION		
	DISTINCTIONS - 19					

III MBBS (P-I)

COLLEGE	RANK	NAME OF THE STUDENT	MARKS		
	I	BARMARE ARSHIYA SUHEL	315	Distinction	
	II	SINGH SAHITYA SANJEEV	309	Distinction	
OVERALL		PUJARI SWARADA SACHIN	307	Distinction	
RANK		JAIN HARDIK MAHENDRA	306	Distinction	
		MEMON AFZAL SHAKEEL	303	Distinction	
		JAIN KALPITA VIJAY	301	Distinction	
		PATEL ARIANA TRIYUG	300	Distinction	
Distinction - 07					

SUBJECT	RANK	NAME OF THE STUDENT	MARKS			
Comm.	I	PUJARI SWARADA SACHIN	158	Distinction		
Med.	II	SINGH SAHITYA SANJEEV	154	Distinction		
		MEMON AFZAL SHAKEEL	151	Distinction		
Distinction - 03						

SUBJECT	RANK	NAME OF THE STUDENT	MARKS	
	I	BARMARE ARSHIYA SUHEL	86	Distinction
	II	JHA MUSKAN AMARNATH	82	Distinction
		MEMON AFZAL SHAKEEL	81	Distinction
		JAIN HARDIK MAHENDRA	80	Distinction
		BHOR MRINAL SUNIL	79	Distinction
		GALA ABHISHEK NILESH	79	Distinction
		MANE ANJALI MACHINDRA	79	Distinction
		PATEL ARIANA TRIYUG	79	Distinction
[		SINGH SAHITYA SANJEEV	79	Distinction
		SUKANYA SATARDEKAR	79	Distinction
[		WANJARI SUBODH KAILASH	79	Distinction
[		AMRUTKAR RUTUJA SUNIL	78	Distinction
		MERLIN SARA MATHEW	78	Distinction
		NAGARE ANJALI SUBHASH	78	Distinction
		PATEL JAINIL DEEPAKKUMAR	78	Distinction
		PATIL PRIYA ULHAS	78	Distinction
Ophthal		VEDANT KINJAL JITEN	78	Distinction
		JAIN KALPITA VIJAY	77	Distinction
		NADRE JANHVI SURESH	77	Distinction
		PAWANARKAR ANOMA JAYANT	77	Distinction
		ANJAN RUTURAJ DNYANOBA	76	Distinction
		GOSAVI PRATHMESH SUNIL	76	Distinction
		KULKARNI SHAMAL MAHESH	76	Distinction
		PUJARI SWARADA SACHIN	76	Distinction
		SUDITI WASNIK	76	Distinction
		SURYAWANSHI INDRAJEET GOVINDRA	76	Distinction
		AGARWAL AKANSHA MANISH	75	Distinction
[		AKSHITA G SAXENA	75	Distinction
		AMBAWALE TEJASHREE DHANANJAY	75	Distinction
		BHOSALE ABHISHEK NANDKUMAR	75	Distinction
		PATIL SURBHI PRAVIN	75	Distinction
		SHEVGAN RAKHI RAMESH	75	Distinction
[		THANEKAR DAKSHATA SANJAY	75	Distinction
		V RENU PRAKASH	75	Distinction
		Distinction - 34		

contd...

SUBJECT	RANK	NAME OF THE STUDENT	MARKS	
	Ι	BARMARE ARSHIYA SUHEL	82	Distinction
	Ш	JAIN HARDIK MAHENDRA	81	Distinction
		AGARWAL AKANSHA MANISH	77	Distinction
ENT		AKSHITA G SAXENA	77	Distinction
		PATEL ARIANA TRIYUG	77	Distinction

	JAIN KALPITA VIJAY Distinction - 07	/5	Distinction
		75	Distingtion
	SINGH SAHITYA SANJEEV	76	Distinction

#### FINAL MBBS :

SUBJECT	RANK	NAME OF THE STUDENT	MARKS	
Medicine		CHANDURKAR AJINKYA DHANANJAY	229	Distinction

SUBJECT	RANK	NAME OF THE STUDENT	MARKS	
	I	NAIK QAIS SHABBIR	158	Distinction
	II	NAIR ANOUSHKA PADMANABHAN	156	Distinction
		CHANDURKAR AJINKYA		Distinction
		DHANANJAY	155	
		GALA KOSHA ANISH	154	Distinction
Obst &		NALAWADE SHWETA SURESH	154	Distinction
Gynec		PRASAD DIVYA JAYNANDAN	153	Distinction
		SATHE SNEHA SANTOSH	152	Distinction
		SHITOLE ADITYA AMAR	151	Distinction
		Distinction - 08		

SUBJECT	RANK	NAME OF THE STUDENT	MARKS	
	I	SHITOLE ADITYA AMAR	84	Distinction
	Ш	CHANDURKAR AJINKYA		Distinction
Paed-	11	DHANANJAY	79	
iatrics		NALAWADE SHWETA SURESH	78	Distinction
		URBHI JHA	77	Distinction
		KANKARIYA BHAVESH		Distinction
		MAHENDRA	76	
		NAIR ANOUSHKA PADMANABHAN	70	Distinction
			76	
		PRASAD DIVYA JAYNANDAN	76	Distinction
		RANAWADE MANJIRI MANGESH	76	Distinction
		C.MARIA	75	Distinction
		JAIN FENIL MUKESH	75	Distinction
		KORE YUGALI VIVEK	75	Distinction
		SURVE KSHITIJA SHASHIKANT	75	Distinction
		Distinction - 12		

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I	PHYSIOLO	GUPTA VIDHI RAKESH	233	Distinction
II		DUBE PRATIMESH RAMESH	232	Distinction

	SAWANT EISHA JITENDRA	230	Distinction	
	WAHEGAONKAR APARNAA CHANDRASHEKHA	230	Distinction	
	LANJEWAR SOUMYA UJJWAL	230	Distinction	
	SHENOY SHONALI SATYENDRA	227	Distinction	
 GY	KHEMLANI DARSHIT SURESH	226	Distinction	
07 Students Passed in Distinction				

RANK	SUBJECT	NAME OF THE STUDENT		MARKS	
1	BIOCHEMI	SAKSHI JAIRAM	241	Distinction	
I		WAHEGAONKAR APARNAA	241	Distinction	
II		LANJEWAR SOUMYA UJJWAL	238	Distinction	
		SAWANT EISHA JITENDRA	238	Distinction	
		NAMRATA AGARWAL	237	Distinction	
		SREYA SUBRAMANYAM	233	Distinction	
		GHAISAS AMEYA SHRINIVAS	229	Distinction	
	STRY	WALKE SAKSHI ANIL	227	Distinction	
	08 Students passed in Distinction				

### MIMER MEDICAL COLLEGE, TALEGAON DABHADE DISTINCTION HOLDERS NAMES OF MUHS EXAMINATION Winter 2019

### II MBBS

COLLEGE	RANK	NAME OF THE STUDENT	MARKS		
OVERALL	I	BARMARE ARSHIYA SUHEL	425	Distinction	
		SINGH SAHITYA SANJEEV	425	Distinction	
RANK	П	PUJARI SWARADA SACHIN	413	Distinction	
Distinction - 03					

SUBJECT	RANK	NAME OF THE STUDENT	MARKS	
	Ι	SINGH SAHITYA SANJEEV	124	Distinction
	Ш	BARMARE ARSHIYA SUHEL	122	Distinction
		SHAIKH SAHIBA SHAHED	119	Distinction
PHARMAC		JAIN HARDIK MAHENDRA	118	Distinction
FIANNAC		JAIN KALPITA VIJAY	117	Distinction
		AGARWAL AKANSHA MANISH	116	Distinction
		WANJARI SUBODH KAILASH	115	Distinction
		PATEL ARIANA TRIYUG	114	Distinction
		DHAKANE ANIKET BABASAHEB	113	Distinction
		Distinction - 09		

SUBJECT	RANK	NAME OF THE STUDENT	MARKS		
PATHOLO	1	PUJARI SWARADA SACHIN	113	Distinction	
GY	I	SHAIKH SAHIBA SHAHED	113	Distinction	
Distinction - 02					

SUBJECT	RANK	NAME OF THE STUDENT	MARKS			
	I	PUJARI SWARADA SACHIN	121	Distinction		
	П	SINGH SAHITYA SANJEEV	119	Distinction		
MICRO-	II	MENON AFZAL SHAKEEL	119	Distinction		
BIOLOGY		-				
		BARMARE ARSHIYA SUHEL	116	Distinction		
		BANGAR SACHIN SUBHASH	114	Distinction		
		PATEL ARIANA TRIYUG	113	Distinction		
	Distinction - 06					

SUBJECT	RANK	NAME OF THE STUDENT	MARKS		
F.M.T.	I	BARMARE ARSHIYA SUHEL	75	Distinction	
Distinction - 01					

III MBBS (P-I)

COLLEGE	RANK	NAME OF THE STUDENT	MARKS		
	I	C.MARIA	307	Distinction	
OVERALL	II	CHANDURKAR AJINKYA DHANANJAY	305	Distinction	
		BHURAN ADVAIT RAJENDRA	301	Distinction	
Distinction - 03					

SUBJECT	RANK	NAME OF THE STUDENT	MARKS		
	I	C.MARIA	165	Distinction	
Comm.	nm. II BHURAN ADVAIT RAJENDRA		155	Distinction	
Med					
		KANKARIYA BHAVESH MAHENDRA	153	Distinction	
		Distinction - 03			
SUBJECT	RANK	NAME OF THE STUDENT	MARKS		
	I	CHANDURKAR AJINKYA DHANANJAY	80	Distinction	
Ophthal	II	NAIR ANOUSHKA PADMANABHAN	76	Distinction	
		KASHYAP GAUTAMI PARAG	75	Distinction	
		MALI UTTKARSHA SANJAY	75	Distinction	
Distinction - 04					

SUBJECT	RANK	NAME OF THE STUDENT	MARKS	
	I	CHANDURKAR AJINKYA DHANANJAY	81	Distinction
ENT		PRASAD DIVYA JAYNANDAN	81	Distinction
	Ш	ARSHIYA HAROON SHAMASHAPURE	77	Distinction
	11	BHURAN ADVAIT RAJENDRA	77	Distinction
		DESHPANDE SAKSHI SACHIN	76	Distinction
		KORE YUGALI VIVEK	76	Distinction
		GANGURDE HARSHALI SANJAY	75	Distinction
		KANKARIYA BHAVESH MAHENDRA	75	Distinction
		RHEA SUNIL	75	Distinction
		SHITOLE ADITYA AMAR	75	Distinction
		Distinction - 10		

Final MBBS :

SUBJECT	RANK	NAME OF THE STUDENT	MARKS	
	Ι	DESHMUKH ASMITA AJAY	168	Distinction
	Ш	CHINCHOLIKAR SANJANA SANJEEV	164	Distinction
		KAZI ANAM ZAFAR	163	Distinction
		CHIKHALIKAR PRACHI SATISHRAO	158	Distinction
Obst &	it&	JOSHI SAKSHI ASHOK	157	Distinction
Gynec		BANDGAR YOGESHWARI APPASO	156	Distinction
		MERLYN MARY VARGHESE	155	Distinction
		NAIK BHAGYESHA JAYENDRA	153	Distinction
		TANYA SINGH	153	Distinction
		SAVLA KHUSHBOO SAMIR	152	Distinction
		SHIDHAYE NIKHIL PRASAD	152	Distinction
		GADA KRUPA GULAB	151	Distinction
		KATKAR SHWETA DATTATRAYA	151	Distinction
		NISHITA SUNIL MANJREKAR	150	Distinction
tinction -	14			

SUBJECT	RANK	NAME OF THE STUDENT	MARKS	
	I	DESHMUKH ASMITA AJAY	77	Distinction
Paed-		SHAIKH TARANNUM NIAZAHMED	77	Distinction
iatrics	=	SHIDHAYE NIKHIL PRASAD	76	Distinction

		BANDGAR YOGESHWARI APPASO	75	Distinction
		KATKAR SHWETA DATTATRAYA	75	Distinction
tinction - 05				

\*\*Ms.Deshmukh Asmita Ajay has been awarded from MUHS by "Dr.Kamaltai Deshmukh Gold Medal" award for securing highest marks (Womens category) in Third MBBS (Part-II) MUHS examination Winter-2019, Subject-Obstetrics and Gynaecology Marks 168/200

### MIMER MEDICAL COLLEGE, TALEGAON DABHADE DISTINCTION HOLDERS NAMES OF MUHS EXAMINATION SUMMER 2019

RANK	COLLEGE	OF THE STU	MARKS		
I	OVERALL RANK	BHUJBAL (	487	Distinction	
II		PATIL MAI	463	Distinction	
		GURAV YAS	456	Distinction	
		SUDNYA VI	454	Distinction	
		BHALGAT S	451	Distinction	
	05 Students Passed in Distinction				

RANK	SUBJECT	OF THE STU	MARKS			
-		BHUJBAL (	163	Distinction		
=	ΑΝΑΤΟΜΥ	PATIL MAI	153	Distinction		
=		SUDNYA V	153	Distinction		
		<b>BICHKAR</b>	152	Distinction		
		DADIA DH	152	Distinction		
		NUPUR M	152	Distinction		
		PIMPALE [	152	Distinction		
-		MAJITHIA	151	Distinction		
	08 Students Passed in Distinction					

RANK	SUBJECT	OF THE STU	MARKS	
I		PATIL MAI	160	Distinction
П	PHYSIOLOGY	BHUJBAL (	158	Distinction
		GURAV YA	153	Distinction
		SUDNYA V	152	Distinction
		SHAIKH N	150	Distinction

RANK	SUBJECT	OF THE ST	Ν	/IARKS
I	BIOCHEMISTRY	BHUJBAL (	166	Distinction
II	DIOCHEIVIISTRY	MAJITHIA	160	Distinction
		BHALGAT	158	Distinction
		NUPUR M	158	Distinction
		SHINGTE S	158	Distinction
		PARMAR I	157	Distinction
		DESHMAN	156	Distinction
		PURVA SA	156	Distinction
		GURAV YA	155	Distinction
		SHAIKH AL	155	Distinction
		DADIA DH	154	Distinction
		NARAYAN	154	Distinction
		PIMPALE [	153	Distinction
		KOTHARI (	150	Distinction
		PATIL MAI	150	Distinction
	15 Students p	assed in Distinctio	n	

### 05 Students Passed in Distinction

## MIMER MEDICAL COLLEGE, TALEGAON DABHADE DISTINCTION HOLDERS NAMES OF MUHS EXAMINATION Winter 2018

#### II MBBS :

Overall : (04 -Distinctions)

RANK	COLLEGE	NAME OF THE STUDENT	MARKS	
I	OVERALL	CHANDURKAR AJINKYA DHANANJAY	432	Distinction
Ш	RANK	C.MARIA	428	Distinction
		ARSHIYA HAROON SHAMASHAPURE	423	Distinction
		KASHYAP GAUTAMI PARAG	415	Distinction

#### Pharmac : (09-distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
		CHANDURKAR AJINKYA DHANANJAY	121	Distinction
1	PHARMA.	C.MARIA	121	Distinction
		NAIR ANOUSHKA PADMANABHAN	118	Distinction
		DOSHI DHARMIN NILESH	117	Distinction

 CHAVAN ONKAR MADHUKAR	115	Distinction
 ARSHIYA HAROON SHAMASHAPURE	114	Distinction
 KASHYAP GAUTAMI PARAG	114	Distinction
 GADE AISHWARYA VIJAY	114	Distinction
 KORE YUGALI VIVEK	113	Distinction

Pathology : (07 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I	PATHOLO	RANAWADE MANJIRI MANGESH	118	Distinction
П	GY	ARSHIYA HAROON SHAMASHAPURE	117	Distinction
		CHANDURKAR AJINKYA DHANANJAY	116	Distinction
		KASHYAP GAUTAMI PARAG	115	Distinction
		PATIL JAYRAJ DEVIDAS	114	Distinction
		C.MARIA	113	Distinction
		GADE AISHWARYA VIJAY	113	Distinction

Micro : (11 - Distinc tions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS		
I		KORE YUGALI VIVEK	123	Distinction	
П		CHANDURKAR AJINKYA DHANANJAY	121	Distinction	
		ARSHIYA HAROON SHAMASHAPURE	119	Distinction	
	]	INGOLE AISHWARYA SANJAY	119	Distinction	
		PRASAD DIVYA JAYNANDAN	119	Distinction	
		NALAWADE SHWETA SURESH	116	Distinction	
		C.MARIA	115	Distinction	
		KATTA MADHAVI RAMESH	115	Distinction	
	]	JETHWA PRACHI DAYANAND	114	Distinction	
	]	BHANGDIA SHIVAM RAJESH	113	Distinction	
	]	GITE SHREYA BHAGWAN	113	Distinction	
		GITE SHREYA BHAGWAN	113	Distincti	

02 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I	F.M.T.	C.MARIA	79	Distinction
II		KASHYAP GAUTAMI PARAG	77	Distinction

### MIMER MEDICAL COLLEGE, TALEGAON DABHADE DISTINCTION HOLDERS NAMES OF MUHS EXAMINATION SUMMER 2018

#### **OVERALL : (01 Distinctions)**

RANK	COLLEGE	NAME OF THE STUDENT	MARKS	
I	OVERALL	BARMARE ARSHIYA SUHEL	473	Distinction
	RANK	PUJARI SWARADA SACHIN	446	

#### Anatomy : (01-Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I	Anatomy	BARMARE ARSHIYA SUHEL	158	Distinction

#### Physiology : (02 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I	Physiology	BARMARE ARSHIYA SUHEL	154	Distinction
		PUJARI SWARADA SACHIN	151	Distinction

#### **Bio-chemistry : (07-distinctions)**

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I		BARMARE ARSHIYA SUHEL	161	Distinction
		VEDANT KINJAL JITEN	155	Distinction
		BHOR MRINAL SUNIL	154	Distinction
	Bio-chem	PUJARI SWARADA SACHIN	152	Distinction
		SHAIKH SAHIBA SHAHED	152	Distinction
		SINGH SATHIA SANJEEV	151	Distinction
		JAIN KALPITA	150	Distinction

### MIMER MEDICAL COLLEGE, TALEGAON DABHADE DISTINCTION HOLDERS NAMES OF MUHS EXAMINATION WINTER - 2017

#### **OVERALL : (09 Distinctions)**

RANK	COLLEGE	NAME OF THE STUDENT	MARKS	
I	OVERALL	CHIKHALIKAR PRACHI SATISHRAO	437	Distinction
- 11	RANK	DESHMUKH ASMITA AJAY	432	Distinction
		KATKAR SHWETA DATTATRAYA	423	Distinction

 PILLAI SREELAKSHMI GOPA KUMAR	422	Distinction
 CHANDE DHRUVI ATUL	421	Distinction
 JOSHI SAKSHI ASHOK	420	Distinction
 KAZI ANAM ZAFAR	419	Distinction
 GADA KRUPA GULAB	418	Distinction
 J MADHUMITHAA R JAGANNATHAN	415	Distinction

### Pharmacology : (03-Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I	PHARMA	CHIKHALIKAR PRACHI SATISHRAO	121	Distinction
Ш		JOSHI SAKSHI ASHOK	118	Distinction
		CHINCHOLIKAR SANJANA SANJEEV	116	Distinction

### Pathology : (06-Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I	PATHOL	DESHMUKH ASMITA AJAY	122	Distinction
I		CHANDE DHRUVI ATUL	122	Distinction
II	OGY	PILLAI SREELAKSHMI GOPA KUMAR	118	Distinction
		CHIKHALIKAR PRACHI SATISHRAO	116	Distinction
		KATKAR SHWETA DATTATRAYA	116	Distinction
		BANDGAR YOGESHWARI APPASO	113	Distinction

### Microbiology : (17-Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS				
I	CROBIOLO	PILLAI SREELAKSHMI GOPA KUMAR	127	Distinction			
II		CHIKHALIKAR PRACHI SATISHRAO	126	Distinction			
		KATKAR SHWETA DATTATRAYA	124	Distinction			
		KAZI ANAM ZAFAR	124	Distinction			
		DESHMUKH ASMITA AJAY	121	Distinction			
		GADA KRUPA GULAB	119	Distinction			
		SHAIKH TARANNUM NIAZAHMED	119	Distinction			
		GARULE MUGDHA DILIP	119	Distinction			
		SHAH AVI NIMESH	118	Distinction			
		BANDGAR YOGESHWARI APPASO	116	Distinction			
		JOSHI SAKSHI ASHOK	115	Distinction			
		J MADHUMITHAA R JAGANNATHAN	115	Distinction			
		GUGALE TANVI ANIL	115	Distinction			
		CHANDE DHRUVI ATUL	114	Distinction			

 MERLYN MARY VARGHESE	114	Distinction
 PILLAI SHARADRAJ VENKATESH	113	Distinction
 TANYA SINGH	113	Distinction

### FMT : (12-Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS				
I	F.M.T.	DESHMUKH ASMITA AJAY	82	Distinction			
	F.IVI.I.	GADA KRUPA GULAB	81	Distinction			
		JOSHI SAKSHI ASHOK	78	Distinction			
		KAZI ANAM ZAFAR	77	Distinction			
		J MADHUMITHAA R JAGANNATHAN	77	Distinction			
		JOSHI SANIYA PRASAD	77	Distinction			
		KATKAR SHWETA DATTATRAYA	75	Distinction			
		CHINCHOLIKAR SANJANA SANJEEV	75	Distinction			
		PRASAD SWAPNIL SURESH	75	Distinction			
		MERLYN MARY VARGHESE	75	Distinction			
		PILLAI SHARADRAJ VENKATESH	75	Distinction			
		PATIL NEHA DNYANESHWAR	75	Distinction			

### Third Year MBBS (Part - I)

### Overall : (03- Distinctions)

RANK	COLLEGE	NAME OF THE STUDENT	MARKS	
I	OVERALL	THAKEKAR KETKI SUNIL	317	Distinction
П	RANK	PATEL DHANANJAY KANTIBHAI	307	Distinction
		WAGH SUYOG SUNIL	300	Distinction

### Comm.Medicine : (02 Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I	Comm.M	THAKEKAR KETKI SUNIL	157	Distinction
I	ed	WAGH SUYOG SUNIL	151	Distinction

### **Ophthal : (27 Distinctions)**

RANK	SUBJECT	NAME OF THE STUDENT	MARKS		
I	OPHTHA	MAKHIJA HITESH NARESH	82	Distinction	
II		KHAN SAFA MAHVISH MOHAMMAD TARIQ	81	Distinction	
II	L.	PATEL DHANANJAY KANTIBHAI	81	Distinction	
		THAKEKAR KETKI SUNIL	80	Distinction	
		KOTHARI PRINCEKUMAR RAKESH	80	Distinction	

 SALUNKHE SHUBHALI RAJENDRAKUMAR	80	Distinction
 BAGUL RAHUL PRAKASH	80	Distinction
 SHAIKH JUVAIRIYA JAMEEL AHMED YUSUF	79	Distinction
 OMBASE SWAPNIL BABASAHEB	79	Distinction
 HONWADKAR NINAD KISHOR	78	Distinction
 SONWANE POOJA BHASKAR	78	Distinction
 NEMANI AAKRUTI ANIL	78	Distinction
 SHAH DIMPY AJIT	78	Distinction
 OSHIN BEHL	78	Distinction
 SANE SANYUKTA VILIN	77	Distinction
 WAGASKAR VIDYA GOVARDHAN	77	Distinction
 SUMANA MEHTA	77	Distinction
 SINHA AMIT AMIYA KUMAR	77	Distinction
 DESAI SHIVANI MAHENDRA	77	Distinction
 WAGH SUYOG SUNIL	76	Distinction
 IYER SRILOKA RANJANI VENKATARAMANAN	76	Distinction
 DESHMUKH SAIJASI SURYAKANT	76	Distinction
 PATIL TANVI MOHIT	76	Distinction
 DUBEY NIHAL ARVIND	76	Distinction
 PHATAK MAYURI RAGHUNATH	76	Distinction
AARATHY VELLALATH	75	Distinction
 SONAWANE TEJASHREE GOKUL	75	Distinction

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
		PATEL DHANANJAY KANTIBHAI	80	Distinction
1	<b>ENT</b>	THAKEKAR KETKI SUNIL	80	Distinction
	E.N.T.	IYER SRILOKA RANJANI VENKATARAMANAN	78	Distinction
11		NEMANI AAKRUTI ANIL	78	Distinction
		KHAN SAFA MAHVISH MOHAMMAD TARIQ	77	Distinction
		GURAV VEDANT SUBHASH	77	Distinction
		SANE SANYUKTA VILIN	76	Distinction
		WAGASKAR VIDYA GOVARDHAN	76	Distinction
		PATHAK VAISHNAVI NARAYAN	76	Distinction
		SONAWANE TEJASHREE GOKUL	76	Distinction
		HONWADKAR NINAD KISHOR	75	Distinction
		PAWAR NEIL DADASAHEB	75	Distinction
		TEKAWADE APURVA UMESH	75	Distinction
		BAGUL RAHUL PRAKASH	75	Distinction

L	RANK	COLLEGE	NAME OF THE STUDENT	MARKS	
	I	OVERALL	SHETTY SHRUTI SOMASHEKHAR	693	Distinction
	II	RANK	ARUNA MUTHUMANICKAM	679	Distinction

## Surgery : (03 : Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I	GENERAL	ARUNA MUTHUMANICKAM	240	Distinction
П	SURGERY	SHETTY SHRUTI SOMASHEKHAR	237	Distinction
		KEVIN KIRAN RAMBHIA	229	Distinction

## Obst & Gynec : (04 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I	OBST. &	SHETTY SHRUTI SOMASHEKHAR	158	Distinction
- 11	GYNA	SATWICK BHAVANA KISHOR	155	Distinction
		ARUNA MUTHUMANICKAM	150	Distinction
		KEVIN KIRAN RAMBHIA	150	Distinction

## Paediatrics : (07 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
		SHETTY SHRUTI SOMASHEKHAR	77	Distinction
PAEDIA	KEVIN KIRAN RAMBHIA	77	Distinction	
п	TRICS	VARSHA PATTANAIK	76	Distinction
II		MONTES DALE JUDE VIVIAN	76	Distinction
		ARUNA MUTHUMANICKAM	75	Distinction
		SATWICK BHAVANA KISHOR	75	Distinction
		NIDHI R NAIR	75	Distinction

\*\* Ms.Shetty Shruti Somashekhar stood <u>Fifth</u> in order of merit at III rd MBBS(P-II) MUHS exam. Winter-17. She was awarded by Vice Chancellor's Certificate of Merit from MUHS, Nashik

## MIMER MEDICAL COLLEGE, TALEGAON DABHADE DISTINCTION HOLDERS NAMES OF MUHS EXAMINATION WINTER 2016

## II nd MBBS

## Pharmacology : (11 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I		KOTHARI PRINCEKUMAR RAKESH	120	Distinction
11		THAKEKAR KETKI SUNIL	117	Distinction
11		MAKHIJA HITESH NARESH	117	Distinction
		SANE SANYUKTA VILIN	116	Distinction
		SHAH DIMPY AJIT	116	Distinction
	PHARMA.	KHAN SAFA MAHVISH MOHAMMAD TARI	114	Distinction
		DESHMUKH SAIJASI SURYAKANT	114	Distinction
		SUMANA MEHTA	114	Distinction
		DUBEY NIHAL ARVIND	114	Distinction
		BHATIA NAYANIKA SANJIV	113	Distinction
		SINHA AMIT AMIYA KUMAR	113	Distinction

#### Microbiology : (08 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
		GAPCHUP TEJAL RAJAN	119	Distinction
		HARIP ADITYA AMOD	119	Distinction
II		HONWADKAR NINAD KISHOR	117	Distinction
		SANE SANYUKTA VILIN	116	Distinction
	ICROBIOLO	KOTHARI PRINCEKUMAR RAKESH	116	Distinction
		SHARMA VEERENDRA NARENDRA	116	Distinction
		NEMANI AAKRUTI ANIL	114	Distinction
		SONWANE POOJA BHASKAR	114	Distinction

## FMT - (03 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I		HONWADKAR NINAD KISHOR	77	Distinction
II	F.M.T.	THAKEKAR KETKI SUNIL	76	Distinction
		NEMANI AAKRUTI ANIL	75	Distinction

## Third Year MBBS (Part - I)

## Overall : (05- Distinctions)

RANK	COLLEGE	NAME OF THE STUDENT	MARKS	
I	OVERALL	SHETTY SHRUTI SOMASHEKHAR	332	Distinction
II	RANK	KEVIN KIRAN RAMBHIYA	307	Distinction
		VARSHA PATTANAIK	306	Distinction
		SHETTY NIDHI VISHWANATH	301	Distinction
		ARUNA MUTHUMANICKAM	300	Distinction

#### **Community Medicine : (04 - Distinctions)**

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I		SHETTY SHRUTI SOMASHEKHAR	167	Distinction
II	Comm.	VARSHA PATTANAIK	158	Distinction
		KEVIN KIRAN RAMBHIYA	152	Distinction
		SHETTY NIDHI VISHWANATH	151	Distinction

## **Ophthalmology :( 07 Distinctions)**

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I		SHETTY SHRUTI SOMASHEKHAR	85	Distinction
П		BIHANI KAUMUDI SANJAY	78	Distinction
		KEVIN KIRAN RAMBHIYA	76	Distinction
	OPHTHAL.	MONTES DALE JUDE VIVIAN	76	Distinction
		ARUNA MUTHUMANICKAM	75	Distinction
		BHAGAT KARISHMA NARAYAN	75	Distinction
		SHASTRI ADITYA BIMAL	75	Distinction

## ENT : (09 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
1		ARUNA MUTHUMANICKAM	81	Distinction
1		SATWICK BHAVANA KISHOR	81	Distinction
Ш		SHETTY SHRUTI SOMASHEKHAR	80	Distinction
		KEVIN KIRAN RAMBHIYA	79	Distinction
	E.N.T.	SHETTY NIDHI VISHWANATH	79	Distinction
		NAIR GREESHMA GOPINATH	79	Distinction
		NAYAK NEHA GANESH	76	Distinction
		VARSHA PATTANAIK	75	Distinction
		BIHANI KAUMUDI SANJAY	75	Distinction

## FINAL MBBS

## Overall - (01-Distinction)

RANK	COLLEGE	NAME OF THE STUDENT	MARKS	
I OVERALL RANK	OVERALL	LIMAYE SAURABH VINAYAK	706	Distinction
	LIIVIATE SAUKADIT VINATAK	706 Dis	Distiliction	

## Medicine - (02 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I	GENERAL	LIMAYE SAURABH VINAYAK	234	Distinction
	MEDICINE	UDDIN AALIYA FAHIM	226	Distinction

## Surgery : (04 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
I		LIMAYE SAURABH VINAYAK	246	Distinction
	GENERAL	UDDIN AALIYA FAHIM	231	Distinction
11	SURGERY	NIRANKARI SWAPNIL RAVINDRA	231	Distinction
		GAITONDE TANVI MILIND	229	Distinction

## OBST & GYNA : (04 - Distinctions)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
		GAITONDE TANVI MILIND	152	Distinction
I	OBST.	KANEEZ FATIMA SYED BAQAR RAZA	152	Distinction
	& GYNA.	BARKASE AKANKSHA ARUN	152	Distinction
II		BALDOTA HEMINA AMRIT	150	Distinction

## Peds : (01 - Distinction)

RANK	SUBJECT	NAME OF THE STUDENT	MARKS	
1	PAEDIA	LIMAYE SAURABH VINAYAK	78	Distinction
	TRICS			

# MIMER MEDICAL COLLEGE, TALEGAON (D) 2.3.4.

# Copy of circular pertaining the details of mentor and their allotted mentees



Pathology Department <pathology@mitmimer.com>

## Mentorship form 2021

1 message

MIMER Mentor <mentorship@mitmimer.com> To: Department <department@mitmimer.com>

Wed, Mar 17, 2021 at 12:51 PM

Respected Madam / Sir.

Please find attached herewith, the new mentorship form for the year 2021. This form will be used hereon for the current and future mentorship programme. All pending mentorship forms of the previous years to be upgraded as per the current format. Kindly ensure back to back printing so as to use just 3 pages of paper and save this valuable resource.

Thanks and regards,

Dr Sushma Sharma Professor, Dept of OBGY.

#### 2 attachments

New Mentorship form 2021.pdf 276K

student admitted year 2020 -2021.xlsx 29K



## Mentorship programme for the new batch admitted in 2019.

1 message

OBST & GYNAE DEPARTMENT <gynaec@mitmimer.com> To: Department <department@mitmimer.com> Cc: sushma sharma <sushmas07@gmail.com> Fri, Oct 11, 2019 at 3:53 PM

Sir/ Madam,

This is with reference to mentorship programme for the new batch admitted in 2019.

Please go through the mentor and mentee distribution list as relevant to your department.

Also sending the student details of the same batch.

This will enable the mentor to fill in the mentorship form at their own level, as the same was not happening when left to the mentee.

Kindly ensure filling up of the same by November 10th 2019.

Mentorship committee members will be visiting individual departments to oversee the same. In case of any doubts, please feel free to contact me.


Regards,

Dr. Sushma Sharma Prof. & HOD Dept. of Obst. & Gyn.

#### 2 attachments

Mentor list of student admitted year 2019-2020.xlsx 18K

Student detail information 2019-20.xlsx 59K





Mon, Sep 17, 2018 at 10:50 AM

# Regarding Mentorship programme for batch admitted 2018-2019.

ressage

OBST & GYNAE DEPARTMENT <gynaec@mitmimer.com> Department <department@mitmimer.com>, STUDENT SECTION MIMER <student\_section@mitmimer.com>, PRINCIPAL MINER <principal@mitmimer.com> Respected Sir/ Madam, Please note the distribution of student under mentorship programme for the batch admitted 2018-2019 All HOD's are requested to ensure implementation of mentorship programme on regular basis . enclosure -1) Student List Student list with phone number 3) Mentorship form Please find the attachments. Thanking you Regards Dr. Sushma Sharma Professor Dept. of Obst. & Gyn 3 attachments Mentorship Form.pdf 741K डी Student list admitted year 2018 -19.xlsx 20K 到 STUDENTS PHONE NUMBER LIST.xlsx 32K wwa or Sust Reg



## MENTORSHIP PROGRAMME

1 message

## OPHTHALMOLOGY DEPARTMENT <ophthal@mitmimer.com>

Wed, Nov 29, 2017 at 10:11 AM

To: PRINCIPAL MIMER <principal@mitmimer.com>, Sushma Sharma <sushmas07@gmail.com>, "Dr. Alka Sontakke" <director\_admin@mitmimer.com>, Department <department@mitmimer.com>, Prajakta Sambarey compatible comparison c

Respected Sir/Madam,

Sending here with Mentorship list of 1st MBBS student with Mentorship form pls find attatchment.

Regards. Dr. Prajakta Sambarey Prof & Head Dept. of Ophthalmology

2 attachments

Mentorship Form (1).pdf

List of students 2017.18 FOR MENTORSHIP DISTRIBITION DR SAMBAREY.xlsx

8 17K



## **Mentorship Committee**

## CIRCULAR

Date: 23.08.2016

To,

Head of Department Pre, Para & Clinical Departments

Subject -Regarding Mentorship programme for batch admitted in 2016-2017.

Respected Sir/ Madam,

Please note the distribution of students under mentorship programme for the batch admitted in 2016- 2017. All HOD's are requested to ensure implementation of mentorship programme on regular basis.

Enclosures -1) Student List

2) Mentorship form

Thanking you

Dr. Sushma Sharma Professor, Dept. of OBGY MIMER Medical College Talegaon Dabhade

Year	Name of Training	Duration
2020.21	Revised Basic Course Workshop	24.03.2021 to
		26.03.2021
2020.21	CISP	29.09.2020 to
		30.09.2020
2019.20	Revised Basic Course Workshop	23.09.2019 to
		26.09.2019
2018.19	CISP	26.06.2019 to
		28.06.2019
2017.18	Basic Research Methodology	16.08.2018 to
		18.08.2018
2017.18	Basic Research Methodology	06.09.2017 to
		08.09.2017
2016.17	Basic Research Methodology	08.02.2017 to
		10.02.2017

## DEPARTMENT OF CLINICAL RESEARCH

## AND INCUBATION CENTER

## MIMER MEDICAL COLLEGE, TALEGAON

## DABHADE PUNE

(JAN 2021 onwards...)

## **Activities Conducted**

#### 1. Workshop-" Selection of Journal" on 30<sup>th</sup> March 2021

MAEER's MIMER Medical College & Dr.BSTR Hospital, Talegaon Dabhade, Pune

Department of Clinical Research & Incubation Center

#### WORKSHOP **SELECTION OF JOURNAL** Targeting the right journal for publishing your research

For : Faculty and PG Students of MIMER & College of Physiotherapy

Date : 30th March 2021 (Tuesday) Time : 2:15 PM Venue : Sushrut Hall

A faculty enrichment activity that aims to have an interactive session to help the researchers understand the various aspects to look for in a biomedical journal, and find the one that is most appropriate for publishing their research work.

#### FACULTY

Dr. Digant Gupta, MBBS, MPH (USA) Clinical Research Consultant, MIMER

Dr. Varoon C Jaiswal, MPTh, PhD scholar Professor, MAEER's Physiotherapy College (86 publications in international journals) Head, Research Dept., Physiotherapy College

#### CONTENT

- Overview of biomedical journals
   Indexing

- The Impact factor
   Publication models
   How to match the journal with your research
- 6. Understanding journal requirements
- Adapting your paper according to the journal guidelines
   Avoiding predatory journals
- Q & A Session 9


e-Certificates will be awarded Registration is free but compulsory E mail : research@mitmimer.com

Click on the active link below for Registration

https://forms.gle/V72ifctJtzpEdq9p7

#### 2.CME (Multidisciplinary)- "Mucormycosis: An Emerging Challenge in COVID -19" on

## 9<sup>th</sup> June 2021



This CME has been organized to present an overview of the condition from the perspective of some of the medical specialties involved in its management.

#### SPEAKERS :

- 1. DR SANTHOSH KUMAR 2. DR PRADNYA BHALERAO
- DR VIBHAVARI BARHATE
- 3. DR HARSH DESAI
- 4. DR SANTOSH SABNIS
- 5. DR SADHNA CHATE
- 6. DR RAJENDRA ZOPE

DEPT. OF OPHTHAL. DEPT. OF DENTISTRY DEPT. OF RADIOLOGY DEPT. OF MICROBIOLOGY DEPT. OF PATHOLOGY

DEPT. OF ENT

DEPT. OF OPHTHAL.

RECOMMENDED FOR FACULTY PG STUDENTS INTERNS

For more information : E mail research@mitmimer.com

#### 3. CME (Webinar)- "Mucormycosis: All that we know today!" on 9th July 2021







MIMER Medical College has organized a CME (Webinar) to equip the medical professionals with the basic knowledge and practical aspects of treating Post-COVID Mucormycosis. It is an opportunity to interact with the experts from different specialties and understand more about the condition, as they share their experience in managing this potentially fatal fungal infection.

#### FACULTY

- DR VIRENDRA GHAISAS MS (ENT), Rhinoplasty Fellowship (Germany) Renowned ENT/Rhinoplasty Surgeon/Author Executive Director, MIMER Medical College & Dr.BSTR Hospital
- DR PARIKSHIT PRAYAG MD, ABIM, ABMS (American Board Certified) Infectious Diseases Consultant, Deenanath Mangeshkar Hospital
- DR SANDEEP KARMARKAR MBBs,DORL, FAINOL (Italy) Senior ENT Surgeon, Ruby Hall Clinic Consultant - Endoscopic Skull Base Surgeon/ Otoneurologist
- COL DR RAJENDRA PRASAD GUPTA MS (Ophthal.), FMRF (V R surgeon)
  Professor Emeritus, Ophthalmology
  Former Principal, MIMER Medical College & Dr.BSTR Hospital
- DR HARSH DESAI MDS (Maxillofacial Surgery) Maxillo-Facial Surgeon & Asst. Professor, MIMER Medical College
- COL DR S S THIND MD (Radiodiagnosis) Senior Radiologist, Pune Professor & Head, Dept. of Radiodiagnosis, MIMER
- DR RENU BHARADWAJ MD (Microbiology) Senior Microbiologist & Visiting Professor Former Dean, BJ Govt. Medical College
- DR SHARADA RANE MD (Pathology)
  Dy. Dean, Govt. Medical College & Hospital, Baramati
  Professor & Head, Dept. of Pathology

RECOMMENDED FOR : MEDICAL PRACTITIONERS, PG & UG STUDENTS, INTERNS

CLICK ON THE ACTIVE LINK BELOW TO REGISTER

https://forms.gle/PjJdd6PCuMCWZZom9

MAEER's MIMER Medical College & Dr.BSTR Hospital, Talegaon Dabhade, Pune

Department of Clinical Research & Incubation Center / research@mitmimer.com APPROVED BY MAHARASHTRA MEDICAL COUNCIL FOR ONE CREDIT POINT NO: MMC/Accre.Cert/MED-0022/2013/ Webinar Code - MMC/WEB/2021/F-000775 4. Workshop- "Conduct of Journal Club" on 18<sup>th</sup> Aug 2021



MAEER'S MIMER Medical College & Dr.BSTR Hospital, Talegaon Dabhade, Pune Department of Clinical Research & Incubation Center

## WORKSHOP CONDUCT OF JOURNAL CLUB

An enrichment activity that aims to train the faculty and PG students on the basic elements of critically reviewing a research paper and on the effective conduct of journal club.

Date	:	18 <sup>th</sup> August 2021 (Wednesday)
Time	:	2:15 to 3:45 PM
Venue	:	Sushrut Hall
Faculty	:	Dr. Digant Gupta

- · For faculty and PG students
- Hands-on activities
- e-certificates
- · Online registrations closed
- Limited SPOT REGISTRATIONS

#### Achievements

- MoU signed between MIMER Medical College, Talegaon Dabhade and DY Patil International University Akurdi Pune for Summer Internship to BSc Biotechnology students of DYPIU in Central Clinical Laboratory of MIMER Medical dated 12<sup>th</sup> Feb 2021 for a period of 03 years.
- 2. Letter of Sanction of Grants issued on 25<sup>th</sup> June 2021 to 11 undergraduate students for research projects.
- "Certificate Course in Clinical Research" inaugurated by Honorable Managing Trustee of MAEER'S group, Shri Rahul V Karad Sir on 15<sup>th</sup> July 2021
- 4. MoU signed between MIMER Medical College and Dr BSTR Hospital Talegaon Dabhade Pune and Dr D Y Patil Medical College Hospital and Research Centre, Dr DY Patil

Vidyapeeth (DPU), Pimpri Pune to form a collective research group for conduction of a research project entitled" Application of American Joint Committee on Cancer Eighth Edition Prognostic Stage Groups in Primary Breast Cancer Patients at a Tertiary Care Centre in Western Maharashtra" dated 13<sup>th</sup> Sept 2021 for a period of 03 years.

## Important Milestones ......

- 06 Research Projects submitted to the Tuberculosis Association of India for Financial Assistance – 31<sup>st</sup> March 2021
- 2. 02 Research Proposals sent to ICMR- Covid  $19 30^{th}$  June 2021
- 3. Discussions of Research Projects with Faculty, Residents and UG students for submission to IEC
  - 26<sup>th</sup> July- 07 projects
  - 5<sup>th</sup> Aug-05 projects
- 4. Online Training Course on Introduction to Data Analysis, Aug 09-11,2021- 02 faculty sponsored by Institute.
- 5. Online Training Course on Demographic Data Analysis for Health Personnel, Aug 23-25,2021- 02 faculty sponsored by Institute
- 2 new members appointed to the Dept of Clinical Research & Incubation Centre
   Dr Priyanka Murgod, Associate Professor, Dept of Pathology
  - Dr. Ashish Arya, Assistant Professor, Dept of Psychiatry
- 7. A Working Template for Reviewing a Research Article/ Conduct of a Journal Club Prepared by Dr Digant Gupta circulated to all departments. The Departments are also Instructed to display the same in the departmental seminar hall for reference during journal club activities. If conveyed in advance about the journal club activity, the Research Consultant/ member from DCRIC can also attend and give inputs.

## **Departmental Meetings Conducted**

- 1. 27<sup>th</sup> Jan 2021
- 2. 16<sup>th</sup> June 2021
- 3. 7<sup>th</sup> Sept 2021

#### DEPARTMENT OF CLINICAL RESEARCH AND INCUBATION CENTER

#### MIMER MEDICAL COLLEGE, TALEGAON DABHADE PUNE

(DEC 2019- DEC 2020)

#### **Activities Conducted**

- Young Researchers Symposium 2020 on 17<sup>th</sup> Feb 2020, Lecture: Scientific Paper Writing, Speaker: Dr Digant Gupta
- Seminar: "Reorientation to Clinical Research A New Outlook" on 19<sup>th</sup> May 2020 Speaker: Dr Digant Gupta
- Collaboration with MIMER Student Research Council (SRC) in conducting "1<sup>st</sup> National Healthcare Digital Symposium 2020" on 6<sup>th</sup> June 2020
- Webinar: "Clinical Research in Medical Institutes in India" on 10<sup>th</sup> June 2020 MUHS Foundation Day.
  - Speaker: Dr Digant Gupta
- Webinar: "Covid -19: Pathogenesis| Diagnosis|Management- Sharing what we know today" on 11<sup>th</sup> June 2020.
  - Speakers: Dr Sameer Melinkeri, Dr Sampada Patwardhan, Dr Parikshit Prayag
- Webinar: "Data Entry and Analysis" on 29<sup>th</sup> June 2020. Resource faculty: Dr Digant Gupta, Dr Swati Raje
- Webinar: "Reference Management Software " on 2<sup>nd</sup> July 2020 by Dr. Varoon Jaiswal and Dr. Digant Gupta
- Webinar: Artificial Intelligence: The scope in Covid Pandemic by Dr Arun Jamkar on 10<sup>th</sup> July 2020
- 9. Find your Icon- Medical Superspecialities Dr. Viren Attarde, Dr. Ashwin Rajbhoj, Dr. Mahadevan

Dr. Saurabh Sancheti, Dr. Anuj Nehete on 14th July 2020

- 10. The Soldiers in White Coat- Bracing for the emerging challenges Dr. Madhuri Kanitkar 21<sup>st</sup> July 2020
- 11. Meet your Icons- Surgical Superspecialists Dr.Aditi Rangnekar.Dr. Vishvesh Agarwal. Dr Kunal Bansal. Dr Monish Patil. Dr Prashant Sawant on 5<sup>th</sup> Aug 2020
- 12. "How to Develop a Research Proposal" by Dr Digant Gupta and Dr Varoon Jaiswal on 20th Oct 2020
- 13. Workshop on Orientation to Methods in Clinical Research: Part I Development of Synopsis for JR 1 & PG guides. 4<sup>th</sup> and 5<sup>th</sup> November 2020
- 14. Dissertation Synopsis- Meeting Schedule with Research Committee: 24<sup>th</sup> -27<sup>th</sup> Nov 2020
- 15. Follow up meeting : Dissertation Synopsis: 3<sup>rd</sup> and 4<sup>th</sup> Dec 2020
- 16. Workshop on Orientation to Central Research Laboratory- 9<sup>th</sup>,11<sup>th</sup>,14<sup>th</sup> and 16<sup>th</sup> Dec 2020 Faculty: Dr Shashwat Banerjee, Dr Yuvraj, Dr Chate

#### Achievements

- 1. 13 projects approved for ICMR STS 2020
- 2. Funding of student projects to be borne by institution after due evaluation. This is a landmark decision taken by the Management which clearly explains their commitment to foster research culture among students.

#### Important Milestones ......

- 1. Timetable 2020-2021 for Departmental activities prepared
- 2. Module for UG Research Course prepared
- Covid Research Consultancy Services- for external faculty/ institutes/ hospitals launched on 21<sup>st</sup> May 2020
- 4. Consultancy Services for Inhouse Faculty and students launched on 21<sup>st</sup> May 2020
- 5. Format for Submission of Research proposal to Institutional Ethics Committee of MIMER Medical College, Talegaon D prepared
- 6. Departmental website created.
- 7. The faculties of the various departments have contributed to prepare a bank of topics for thesis.

#### **Departmental Meetings Conducted**

- 1. 13<sup>th</sup> Dec 2019
- 2. 3<sup>rd</sup> Feb 2020
- 3. 19<sup>th</sup> May 2020
- 4. 17<sup>th</sup> June 2020
- 5. 3<sup>rd</sup> Aug 2020
- 6. 6<sup>th</sup> Aug 2020
- 7. 20<sup>th</sup> Oct 2020



• Website : www.mitmimer.com Email :-info@mitmimer.com

## Details of ICT-enabled tools used for teaching and learning

Sr. No	ICT tools
1	Computer with internet facility
2	LCD Projector with screen
3	Wi-Fi access
4	Scanner & printer, Photocopier
5	DVDs & CDs
6	Microphones
7	SPSS Software
8	Delnet
9	Digital Camera
10	Pen drive
11	Tablet

#### E-resources and techniques used for teaching and learning

Sr. No	E-resources
1	e- books & e- journals
2	Power point Presentations
3	You tube video lectures
4	Webinars
5	Online databases
6	Presentations from Slide share
7	Virtual encyclopedia
	Online (videoconferencing) lectures using ZOOM,
8	Google Meet and Microsoft Teams
9	Google Classroom
10	Kahoot quizzes

incipal MIMER Medical College Talegaon Dabhade - 410 507

## MIMER MEDICAL COLLEGE, TALEGAON DABHADE

## **Student Funded Research Projects**

Year	ICMR	STRG MUHS
2020-21	13	Nil
2019-20	11	15
2018-19	11	Nil
2017- 18	02	Nil
2016- 17	Nil	Nil

Mus

PRINCIPAL MIMER MEDICAL COLLEGE TALEGAON DABHADE PUNE 410507



## Mumbai Mumbai News

# Nanorobot technology might soon be India's new cancer weapon

o5 July,2020 05:49 AM IST | Mumbai <u>Vinod Kumar Menon</u> | vinodm@mid-day.com





A junior scientist seen in the laboratory of MIMER Medical college, where the technology is being researched

A team of cancer scientists in Pune are researching a unique nanorobot technology that

 <u>They shouldn't have gone to</u> <u>deserted place: K'taka Home</u> <u>Minister on Mysuru rape</u>

Game Zone

**More Games** 

Manjul

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our **Privacy Policy** and **Cookie Policy**.

# **SCIENTIFIC** REPORTS

natureresearch

# **OPEN** Self-Propelling Targeted Magneto-**Nanobots for Deep Tumor Penetration and pH-Responsive Intracellular Drug Delivery**

Saloni S. Andhari<sup>1,4</sup>, Ravindra D. Wavhale<sup>2,4</sup>, Kshama D. Dhobale<sup>2</sup>, Bhausaheb V. Tawade<sup>2</sup>, Govind P. Chate<sup>2</sup>, Yuvraj N. Patil<sup>2</sup>, Jayant J. Khandare<sup>3\*</sup> & Shashwat S. Banerjee<sup>2\*</sup>

Self-propelling magnetic nanorobots capable of intrinsic-navigation in biological fluids with enhanced pharmacokinetics and deeper tissue penetration implicates promising strategy in targeted cancer therapy. Here, multi-component magnetic nanobot designed by chemically conjugating magnetic Fe<sub>3</sub>O<sub>4</sub> nanoparticles (NPs), anti-epithelial cell adhesion molecule antibody (anti-EpCAM mAb) to multiwalled carbon nanotubes (CNT) loaded with an anticancer drug, doxorubicin hydrochloride (DOX) is reported. Autonomous propulsion of the nanobots and their external magnetic guidance is enabled by enriching Fe<sub>3</sub>O<sub>4</sub> NPs with dual catalytic-magnetic functionality. The nanobots propel at high velocities even in complex biological fluids. In addition, the nanobots preferably release DOX in the intracellular lysosomal compartment of human colorectal carcinoma (HCT116) cells by the opening of Fe<sub>3</sub>O<sub>4</sub> NP gate. Further, nanobot reduce ex vivo HCT116 tumor spheroids more efficiently than free DOX. The multicomponent nanobot's design represents a more pronounced method in targeting tumors with selfassisted anticancer drug delivery for 'far-reaching' sites in treating cancers.

Designing miniaturized and versatile robots in the dimensional-range of a few micrometers or less offer potential for unprecedented biomedical applications, such as refinements in targeted drug delivery platforms<sup>1-7</sup>. Miniature robotic systems provide considerable benefits over conventional and micro/nanoparticle-based therapies<sup>8,9</sup>. Existing anticancer drug delivery systems demonstrate pharmacokinetic (PK) limitations as they are passive systems driven by the blood fluidics and lack intrinsic navigation for long circulation time, targeting, localized delivery, and tissue penetration<sup>10,11</sup>. Furthermore, despite surface functionalization with a specific ligand that allows nanocarriers to increase the active targeting ability; the nanocarriers are unable to guide themselves to a target. Hence, for targeted anticancer delivery of therapeutic payloads to disease sites, drug carriers are desired to possess some distinctive traits, including self-propelling force and velocity, navigational functions, precise cell targeting, drug cargo-towing and finally tissue penetration with the release of drug payload<sup>12-16</sup>.

Micro/nanomotors with efficient cargo towing and effective penetrating abilities make them excellent delivery vehicles that can meet the necessary features for targeted delivery of therapeutics<sup>6</sup>. Chemically propelled micro-/ nanorobots have been widely explored for active drug delivery, and tremendous progresses has been made in the past few years<sup>17</sup>. However, designing nanobots for biological functionality is still a challenge as they have some inherent limitations, such as complex preparation technology, difficulty of surface modification, difficulty of motion in biological fluids and depending on the material, poor biocompatibility or biodegradability<sup>6,18,19</sup>. Furthermore, none of the reported micro/nanobot system has demonstrated practically useful speed high enough for biomedical applications due to high-speed blood flow in human arteries (dimensions from 4 to 25 mm) with a blood flow velocity from 100 to 400 mm/s<sup>20</sup>.

Herein, we report for the first time a smart H<sub>2</sub>O<sub>2</sub> and pH-responsive nanobot system to transport anticancer drug deep inside the three dimensional (3D) tumors by exploiting  $Fe_3O_4$  dependent decomposition of  $H_2O_2$ 

<sup>1</sup>Maharashtra Academy of Engineering Education and Research's Maharashtra Institute of Pharmacy, Pune, 411038, India. <sup>2</sup>Maharashtra Institute of Medical Education and Research, Talegaon Dabhade, Pune, 410507, India. <sup>3</sup>School of Pharmacy, Dr. Vishwanath Karad MIT World Peace University, Pune, 411038, India. <sup>4</sup>These authors contributed equally: Saloni S. Andhari and Ravindra D. Wavhale. \*email: jayant.khandare@mippune.edu.in; shashwatbanerjee@ mitmimer.com





C NTINI SIDERTY

rsc i//material8-b

Novel Adsorbents for Water Treatment

Shashwat Banerjee



Shashwat Banerjee

## Application of Simple and Modified Adsorbents in Water Treatment

Novel and Inexpensive Adsorbents for Treating Major Water Pollutants




#### Shashwat Banerjee

Shashwat banejee received his PhD in Chemistry from the Institute of Chemical Technology, University of Mumbai in 2003. After postdoctoral work at the National Cheng Kung University and Washington State University, he joined Piramal Life Sciences Ltd. as a Research Scientist, His research interest is in surface chemistry and biomaterials.



LAMBERT Academic Publishing



## SR/NM/NS-1189/2016(G)

Government of India Ministry of Science & Technology Department of Science & Technology (Neno Mission)

> Technology Bhavan New Mehrauli Road New Delhi -110 016 Dated: 16,08,2017

#### <u>ORDER</u>

Sub: Financial assistance for the technology project entitled "Self-propelled water driven nanomachine for rapid capture and isolation of circulating tumor cells." under the guidance of Prof.Shashwat Banerjee, Associate Professor, Central Research Laboratory, Maharashtra Institute of Medical Education and Research (MIMER) Medical College, Talegaon Dabhade. Dist Pune 410507.:regarding release of 1<sup>st</sup> installment of the grant.

Sanction of the President is accorded to the approval of the mentioned project at a total cost of **Rs. 48,76,944/- (Rupees Forty-Eight Lakh Seventy-Six Thousand Nine Hundred and Forty-Four Only)** for a duration of 3 years. The detailed break-up of the grant General as well as Capital Components are given below:-

#### General Component: Rs. 39,26,944/-Capital Component: Rs. 9,50,000/-

\_\_\_\_

1.29 . .

na na zazi Na seriese	Budget Head	I" year	2 <sup>nd</sup> year	3 <sup>rd</sup> year	Total
2 654569	Manpower-as per DST norms				
viu line du	1 RA: @ INR.36.000/- p.m. +HRA@30% for 3 years.	8.25.600	8,25,600	8.25,600	24,76,800
ne versieder of de Versie der Robert			lan, thé ≞ •ga na ang		
l forme frank Lender franklige Stationer i fra	Equipment Inverted Fluorescence Microscope	9,50,000	NIL NIL NIL NIL	nan <b>-NIC-</b> Collin Statument	- <b>9_50</b> ,000 <sup>°  </sup>
	Consumables	3,50,000	2.50.000	2,00,000	8,00.000
en den diezezez	National Travel	50.000	50,000	50,000	1.50.000
-1621 (17769) 	Contingencies	50.000	50,000	50,000	1.50.000
s that yealor	Sub-total	22,25,600	11,75,600	11,25,600	45,26,800
	Overhead Charges (@8% of Total project cust)	1,74,048	90.048	<b>86,048</b> - <sup>2</sup> 1	3,50,144
	Tale]	23,99,648 <sup>-</sup>	12,65,648	12,11.648	48.76.944

3. The sanction of the President is accorded to the release of Rs. 13,87,000/- (Rupees Thirteen takh Eighty-Seven Thousand only) to "The Director, Maharashtra Institute of Medical Education and Research (MIMER) Medical, College, Talegaon Dabhade, Dist. Pune 410507% being the first installment of the grant under Grants-in-aid General' for implementation of above mentioned project

4. This sanction is subject to the condition that the grantee organisation will furnish to the Department of Science & Technology, financial year-wise Utilization Certificate (UC) in the proforma prescribed as per GFR 2017 and audited statement of expenditure (SE) along with up to date progress report at the end of each financial year duly reflecting the interest earned/accrued on the grants received under the project. This is also subject to the condition of submission of the final statement of expenditure, itilization certificate and project completion report, within one year, from the scheduled date of the project.

5. The grantee organisation will have to enter & upload the Utilization Certificate in the PFMS portal \_\_\_\_\_besides\_sending.it\_in physical form to this Division? The subsequent/final instalment will be released only after confirmation of the acceptance of the UC by the Division and entry of previous Utilization and entry of previous Utilization of the PFMS.

· ·	1-00120-2	Cont. on page no2-
:	17 1. Sec. 19 1. 19	R768 (FS0 07.1
	经销售 异种间的 医乙酰氨酸丁酮	
Approximation and the matrix of the	an a	1

#### No. BT/PR21922/NNT/28/1241/2017 GOVERNMENT OF INDIA -MINISTRY-OF-SCIENCE & TECHNOLOGY DEPARTMENT OF BIOTECHNOLOGY

ſ

Block 2, 6-8th Floors CGO Complex, Lodhi Road, New Delhi- 110 003 Dated: 20 / 03/2018

#### ORDER

Sanction of the President is hereby accorded, under Rule 18 of the Delegation of Financial Powers Rules ,1978 , for the Implementation of the project entitled: "Self-propelled magnetically controlled nanorockets for transportation and pH triggered drug delivery" for a period of 3 Year 0 Month at a total cost of Rs. 4159400 (Rupees Fourty One Lakhs Fifty Nine Thousand Four Hundred Only) on the terms and conditions detailed here under:-• • 2 The Protect • 

.

		d pH triggered d				
2.2	Details of th	e Investigati <u>or</u> s:	· · · · · - · ·		·- ·	
	Principal In	vestigators:				
		at Banerjee			- <del>,</del>	
	PI			· · · · · · · · · · · · · · · · · · ·		
	MIMER Medic	al College Talegao		· · · ·		· · _ ·
	. Maharashtra Sciences	University of Healt	h		1.267.77.4 	· · · · · · · · · · · · · · · · · · ·
	MIMER Medic	al College	100.53	$(e_{i},e_{i}) \in \{e_{i}\}$	T RUR LEDY C	· · · · · · · · · · · · · · · · · · ·
	Talegaon Dat Pune Maharas	ohade, shtra, 410507				
		Helio kansi tigʻr		··· · ··		n na ser
	CO-PI:					
	Dr. Jayant 🖡					
		faltar montur	111 <u>11</u> 111			
	Pharmacy			 e		
	Pharmacy Maharashtra	Institute of Techno			· · · · · · · · · · · · · · · · · · ·	
	Pharmacy Maharashtra Engineering Maharashtra	Institute of Techno Institute of Pharma	logy College o		torna († 1945 - Land	n an
	Pharmacy Maharashtra Engineering Maharashtra Campus, Koth	Institute of Techno Institute of Pharma inid, Puné, India,	logy College o acy, MIT Solapur			
	Pharmacy Maharashtra Engineering Maharashtra Campus, Koth	Institute of Techno Institute of Pharma	logy College o acy, MIT Solapur			
	Pharmacy Maharashtra Engineering Maharashtra Campus, Koth	Institute of Techno Institute of Pharma inid, Puné, India,	logy College o acy, MIT Solapur			
	Pharmacy Maharashtra Engineering Maharashtra Campus, Koth	Institute of Techno Institute of Pharma inid, Puné, India,	logy College o acy, MIT Solapur			
_	Pharmacy Maharashtra Engineering Maharashtra Campus, Koth	Institute of Techno Institute of Pharma arashtra	logy College o acy, MIT Solapur		nin de l' 1933 - La Standol 1935 - La Standol	
-	Pharmacy Maharashtra Engineering Maharashtra Campus, Koth	Institute of Techno Institute of Pharma and, Puné, India, arashtra	logy College o scy, MIT Solapur		2000 (00) 2000 (00) 2000 (00) 2000 (00)	
- ,	Pharmacy Maharashtra Engineering Maharashtra Campus, Koth	Institute of Techno Institute of Pharma arashtra	logy College o acy, MIT Solapur		2000 (00) 2000 (00) 2000 (00) 2000 (00)	
- ,-	Pharmacy Maharashtra Engineering Maharashtra Campus, Koth	Institute of Techno Institute of Pharma and, Puné, India, arashtra	logy College o scy, MIT Solapur		2000 - 00 2000 - 2000 2000	
	Pharmacy Maharashtra Engineering Maharashtra Campus, Koth	Institute of Techno Institute of Pharma and, Puné, India, arashtra	logy College o acy, MIT Solapur		2000 00 1 2000 2001 2000 2000 2000 200 2000 200 2000 200	
- ,-	Pharmacy Maharashtra Engineering Maharashtra Campus, Koth	Institute of Techno Institute of Pharma and, Puné, India, arashtra	logy College o		2000 - 00 2000 - 2000 2000	

Generated through eProMIS

ſ

	Reco
एक सो रुपये	<b>IS. 100</b>
	ONE
755100 HUN	DREDIRUPEES
ATTER INDIA	
् महाराष्ट्र MAHARASHTRA 0 2018 0	<u>TL_030598</u>
दस्ताचा प्रकार/अनुकोद क्रमांक से से में द्वाहान झौ कु झेकीमेंट	The The Strafters
िः ् दस्त नॉदणी काशीत आहेत का 😁 ———————————————————————————————————	Banta Dian
ू तिद्धी होणार असल्यास दुय्यम निषयक कार्यालयाचे नाव प्रित्यकतीचे वर्णन्	2 <sup>2</sup> 35 SEP 2018
र्थः स्वयंत्राच वर्णः हेः हेः मोवदला रक्तम्	4
	उप की थोगार अधिकारी
दुगऱ्य पश्वकाराचे नाव	र्स्स च लोकगांग १०
हरने असल्यास राव व पता- स्तुनिमेठ द्या आ छाने - हर 65	
मुद्रांक गुल्क रक्षान	
ि मुद्रा क विकत पेष्ट्रान्याची सही	
AS A	
المعلمة معلمة المعلمة معلم	MENT
्रिजामाल घोढ, तलेगांव राघडे. This MEMORANDUM OF AGREEMENT is mad	$e$ on this $A^{th}$ dev. of
October Two thousand and Eighteen BY ND BETWEEN acting through, Department of Biotechnology, Minist Technology, Government of India, New Delhi, hereinaft 'DBT' (which expression unless excluded by or repugnan mean and include its successor-in-office and assigns) of life	I President of India, ry of Science and er referred to as the to the subject shall ONE PART;
Dr. R P GUPTA PRINCIPAL MiMER Medical Collége Talegaon Dabhade, Pune - 410507.	Contd.pg:2/-
μ	

•

• • • •

. .

. .

Maharashtra Institute of Medical Education and Research (MIMER) Medical College, Talegaon Dabhade, a society under the Societies Registration Act-1860, having its registered office in/at Yashwant Nagar, Talegaon Dabhade 410507, hereinafter referred to as 'MAEER's Maharashtra Institute of Medical Education and Research' (which expression shall where the context so admits include its successors and permitted assigns) of the OTHER PART;

WHEREAS DBT being desirous of Nanosystems for cancer therapy decided to support a project submitted by Maharashtra Institute of Medical Education and Research (MIMER) Medical College, Talegaon Dabhade for the attainment of the objectives, hereinafter described in the Annexure I annexed hereto;

, This Memorandum of Agreement (MoA) defines the role and responsibilities of the participating agencies, monitoring and other matters related to the Self-propelled magnetically controlled nanorockets for transportation and pH triggered drug 👍 delivery.

NOW THE PARTIES HERETO AGREE AS FOLI

the st

 $\odot$ 

## 1.9., ROLE OF DEPARTMENT OF BIOTECHNOLOGY, NEW DELHT

To provide funds to the extent of 41, 59,400/- over a period of 3 years from the date of , sanction of the project, to 14, March 2021 for undertaking activities as detailed in Annexure 1. Details of the funds to be provided are given in Annexure II.

ROLE OF Maharashtra Institute of Medical Education and Research (MIMER) Medical College, Talegaon Dabhade and San Antonio with the second second second states of the second s

To provide their contribution of Nil for NA years from date of sanction of the 2.1. 3305351 project as detailed in Annextire - II. (if a jointly supported project) To provide existing facilities as mentioned in the project document.

To be responsible for accomplishing objectives identified and activities listed.

MIMER Medical College Talegaon Dabhade; Pune - 419507.

يدتجر بدو

# **SCIENTIFIC** REPORTS

natureresearch

# **OPEN** Self-Propelling Targeted Magneto-**Nanobots for Deep Tumor Penetration and pH-Responsive Intracellular Drug Delivery**

Saloni S. Andhari<sup>1,4</sup>, Ravindra D. Wavhale<sup>2,4</sup>, Kshama D. Dhobale<sup>2</sup>, Bhausaheb V. Tawade<sup>2</sup>, Govind P. Chate<sup>2</sup>, Yuvraj N. Patil<sup>2</sup>, Jayant J. Khandare<sup>3\*</sup> & Shashwat S. Banerjee<sup>2\*</sup>


Self-propelling magnetic nanorobots capable of intrinsic-navigation in biological fluids with enhanced pharmacokinetics and deeper tissue penetration implicates promising strategy in targeted cancer therapy. Here, multi-component magnetic nanobot designed by chemically conjugating magnetic Fe<sub>3</sub>O<sub>4</sub> nanoparticles (NPs), anti-epithelial cell adhesion molecule antibody (anti-EpCAM mAb) to multiwalled carbon nanotubes (CNT) loaded with an anticancer drug, doxorubicin hydrochloride (DOX) is reported. Autonomous propulsion of the nanobots and their external magnetic guidance is enabled by enriching Fe<sub>3</sub>O<sub>4</sub> NPs with dual catalytic-magnetic functionality. The nanobots propel at high velocities even in complex biological fluids. In addition, the nanobots preferably release DOX in the intracellular lysosomal compartment of human colorectal carcinoma (HCT116) cells by the opening of Fe<sub>3</sub>O<sub>4</sub> NP gate. Further, nanobot reduce ex vivo HCT116 tumor spheroids more efficiently than free DOX. The multicomponent nanobot's design represents a more pronounced method in targeting tumors with selfassisted anticancer drug delivery for 'far-reaching' sites in treating cancers.

Designing miniaturized and versatile robots in the dimensional-range of a few micrometers or less offer potential for unprecedented biomedical applications, such as refinements in targeted drug delivery platforms<sup>1-7</sup>. Miniature robotic systems provide considerable benefits over conventional and micro/nanoparticle-based therapies<sup>8,9</sup>. Existing anticancer drug delivery systems demonstrate pharmacokinetic (PK) limitations as they are passive systems driven by the blood fluidics and lack intrinsic navigation for long circulation time, targeting, localized delivery, and tissue penetration<sup>10,11</sup>. Furthermore, despite surface functionalization with a specific ligand that allows nanocarriers to increase the active targeting ability; the nanocarriers are unable to guide themselves to a target. Hence, for targeted anticancer delivery of therapeutic payloads to disease sites, drug carriers are desired to possess some distinctive traits, including self-propelling force and velocity, navigational functions, precise cell targeting, drug cargo-towing and finally tissue penetration with the release of drug payload<sup>12-16</sup>.

Micro/nanomotors with efficient cargo towing and effective penetrating abilities make them excellent delivery vehicles that can meet the necessary features for targeted delivery of therapeutics<sup>6</sup>. Chemically propelled micro-/ nanorobots have been widely explored for active drug delivery, and tremendous progresses has been made in the past few years<sup>17</sup>. However, designing nanobots for biological functionality is still a challenge as they have some inherent limitations, such as complex preparation technology, difficulty of surface modification, difficulty of motion in biological fluids and depending on the material, poor biocompatibility or biodegradability<sup>6,18,19</sup>. Furthermore, none of the reported micro/nanobot system has demonstrated practically useful speed high enough for biomedical applications due to high-speed blood flow in human arteries (dimensions from 4 to 25 mm) with a blood flow velocity from 100 to 400 mm/s<sup>20</sup>.

Herein, we report for the first time a smart H<sub>2</sub>O<sub>2</sub> and pH-responsive nanobot system to transport anticancer drug deep inside the three dimensional (3D) tumors by exploiting  $Fe_3O_4$  dependent decomposition of  $H_2O_2$ 

<sup>1</sup>Maharashtra Academy of Engineering Education and Research's Maharashtra Institute of Pharmacy, Pune, 411038, India. <sup>2</sup>Maharashtra Institute of Medical Education and Research, Talegaon Dabhade, Pune, 410507, India. <sup>3</sup>School of Pharmacy, Dr. Vishwanath Karad MIT World Peace University, Pune, 411038, India. <sup>4</sup>These authors contributed equally: Saloni S. Andhari and Ravindra D. Wavhale. \*email: jayant.khandare@mippune.edu.in; shashwatbanerjee@ mitmimer.com



**Figure 1.** (A) Schematic representation of mechanism of oxygen bubble induced autonomous propulsion of nanobot and deep penetration in the tumor due to the generated thrust, fate of 3D spheroid treated with CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf/CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb nanobot, trajectories of nanobots in physiologically relevant media (trajectories obtained using Dino-Capture 2.0 v (https://www.dino-lite.com/), VirtualDub 1.10.4 v (http://www.virtualdub.org/) and MTrackJ plugin from ImageJ 1.8.0\_112v (https://imagej.net/MTrackJ), followed by illustration of targeting DOX-loaded nanobot to transferrin/EpCAM receptor and entry in cancer cell, and finally, mechanism of triggered drug release under intracellular endo/lysosomal conditions. (B) Schematic illustration indicating the step-by-step synthesis of DOX loaded CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf/ CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb.

existing in the tumor microenvironment (TME) into water and oxygen. Tumor cells are known to produce  $H_2O_2$ at the rate of 0.5 nmol/10<sup>4</sup> cells/h<sup>21</sup>. The nanobot was designed by chemically coordinating Fe<sub>3</sub>O<sub>4</sub> NPs, conjugating anti-EpCAM mAb to carbon nanotubes (CNT) through reactive spacer glutathione (GSH) and loading of anticancer drug DOX. The unique advantages of anchoring Fe<sub>3</sub>O<sub>4</sub> NPs are, as they impart autonomous propulsion ability and superparamagnetic property to the nanobot system. Further they also impart mechanism of "on demand" intracellular release of the encapsulated DOX. Thus, the Fe<sub>3</sub>O<sub>4</sub> NP gates retard premature and non-specific release of DOX encapsulated in CNT thus minimizing therapy side effects. CNT platform was utilized as a carrier because it offers the benefit of chemical tunability, allowing integration of multiple component by conjugation chemistry including targeting moieties<sup>22</sup>. Importantly, functionalized CNTs have shown low toxicity and enhanced clearance, and even can be decomposed inside the human body<sup>23</sup>. CNTs with such advantages have been exploited to deliver various bioactive substances and contrasting agents. However, they have primarily been used as passive nanocarriers. Here, we have transformed passive CNTs into active autonomous nano-propelled-bots with controlled anticancer drug delivery platform, cellular specificity, targeting and deep 3D tumor penetration capability (Fig. 1A). Further, Fe<sub>3</sub>O<sub>4</sub>-catalyzed *in-situ* generation of oxygen from TME H<sub>2</sub>O<sub>2</sub> may also help in relieving tumor hypoxia with potential augmentation of antitumor influence. The present work, demonstrates a nanobot drug delivery platform that facilitates propulsion in biological fluids, cellular targeting, modulates the intracellular release and enhanced penetration to TME for improved anti-cancer therapy.

#### **Results and discussion**

**Antibody/Tf-targeted nanobot conjugation and characterization.** Tf and anti-EpCAM mAb conjugated nanobots were designed by multi-step chemical conjugation process (Fig. 1B). CNTs were first subjected to oxidation treatment to create abundant carboxylic groups mostly at the tips and defect sites of CNT surfaces. DOX was successfully encapsulated in the hollow CNTs (with inner diameter of ~11 nm) as the inner surface is hydrophilic, and aqueous solutions containing DOX can be loaded inside through the open ends. Here, we hypothesize that loading of DOX in CNTs will protect it from the early exposure to physiological milieu. Further, Fe<sub>3</sub>O<sub>4</sub> NP was conjugated to DOX loaded CNT through the GSH linker by the EDC coupling method. Thereafter, anti-EpCAM mAb was conjugated to the surfaces of CNT by EDC coupling reaction using the carboxyl groups on the CNT resulting in CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb nanobots. Similarly, Tf was conjugated to the reactive surface of CNT resulting in CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb nanobots. Tf protein has been used as a model targeting moiety to the cancer cells with overexpressed Tf receptors (TfR<sup>+</sup>).


Transmission electron microscope (TEM) images of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot revealed the presence of spherical Fe<sub>3</sub>O<sub>4</sub> NPs of average diameter ~16 nm at the tip ends of CNTs (Fig. 2A and Supplementary Fig. S1). Crystallographic structure of the Fe<sub>3</sub>O<sub>4</sub> NPs analyzed by high resolution TEM (HRTEM) showed magnetite crystalline nature (Fig. 2B). Furthermore, the identified lattice fringes co-related well to the structure of magnetite planes with a plane-to-plane separation of 0.486 nm. The Selected Area Electron Diffraction (SAED) pattern revealed spotty diffraction rings and well resolved spots thus confirming crystalline Fe<sub>3</sub>O<sub>4</sub> structure for the conjugated NPs (Fig. 2C).

The CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot was also characterized by FTIR to verify the successful covalent conjugation between CNT, Fe<sub>3</sub>O<sub>4</sub> and Tf. Figure 2D shows the FTIR spectra of oxidized CNT, CNT-DOX, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf, respectively. The IR spectrum of CNT showed characteristic peak at 1715 cm<sup>-1</sup> due to the presence of carbonyl groups. DOX loaded CNT showed characteristic peaks of DOX at 998 cm<sup>-1</sup> and 1213 cm<sup>-1</sup> indicating presence of DOX in CNT. The IR spectrum of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> showed prominent peaks at 575 cm<sup>-1</sup>, 629 cm<sup>-1</sup> due to Fe-O stretching thus confirming the conjugation of GSH-Fe<sub>3</sub>O<sub>4</sub> to the CNT<sup>21,24,25</sup>. Furthermore, the spectrum of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> conjugated with Tf showed new peaks at 3448 cm<sup>-1</sup> for free amine, and sharp peak at 1645 cm<sup>-1</sup> for amide linkage, providing clear evidence for conjugation of Tf with CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>. We also evaluated the conjugation reaction with respect to the change in zeta potential of the individual step during the synthesis of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf (Fig. 2E). The zeta potentials of CNT-COOH, Fe<sub>3</sub>O<sub>4</sub>, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf were determined to be -4.07, -18.6, -8.9, and -22.2 mV, respectively. The step-wise altered zeta potentials indicated successful conjugation of the multiple components with CNT. Tf conjugation quantified by a modified Bradford procedure was found to be  $\sim$ 326 mg per g of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>.

The drug loading and encapsulation efficiency of DOX was determined to be  $63.8 \mu g/mg$  in CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> nanobots using UV-visible spectrophotometry. DOX loading and Tf conjugation in CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf was analyzed and confirmed by UV-visible and fluorescence spectroscopy methods. The UV-visible spectrum of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf was compared with the spectra of free DOX and Tf (Fig. 2F). The spectra revealed the presence of characteristic peaks of DOX ( $\lambda_{max} = 480 \text{ nm}$ ) and Tf ( $\lambda_{max} = 280 \text{ nm}$ ) in the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots. Furthermore, the fluorescence spectrum of the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf was compared to that of the free DOX under identical optical conditions (480 nm excitation). As depicted in Fig. 2G, typical DOX in PBS displayed  $\lambda_{em}$  at ~590 nm. The spectrum of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf also displayed the typical absorption band from DOX indicating loading of DOX. In addition, the presence of DOX in CNT was also confirmed using 2.5D fluorescence microscopy imaging of the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> nanobots. The image revealed presence of DOX (red) within the nanopores of the CNT carrier particle (gray) (Supplementary Fig. S2).

Motion and position-kinetic analysis of nanobots. The self-propelling abilities of the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot in different fluids simulating physiological environments such as in phosphate buffer saline (PBS; pH 7.4), Dulbecco's modified eagle medium (DMEM) cell media and serum were characterized to verify the compatibility in relevant biological fluids. Some organic and/or biological molecules are capable of quenching or inhibiting the  $H_2O_2$  decomposition reactions catalyzed by  $Fe_3O_4$  NPs and thus can significantly hamper the motion of the nanobot. NP tracking analysis was used to track in real-time the movement of the nanobots under a range of H<sub>2</sub>O<sub>2</sub> concentrations (Fig. 3A). The nanobots propelled upward instantaneously and gradually reverted in the downward direction. For the mechanism of motion,  $O_2$  bubbles generated by Fe<sub>3</sub>O<sub>4</sub> NPs catalyzed decomposition of H<sub>2</sub>O<sub>2</sub> are responsible for propulsion in this system. The catalytic ability of Fe<sub>3</sub>O<sub>4</sub> evaluated in PBS comprising a range of  $H_2O_2$  (0.006 w/v% to 0.05 w/v%) concentrations revealed increased rate of reaction with increase in H<sub>2</sub>O<sub>2</sub> concentration (Supplementary Fig. S3). Supplementary Fig. S4 shows propelling CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots in PBS buffer at pH 7.4 with 0.5% H<sub>2</sub>O<sub>2</sub> composition (Supplementary Fig. S4A) and its response when held next to a permanent magnet (Supplementary Fig. S4B). CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots moving in vertical trajectory was acquired through the solution and got accumulated at the side of the tube where the magnetic field gradient was the strongest. Hence, the direction of the nanobots can be remotely controlled by a magnetic field and thus enabling it a cooperative propulsion mode under magnetic field in the presence of the chemical fuel.


Figure 3B shows images of the nanobot at different positions during its motion for a complete cycle. As evident from the images, the nanobot stayed away from the wall and moved through nearly the center of the liquid column during its flight. The average propulsion speed of the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot during its upward



**Figure 2.** Characterization of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf and CNT modifications to obtain the multicomponent CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf (nanobot). (**A**) TEM microscopy images of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf, (**B**) evidencing Fe<sub>3</sub>O<sub>4</sub> structure, and (**C**) crystalline features of the NPs. (**D**) FTIR spectra of of (a) CNT-COOH, (b) CNT-DOX, (c) CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and (d) CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf. (**E**) surface charge evolution upon loading of CNT with DOX and further conjuagtion of Fe<sub>3</sub>O<sub>4</sub> and Tf, (**F**) UV-visible spectra of DOX ( $\lambda_{max} = 480$  nm), Tf ( $\lambda_{max} = 280$  nm) and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf (Tf peak at 280 nm and DOX peak at 480 nm). (**G**) Normalized fluorescence spectra of DOX and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf ( $\lambda_{ex} = 480$  nm,  $\lambda_{em} = 590$  nm).

movement velocity in PBS, DMEM, and the blood serum was 0.338, 0.831 and 1.011 mm s<sup>-1</sup> respectively, in 0.5%  $H_2O_2$ . On the other hand, the downward velocity of nanobots was measured to be 0.208, 0.221 and 0.502 mm s<sup>-1</sup>, respectively. The velocity and speed of nanobots was virtually stable without obvious deceleration for more than 5 cycles.

Interestingly, the upward and downward velocity of the nanobot in PBS, DMEM, and serum increased significantly to 0.972, 2.333, 8.026 mm s<sup>-1</sup> (equal to a relative speed of nearly 119 body length per second) and 0.535, 1.120, 1.120 mm s<sup>-1</sup> when the concentration of H<sub>2</sub>O<sub>2</sub> increased to 8% H<sub>2</sub>O<sub>2</sub> (Fig. 3C–E). This corresponds to a large driving force of 592, 1304 and 5435 pN in the upward direction, based on the drag force  $F = 6\pi\mu rv$ , where v is the speed, r is the radius of the nanobot and  $\mu$  is the viscosity of the medium (Fig. 3F). The increase in speed




**Figure 3.** (A) Analysis of the motion behavior of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot. The videos were recorded with Dino-Lite digital microscope at 50× magnification, using the Dino-Capture 2.0 v (https://www.dino-lite.com/), best clip was chosen using VirtualDub 1.10.4 v (http://www.virtualdub.org/) and finally tracking and speed calculations were performed using MTrackJ plugin from ImageJ 1.8.0\_112v (https://imagej.net/MTrackJ). (a) Representative tracking trajectories of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots with different biologically relevant media. (B) Time-lapse images of the nanobot driven by oxygen bubble propulsion after time intervals of (a) 0, (b) 2.0, 4.6, 6.5 and 10 s. Speed of nanobot in the presence of different concentration of  $H_2O_2$  (0.5–8 w/v %) in (C) PBS, (D) DMEM and (E) serum, (F) Analysis of force of nanobot in PBS, DMEM and serum in presence of different concentration of  $H_2O_2$  (0.5–8 w/v %).

with increasing  $H_2O_2$  concentration is due to influence of surrounding  $H_2O_2$  concentration on the reduction rate of the Fe<sup>3+</sup> to Fe<sup>2+</sup>. Hence, with the presence of higher localized concentration of  $H_2O_2$  lead to an increased production of  $O_2$  bubbles thus resulting in generation of strong thrust and buoyancy thereafter for the upward as well downward motion of the nanobots (Fig. 3F). Further, the speed of the nanobot in serum was ~8.3 and ~3.4 times the speed seen in PBS and DMEM. The distance travelled by the nanobot in serum changed with change in  $H_2O_2$ concentration. At low  $H_2O_2$  concentration (0.5%) the average distance travelled was low (19.069 mm), while it was high (63.543 mm) at higher concentration (8%). The three-fold enhancement of distance travelled by nanobots was influenced due to innate  $H_2O_2$  present in blood.  $H_2O_2$  has diverse roles in normal physiological context. It serves as a blood borne signaling molecule, while at the same time it is produced intra-mitochondrially in most live cells. While these sources produce small amount of  $H_2O_2$ , the circulatory system conceivably accumulates this product. Additionally, immune cells, endothelial, and unbound xanthine oxidase generate  $H_2O_2$  which also increase the cumulative  $H_2O_2$  serum levels<sup>26.27</sup>. Serum  $H_2O_2$  content varies between  $0-5\,\mu$ M depending on physiological conditions<sup>28</sup>. Significantly, tumor cells influence  $H_2O_2$  content locally and presumably systemically<sup>29-31</sup>. Tumors are known to demonstrate the capability of exploiting  $H_2O_2$  in cell proliferation<sup>32</sup>. However, a restrained capacity to metabolize  $H_2O_2$  drives tumor masses to drain nascent  $H_2O_2$  in the surrounding tissue space which may ultimately reach systemic circulation and may increase systemic levels by up to 10  $\mu$ M and higher<sup>33</sup>. Further, the catalase enzyme present in serum may also be imparting catalytic property by getting adsorbed on the surface of nanobots and thus greatly enhancing generating of oxygen bubbles. In addition, it is conceivable that as a result of localized protein oxidation in the presence of  $H_2O_2$ , the protein aggregation leads to the adsorption of serum proteins such as albumin and immunoglobulins on the surface of the NPs<sup>34,35</sup>. Aggregated proteins have a cascading effect which may further influence binding of other serum proteins including enzymes such as serum catalase onto the surface of the protein-masked NPs<sup>36</sup>. This synergistic effect may also be responsible for the rapid propulsion of nanobots in blood serum even at low  $H_2O_2$  concentration as compared to PBS and DMEM<sup>4,36-40</sup>. The results indicate an appropriate pairing of the propulsion mechanism pre-assumed for its physiological fate and subsequently for the clinical context. It may be possible to exploit the natural  $H_2O_2$  decomposition system in combination with limited exogenous  $H_2O_2$  and attain high propulsion resulting in significant driving force to nanobots for rapid transport of drug cargo followed by deep tumor penetrating capability.

Drug release profiles of the nanobots. To investigate the pH dependent control release of DOX, we performed drug release study at two different pH conditions, one representing the physiological pH i.e. 7.4 and the other cell lysosomal pH (~pH 5) in presence and absence of proteases enzyme-cathepsin B. As shown in Supplementary Fig. S5, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot demonstrated low release of DOX (~26%) even after 48 h at pH 7.4, signifying efficient trapping of DOX in the CNT cavities by with  $Fe_3O_4$  NPs exterior cap. The observed small DOX release is probably of the loosely surface-bound DOX. Conversely at pH 5 and in presence of cathepsin B, a controlled DOX release pattern was observed. Around ~76% DOX got released till 4h which then increased to ~94% at 48 h. This remarkable multi-order kinetics pattern of DOX release from the designed nanobot is due to the degradation of amide linkage resulting in time-dependent uncapping of CNT<sup>41</sup>. TEM images of nanobots after release study confirmed the uncapping of CNTs as no  $Fe_3O_4$  NPs were seen near the tip of the CNTs (Supplementary Fig. S6). However, in absence of cathepsin B ~75% DOX got released till 48h in pH 5.0. The release of DOX is most likely due to the degradation of amide linkage in acidic pH<sup>42</sup>. Similarly, at pH 6.5 and in presence of cathepsin B, ~85% DOX got released till 48 h. However, in absence of cathepsin B only ~56% DOX got released. Further, to confirm the capping efficiency, release of DOX from CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot without the Fe<sub>3</sub>O<sub>4</sub> NP cap was also examined. Nanobot without cap demonstrated a predictable immediate burst-release of ~61% and ~18% of DOX within 30 min in pH 5.0 and 7.4, respectively. As mentioned earlier, the open-ended CNT allow cross-flow in the CNT cavity and consequently allow rapid release of the entrapped DOX. This pH-sensitive release behavior is of particular interest as it can reduce untimely drug release during systemic circulation and can specifically enhance intracellular (lysosomal) DOX release. This will be beneficial in cancer treatment as it will help in significantly lowering the dosage, few side effects and limited drug toxicity.

Time dependent cell entry kinetics studies. The cellular uptake and intracellular pH-dependent endo/ lysosomal release of DOX from nanobots was studied over time by fluorescent cell imaging (Fig. 4). HCT116 colon cancer cells were cultured, and subsequently incubated with DOX, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf at 37 °C before examination under fluorescence microscope at definite time intervals. The inherent fluorescence emissions of DOX were red, which were utilized as indicators for their corresponding distribution inside the cells (Fig. 5A). Figure 4 and Supplementary Fig. S7 depict the entry of free DOX influx, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf into HCT116 cells, implied by rapid cytosolic DOX labeling followed by DOX importation into the nucleus. At the 1 h, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf internalized into the cells by mechanisms including endocytosis and energy-independent, direct penetration and were localized mainly in the cytoplasm and subcellular vesicles. The (DAPI-stained) nucleus displayed a low DOX presence as compared to the cytosolic compartment (Supplementary Fig. S7A). Interestingly, the emission of DOX overlapped exactly with that of  $CNT-DOX-Fe_3O_4$ -Tf. In contrast, cells treated with free DOX showed red fluorescence accumulation mainly in the cell nuclei. Exposure of the cancer cells to free DOX resulted in rapid influx owing to passive diffusion as well as carrier-mediated uptake of DOX<sup>43</sup>. The fluorescence intensity of free DOX in the cell was  $\sim$ 1.7 times higher than that of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf. On the other hand, the intensity of DOX released from CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> was 3.3 times less than CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf. The influx of DOX into the nucleus is believed to be facilitated by binding to proteasomes<sup>44,45</sup>. On the other hand, energy-dependent drug efflux mechanisms such as ATP-binding cassette subfamily C member 1 (ABCC) are implicated in active efflux of DOX out of the cell<sup>46</sup>. The efflux machinery in turn contributes to the drug resistance of cancer cells. Furthermore, to understand how the TME affect the nanobot internalization process and intracellular delivery of DOX, the cellular entry kinetics was also studied at an acidic pH of 6.5. The pH of the media showed a clear influence on nanobot cell internalization and intracellular DOX release. While the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> nanobot showed comparable DOX presence at 1 h in both pH environments, the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot demonstrated ~1.7 fold increase in cellular DOX content in the acidic pH of 6.5, compared to the normal physiological pH 7.4 (Supplementary Fig. S7B, and Fig. 5A). The study clearly reveals higher cell entry of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot at pH 6.5.

After incubation for 4 h, DOX released from CNT-DOX- $Fe_3O_4$  and CNT-DOX- $Fe_3O_4$ -Tf was observed to be localized in the nuclear region (Fig. 4A,B). The intracellular release of DOX can be attributed to the opening of pH-sensitive nanogates due to amide bond cleavage in the acidic lysosomal compartments (Fig. 1). Additionally, the release of DOX was studied using confocal laser scanning microscopy (CLSM). At 4 h the LysoTracker labeled acidic organelles appeared yellow-orange, owing to merging of the green (LysoTracker) and red (DOX) fluorescence, due to the release of DOX from CNT-DOX- $Fe_3O_4$ -Tf (Fig. 4E). Subsequently, to further confirm the uncapping of CNT-DOX- $Fe_3O_4$ -Tf nanobots,  $Fe_3O_4$  NPs in CNT-DOX- $Fe_3O_4$ -Cy5-Tf were labeled with a fluorescent dye, Cyanine 5 (Cy5). As depicted in Supplementary Fig. S8, a strong localization of Cy5 (purple signal,



**Figure 4.** Fluorescent images of HCT116 cells treated with free DOX, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf. (**A**) At 4 h exposure and at pH 7.4, DOX released from CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf was observed to be localized in the nuclear region (**A**,**B**). The intracellular release of DOX can be attributed to the opening of pH-sensitive nanogates due to amide bond cleavage in the acidic lysosomal compartments. Cells incubated with free DOX showed efflux of DOX from the nucleus back into the cytoplasm, which is in contrast to the findings for CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf. (**B**) At 4 h exposure and at pH 6.5, the fluorescence intensity of DOX from CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot was higher due to faster cellular internalization of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf. (**C**) At 24 h and at pH 7.4, most of the DOX was released from CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf suggesting the efficient release of DOX from interior cavity of CNT after opening of Fe<sub>3</sub>O<sub>4</sub> nanogate in lysosomal conditions. (**D**) At 24 h and at pH 6.5, the fluorescence intensity of DOX in the cells was more pronounced suggesting enhanced cellular internalization of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot (Scale bars indicate 20 µm). (**E**) Kinetic study of Fe<sub>3</sub>O<sub>4</sub> NP uncapping and DOX release from CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Cy5-Tf nanobots in cells using confocal microscopy. Time-dependant release of DOX (red) into the acidic lysosomal compartment (green, LysoTracker) over 4 h, indicating -cleavage of CNT- Fe<sub>3</sub>O<sub>4</sub> amide-bond, subsequent

uncapping and DOX release. The merged image of the cells at 4 h shows a prominent yellow-orange signal indicating co-localization of DOX and lysosomes around the nucleus (blue), scale bars indicate 10  $\mu m$ .

 $Fe_3O_4$  NPs) with DOX (red) at 1 h was suggestive of site-restriction of DOX within CNT-DOX- $Fe_3O_4$ -Cy5-Tf nanobots. However, in 4 h post-treatment images the whole LysoTracker labelled acidic organelles appeared orange indicating separation of  $Fe_3O_4$  and DOX signals, consistent with detachment of  $Fe_3O_4$  caps from CNT and subsequent release of DOX from CNT. This finding is consistent with the DOX release patterns from CNT-DOX- $Fe_3O_4$  and CNT-DOX- $Fe_3O_4$ -Tf at pH 5.0 (Supplementary Fig. S5). The fluorescence intensity of DOX for CNT-DOX- $Fe_3O_4$ -Tf was ~8 times higher than that of free DOX (Fig. 5A). Cells incubated with free DOX showed efflux of DOX from the nucleus back into the cytoplasm, which is in contrast to the findings for CNT-DOX- $Fe_3O_4$  and CNT-DOX- $Fe_3O_4$ -Tf. Efflux of DOX prior to its activity in arresting topoisomerase is likely the reason for reduced efficacy of DOX. A rapid back-efflux phenomenon indicated an adaptive mechanism for drug resistance. It is conceivable that the efflux transport of free DOX occurs at a significantly higher velocity than that afforded by the DOX-proteasome nuclear import mechanism. On the other hand, the fluorescence intensity of DOX at pH 6.5 from CNT-DOX- $Fe_3O_4$ -Tf nanobot was ~2.4 times higher than that observed in pH 7.4 (Figs. 4B and 5A). The presence of higher DOX could be attributed to faster cellular internalization of CNT-DOX- $Fe_3O_4$ -Tf in pH 6.5 as compared to pH 7.4.


Tf is a vital protein for cellular uptake of systemic iron, consequently, the receptor mediated endocytosis which drives the import of exogenous CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot ensures the capture, internalization, processing and release of DOX intracellularly. While diffusion of DOX and transporter mediated DOX import appears faster in the free DOX state, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf seemingly maintains molecular efficiency in DOX import<sup>47</sup>. Put differently, the deficiency of the Tf-conjugated nanobot in rapid initial diffusion velocity, as seen in free DOX, is compensated by the sustained import of Tf-nanobot-borne DOX. It is possible that the endosomal processing of nanobot-encapsulated DOX results in efficient presentation of liberated DOX to cellular proteasomes which in turn deliver it to the nucleus. In contrast, the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-borne DOX is introduced within the cell in a diffusion and energy-independent membrane flipping manner. Presumably this exposes the DOX to cellular environment and therefore the efflux machinery resulting in poorer DOX nuclear import as compared to the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots.

At 24 h, DOX was almost exclusively present in the nucleus of the cells treated with the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots (Fig. 4C,D). Post-endosomal and lyzosomal processing and Fe<sub>3</sub>O<sub>4</sub> amide-bond cleavage, the released DOX undergoes the same nuclear entry pathway as free DOX, i.e. *via* proteasomes. However, the 24 h retention of DOX within the nuclear compartment is a significant improvement over free DOX. The nuclear efflux is apparently low or virtually non-existent in case of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf, which is further evidenced by a virtual absence of DOX from the cytoplasm. Strongly contrasted with this nanobot-borne DOX behavior is the gradual disappearance of DOX from the cellular compartments in cells treated with free DOX. The fluorescence intensity of DOX for CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf was ~35 times higher than free DOX (Figs. 4C and 5A). It is conceivable that the DOX, free from the influence of nanobot-mediated outcomes, is rapidly effluxed from the cell. ATP-dependent ABCC1 drug transporter is postulated to work even against the DOX concentration gradient across the cell membrane and achieve high DOX clearance. Interestingly, at pH 6.5, the fluorescence intensity of DOX in the cells exposed to CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot was more pronounced than in pH 7.4. The intensity was ~1.3 times more in pH 6.5 suggesting enhanced cellular internalization of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot at pH 6.5 (Figs. 4B and 5A). The presence of higher DOX could be attributed to faster cellular internalization of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot at pH 6.5 (Figs. 4B and 5A).

At the 48 h, most of the DOX resided in the nuclei of the cells treated with CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf (Supplementary Fig. S7C,D), similar to the outcome seen at 24 h. While nuclear retention was apparent for both treatments, DOX intensity appeared greater for CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf indicating efficient and steady release of DOX from the target-specific CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot. The amount of DOX effluxed from the cell was as high as 93% as determined from the kinetic study for free DOX. While the efflux kinetics for the free DOX was similar in the both the pH conditions, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot demonstrated pH sensitivity even at 48 h. As shown in Supplementary Fig. S7C,D, DOX released from CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot co-localized with DAPI concentrated in the nuclear region highlighting the nucleosome bodies, which contain the chromatin matter. The effect is more pronounced at pH 6.5 and the DOX accentuation in the nucleus suggests preferential binding of DOX to DNA and nucleosome-bound topoisomerases (Fig. 5B). The consequence of targeted delivery of DOX using the CNT-DOX-F<sub>3</sub>O<sub>4</sub>-Tf vehicle was the inversion of the net efflux kinetics seen in free drug to the net accumulation kinetics of DOX when administered *via* targeted nanobots (Supplementary Fig. S9).

As mentioned earlier, while the efflux velocity of the free DOX may overcome its nuclear entry, the proteasome-facilitated DOX nuclear import may be instrumental in enhanced DOX entry into the nucleus when cells are treated with DOX-nanobots. Moreover, the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> borne DOX may have secondary roles in enhanced nuclear delivery and nuclear retention which allow DOX to show nuclear presence past the clearance period for free DOX (Supplementary Fig. S7C,D). The proposed nanobot thus present a mechanism for evading drug efflux in cancerous cells and ensuring drug accumulation to achieve its cytotoxic goal.


To highlight the role of TME acidic milieu and  $H_2O_2$  in the uptake of nanobots, zeta potential of the cells exposed to CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot was evaluated at two different pH conditions, physiological pH 7.4 and pH 6.5 which exists in TME in presence of  $H_2O_2$  as shown in Fig. 5C. The HCT116 cells demonstrated a negative surface charge in pH 7.4. However, at lower pH values (pH 6.5), the cells underwent surface charge modifications and exhibited a predominantly positive charge due to protonation of free fatty acid head groups in the outer



**Figure 5.** (A) Fluorescence intensity of intracellular DOX accumulation upon treatment with nanobots at varying pH. (B) DOX binding of nucleoli. The nucleolar enrichment of DOX post NP administration is suggestive of high-affinity binding of DOX to nucleoli. (C) Surface charge evolution upon exposing to CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf in presence and absence of  $H_2O_2$ .

lipid<sup>48</sup>. Furthermore, cells exposed to CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot resulted in a significant alteration of the cell's surface charge, regardless of the pH conditions. The zeta potential of the cells exposed to CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot in pH 6.5 was roughly 3-times higher as compared to the cells alone. The increase in zeta potential of the cells can likely be attributed to surface-attachment of the nanobot which are also positively charged in acidic pH of 6.5. The increase in surface charge of the cells is shown to be reduced over time (24h) and furthermore by co-incubation with  $H_2O_2$  in acidic media. This may be interpreted as a gradual reduction in surface charge due to internalization of the nanobot demonstrated a restoration to the initial zeta potential in acidic condition. It may be due to near-complete internalization of the attached CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot in the cell. The acidic condition may have played a role in uptake of nanobots which is further accentuated in the presence of  $H_2O_2$  as shown in Fig. 5C. Interestingly, the cells exposed to the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot at physiological pH did not show any major change over time or by the presence of  $H_2O_2$  suggesting a slow internalization under physiological conditions. In accordance with the cell kinetics images (Fig. 4A–D), HCT116 cells do show greater DOX accumulation in acidic conditions.


**Nanobot's efficacy as a drug delivery vehicle.** Concurring with the microscopy data presented, cell viability assays were performed to compare the cytotoxic effects of DOX,  $CNT-Fe_3O_4$ ,  $CNT-DOX-Fe_3O_4$ -Tf and  $CNT-DOX-Fe_3O_4$ -mAb nanobot, show anticancer effect of the targeted nanobots. The control treatment with CNT (CNT-COOH) showed no cytotoxicity in the treated HCT116 cells.  $CNT-Fe_3O_4$  nanobot showed a mild influence on decreasing viability of treated cells, however there was no statistical difference in the effects of




**Figure 6.** Cytotoxicity analysis of free DOX, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>mAb nanobots incubated for 48 h with HCT116 cells. Cell viability study of treatments with free DOX and nanobots reveals a statistical improvement of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb nanobots over free DOX treatment of HCT116 cells. The CNT-Fe<sub>3</sub>O<sub>4</sub> nanobot does not show greater cytotoxic effect as compared to the control-CNT treatment. The free DOX shows limited toxicity to the model cancer cells at the end of the treatment. In contrast, the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb nanobot loaded with an equivalent dose of DOX shows statistically significant improvement in the toxicity induced, suggesting greater efficacy of the DOX delivery by nanobot.


control CNT and CNT-Fe<sub>3</sub>O<sub>4</sub> as shown in the Fig. 6. DOX on the other hand showed anticancer effect in HCT116 cells, based on the reduced viability of treated cells. The reduced cytotoxicity of the topoisomerase inhibitor *viz a viz* drug is attributed to the activity of the efflux pump which drive DOX out of the cell and decrease its intercalation with DNA<sup>33</sup>. As also seen in the cellular kinetics study (Fig. 4), DOX rapidly localizes to the nuclear region, however the energy-dependent efflux pumps are credited with effective removal of DOX from the nuclear compartment and eventually the cytoplasm as well. In contrast the targeted nanobots demonstrated superior nuclear DOX retention and maintained nuclear localization of the DOX for up to 48 h. The greater cytotoxicity of the targeted CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf/mAb and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb nanobot maybe likely a result of the enhanced nuclear accumulation of DOX, as compared to the free DOX.

Antitumor efficacy of drug loaded nanobots on 3D spheroidal tumors. To verify the proposed enhanced tumor penetration of DOX loaded nanobots, multicellular cancer cell 3D spheroids were used to simulate in vivo tumors (Fig. 7)<sup>49</sup>. HCT116 spheroids were cultured for 3 days by hanging drop method which promoted 3D tumor formation. The spheroids cultured from single cell suspensions are known to mimic in vivo cell-cell interactions via formation of inter-cellular junctions contributing to their in vitro integrity. Spheroid tumors sustain a balance between cell proliferation and cell death depending on the nutrient supply, DNA replication machinery and death-inducing stimuli. Furthermore, the TME gradient produced due to cellular heterogeneity (outer proliferating layer, followed by a quiescent region and inner necrotic core) is also believed to mimic native tumor physiology, the primary difference being intra-tumor mass vascularization under in vivo physiological conditions. In vivo tumors are characterized by angiogenesis as a result of complex biochemical interplays to enable tumor survival via vascularization<sup>50,51</sup>. Lab-grown spheroids thus, have to rely on surrounding media for nutrient supply. Consequently, as a result of nutrient gradient, the spheroids develop cellular heterogeneity as described above. As the cells proliferate, the number of dead cells accumulates as well, especially in the necrotic core of the spheroid leading to the formation of a dense inner core and an outermost scattered mono layer of shed cells (Fig. 7A, control). Since free DOX can be rapidly taken up by the outer layer of the spheroid cells, a pronounced DOX effect was observed initially. However, DOX effect dissipated in the cell medium as a relatively dilute anti-neoplastic drug, DOX was apparently not sufficient to induce death of remaining cells even after 72 h (Fig. 7A). Note that the inner dense (darker) core is reduced, despite the apparent growth of the tumor area. The widening of the tumor base is attributed to the reduced cell-cell adhesions resulting from DOX treatment which consequently undermines the integrity of the spheroid mass causing it to settle downward and spread. CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots were significantly more efficacious in tumor reduction than free DOX and the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> nanobot. CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots were able to induce cell death resulting in tumor spheroid disintegration compared to control after 72h of treatment, as shown in Fig. 7A. The lack in spheroid cohesion is apparent from 48 h for both treatments, while the inner dense cores were abolished completely by 72 h. On the



**Figure 7.** (A) Anti-tumor effect of free DOX, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf on HCT116 spheroids. Red color shows the fluorescence of DOX under an excitation light with a wavelength of 488 nm. After 72 h exposure, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf were efficacious in tumor-spheroid disintegration and were able to induce significant cell death due to enhanced tumor penetration compared to control (untreated tumor). Scale bar for panel represents 100  $\mu$ m. (B) Deep penetration of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Cy5-Tf NPs into the tumor-spheroid core. Confocal microscopy of spheroid reveals co-localization of DOX (red) and Cy5 tagged CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Cy5-Tf NPs (green) at various depths in the tumor mass suggesting deep penetration of the NPs. The schematic depicts the spheroid thickness (58  $\mu$ m) and the representative planes shown in the confocal image panel below. Scale bar for panel represents 200  $\mu$ m.





other hand, the control tumor after 72 h depicted an increase in core area by ~104% (from ~9.8  $\times$  10<sup>4</sup> to ~20.3  $\times$  10<sup>4</sup>  $\mu$ m<sup>2</sup>) and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> nanobot treated tumor by ~62% (from ~9.9 × 10<sup>4</sup> to ~15.8 × 10<sup>4</sup>  $\mu$ m<sup>2</sup>) compared to their respective before treatment area. One reason for the enhanced efficacy may be the deep tumor penetration ability of CNT-DOX- $Fe_3O_4$ -Tf and CNT-DOX- $Fe_3O_4$ -mAb due to the forward thrust obtained by nanobots and the delayed DOX clearance at the tumor site because of the retention property of the NPs. DOX is also responsible for inhibiting/blocking the transcriptome<sup>43</sup>, which may also affect the cancer cells ability to maintain the cell adhesion/ cell contact machinery. It is conceivable that sustained DOX exposure may reduce the ability of spheroid cells to self-adhere/assemble and be subject to disaggregation and thus be increasingly more prone to the cytotoxic effects of DOX. The effects of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb appear to manifest in a manner consistent with the above statement (Fig. 7A). Additionally, deep tumor penetration of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Cy5-Tf nanobots into the tumor-spheroid core was studied using confocal microscopy. Z-stack images of the spheroids revealed co-localization of DOX (red) and Fe<sub>3</sub>O<sub>4</sub>-Cy5 (green) signals at various planes, suggesting deep penetration of NPs as well as their internalization into individual tumor cells (Fig. 7B). The DOX and  $Fe_3O_4$ -Cy5 signals were visible with substantial intensity up to the core ( $\sim 29 \,\mu m$ ) of the entire tumor mass ( $\sim 58 \,\mu m$ ). The ablation of the dense tumor cores (Fig. 8A) are indicative of exposure to CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb particles. Furthermore, the protection of CNT-encapsulated DOX against rapid drug efflux prior to endocytosis and the subsequent intracellular release of DOX may contribute to the enhanced antitumor effect. In contrast, free DOX and CNT-DOX-Fe<sub>3</sub> $O_4$  were less effective in tumor regression possibly as a result of the small size of free DOX or extracellularly released DOX that would be rapidly diffused away from the tumor interstitium. Interestingly, tumor viability studies demonstrated a greater anticancer activity for CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> particles (Fig. 8B), compared to the targeted NPs. This may result from sustained non-specific TME-acid triggered  $Fe_3O_4$  uncapping and DOX release in the immediate vicinity and interior of the spheroid. The resultant system is hypothesized to have generated a very high localized DOX concentration in the TME resulting in significant cell death, but insufficient impact to destroy the tumor integrity. Tf and anti-EpCAM mAb conjugated nanobots exhibited greater cell surface targeting, however this delayed the release of DOX payload intracellularly. The effect can be attributed to surface epitope interactions between Tf as well as anti-EpCAM mAb nanobot ligands and over-expressed cell surface receptors.

Finally, although Tf and anti-EpCAM mAb conjugated nanobots achieve greater targeting their cellular internalization mechanism, release from the overexpressed cell surface receptors, and the release of DOX inside the cells seems to be delayed. This can be attributed to the specific and tight interactions between over-expressed cell surface receptors and the Tf as well as anti-EpCAM mAb nanobots. However, the self-propulsion, cell surface specificity, cell kinetics, and finally the anticancer activity measurements makes these nanobots interesting to be further explored in anticancer therapy.

#### Conclusions

We have demonstrated a novel self-powered multifunctional gated nanobot that offers promising alternative drug delivery system based on rapid autonomous motion for quicker and deeper delivery to the tumor site. The nanobots were fabricated by chemically coordinating and conjugating multiple components such as Fe<sub>3</sub>O<sub>4</sub> NPs and targeting moiety such as Tf or anti-EpCAM mAb to CNT. This nanobot system combines several intriguing

features, namely self-propulsion, high DOX loading, tumor targeting and profound penetration ability, in situ pH triggered release of the DOX, and improved drug availability. The CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots demonstrated ultrafast self-propulsion (0.972 and  $0.535 \,\mathrm{mm\,s^{-1}}$ ) not only in high ionic media (PBS buffer) but also in biological media such as DMEM (2.333 and  $1.120 \text{ mm s}^{-1}$ ) and blood serum (8.026 and  $1.120 \text{ mm s}^{-1}$ ), a crucial ability necessary for its use in biomedical applications. The speed of the nanobot in serum was  $\sim$ 8.3 and  $\sim$ 3.4 times the speed seen in PBS and DMEM. The driving force of 592, 1304 and 5435 pN for the nanobot's upward propulsion was significantly higher. The high driving force and thus higher speed of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot in serum is maybe due to adsorbed serum catalase enzyme which may be imparting additional propulsion by catalytic property and thus enhancing generating of oxygen bubbles. Thus, propulsion of nanobot was also observed in serum with no external  $H_2O_2$  indicating ability of the nanobot to propel in blood and penetrate tumor by utilizing H<sub>2</sub>O<sub>2</sub> present in the TME. The cellular uptake study showed controlled release of DOX due to opening of pH-sensitive nanogates by cleavage of amide bond in the acidic lysosomal compartments. Further, higher intensity of DOX in nucleus for CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot indicated not only efficient and steady release of DOX but also superior retentive property of the nanobot carriers. Upon administration to tumor spheroids, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb nanobots were significantly more efficacious in tumor reduction at 72 h than the control groups including free DOX and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> nanobot. One reason for the enhanced efficacy might be the profound tumor penetration ability due to the propulsion of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb nanobots, and the delayed clearance at the tumor site because of the retention property of the NPs. Thus, the synthesized CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots would be effective in smaller numbers, designed to selectively and efficaciously deliver the drug payload in targeted cancer cells alone within the TME.

#### Materials and methods

**Reagents.** Multi-walled carbon nanotubes (CNTs) having outer diameter of 10–15 nm; length 1–5  $\mu$ m; and purity >99%, were purchased from Ad-Nano Technologies, India. Ferric chloride tetrahydrate, ferrous chloride hexahydrate, transferrin (Tf), *N*-(3-Dimethylaminopropyl)-*N*'-ethylcarbodiimide (EDC.HCl), glutathione (GSH) and horeseradish peroxidase (type VI) were purchased from Sigma-Aldrich, USA. Doxorubicin hydrochloride (DOX) was received as a gift from Naprod Life Sciences, India. Cy5 mono NHS ester was procured from GE Healthcare UK Limited, and LysoTracker Green DND-26 was procured from Invitrogen, Thermo Fisher Scientific. HCT116 cells were obtained from the National Centre for Cell Science, India. McCoy's 5A, fetal bovine serum (FBS), Penicillin and streptomycin were purchased from Sigma-Aldrich, USA. Ultrapure water (MilliQ) acquired from a Merck Millipore system, Germany, was used throughout. All other chemicals procured were of analytical grade and utilized without further purification.

**Functionalization of CNTs (CNT-COOH).** CNT was purified and oxidized using a modified literature procedure<sup>52</sup>. In brief, 85 mg of CNT was dispersed in 100 mL mixture of  $H_2SO_4/HNO_3$  (3:1) and then sonicated for 6h. The mixture was diluted with 100 mL ice cold water, concentrated by centrifugation and washed with 5% NaOH solution and ultra-pure water. Resulting functionalized CNT was dried at 80 °C (12h).

**Synthesis of Fe<sub>3</sub>O<sub>4</sub>-GSH.** Fe<sub>3</sub>O<sub>4</sub> NPs were prepared by co-precipitation of ferric and ferrous ions (2:1) using aqueous ammonium hydroxide solution and then heated at 80 °C for 30 min, washed for several times with ultra-pure water and ethanol and finally dried at 70 °C (4–6 h)<sup>53</sup>. 5 mg of Fe<sub>3</sub>O<sub>4</sub> NPs were dispersed in 150 µl of ultra-pure water and 50 µl of methanol and sonicated for 15 min. 4 mg of GSH was dissolved in 50 µl of ultra-pure water, added in above solution and again sonicated for 2 h. The GSH functionalized NPs were then isolated by magnetic separation, washed repeatedly with ultra-pure water and dried well<sup>54</sup>.

**Loading of DOX in CNT-COOH (CNT-DOX).** Loading of DOX in CNT-COOH was carried using a modified procedure previously reported by us<sup>24</sup>. Briefly, 20 mg of CNT-COOH were suspended in 5 mL solution of DOX (8 mg/mL). The solution was sonicated for 6 h and was allowed to stand for further 12 h. The synthesized product, CNT-DOX was collected by centrifugation and dried well at room temperature.

**Synthesis of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>.** 20 mg of CNT-DOX and 5 mg of EDC were added in 5 ml of phosphate buffer (pH 7.4) and then agitated for 30 min. 20 mg of  $Fe_3O_4$ -GSH was added in the same mixture and agitated for another 1 h. The conjugated CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> NPs were magnetically separated, washed extensively with phosphate buffer to remove externally adsorbed DOX and then dried well at 40 °C.

**Synthesis of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf.** 10 mg of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> were treated with 1 mL of EDC and NHS solution (50 mM each solution in phosphate buffer (pH 7.4). After 30 min of agitation, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> NPs were separated with magnet and washed with PBS (3 times). 1 mL of Tf solution (5 mg/mL) was added. The reaction was then agitated for 4 h. The synthesized product, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf NPs were collected by magnetic separation and dried well at room temperature. Similarly, conjugation of anti-EpCAM mAb to CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> NPs was carried out.

**Characterization.** TEM analysis was carried out using Tecnai FEI G2 (accelerating voltage of 300 kV). The samples were prepared by placing a drop of CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf suspensions (in DI water) onto a Formvar-covered copper grid. The water was allowed to evaporate in air at room temperature before imaging. FTIR spectral studies were carried out using a Perkin Elmer Fourier Transform Infrared (FTIR) spectrometer, USA in the range between 4000 and 400 cm<sup>-1</sup>, with a resolution of 2 cm<sup>-1</sup>. The UV-Vis absorption spectra were recorded on Agilent Technologies Cary 60 UV spectrophotometer.

**Catalytic activity of Fe<sub>3</sub>O<sub>4</sub> in H<sub>2</sub>O<sub>2</sub>.** The catalytic activity of Fe<sub>3</sub>O<sub>4</sub> in H<sub>2</sub>O<sub>2</sub> was evaluated by incubating a 500 µg/mL dispersion of Fe<sub>3</sub>O<sub>4</sub> in PBS pH 7.4 with various concentrations of H<sub>2</sub>O<sub>2</sub> (0.006 w/v% to 0.05 w/v%) for 30 min. The difference in initial concentration of H<sub>2</sub>O<sub>2</sub> and the concentration of H<sub>2</sub>O<sub>2</sub> after 30 min was used to determine the rate of reaction. The concentration of H<sub>2</sub>O<sub>2</sub> in solution was determined using a modified horse-radish peroxidase (HRP) based colorimetric assay<sup>55</sup>. Briefly, 10 µL of test sample (either standard H<sub>2</sub>O<sub>2</sub> solutions for calibration curve or reaction samples) was added to 990 µL of an enzyme mixture and incubated for 30 min in dark. The enzyme mixture comprised of 500 µL of 84 mM phosphate buffer pH 7, 350 µL of 12 mM phenol, 100 µL of 0.5 mM 4-aminoantipyrene and 40 µL of 1 U/mL of HRP in 84 mM phosphate buffer pH 7. The absorbance was read at 505 nm.

**Motion behavior of nanobot in different fluids.** The self-propulsion of the CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobot in PBS, DMEM and serum with different concentrations of  $H_2O_2$  (0, 0.05, 0.1, 0.5, 1, 2, 4, 6 and 8%), was recorded with Dino-Lite digital microscope at  $50 \times$  magnification, using the Dino-Capture 2.0 v (https://www.dino-lite.com/). This was then processed to convert in to Avi format using Format Factory and chosen best clip using VirtualDub 1.10.4 v (http://www.virtualdub.org/). The propelling microparticles were tracked and calculated its speed using MTrackJ plugin from ImageJ 1.8.0\_112v (https://imagej.net/MTrackJ).

**Drug release profiles of the nanobot.** pH dependent *in vitro* release profile of DOX from CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf was evaluated by suspending 10 mg of material in 20 ml of pH 5 and pH 7.4 phosphate buffer. The nano system was stirred continuously at ambient temperature. 1 ml of aliquot was withdrawn at different time intervals, centrifuged and was analyzed using UV spectroscopy at  $\lambda_{max}$  of 484 nm. 1 ml of fresh phosphate buffer of same pH was replaced at every time point in the dissolution media. All the experiments were performed in triplicate.

**Cell culture.** HCT116 was procured from NCCS and cultured in McCoy's 5A, supplemented with 10% fetal bovine serum and 100 unit/ml penicillin, 100 mg/ml streptomycin and maintained in  $CO_2$  incubator at 37 °C and 5%  $CO_2$  saturation.

**Nanobot's efficacy as drug delivery vehicle.** The cytotoxic activity of compounds was quantitatively determined by a colorimetric assay utilizing (3-(4, 5-dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium bromide) (MTT). HCT116 cells were seeded in 96-well plates (5000 cells/well) and maintained in  $CO_2$  incubator for 24 h at 37 °C in McCoy's 5A medium supplemented with 10% FBS and 1% antibiotics. The free DOX, CNT-COOH, CNT-Fe<sub>3</sub>O<sub>4</sub>, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-mAb nanobots were added in the wells and incubated for 48 h. The DOX concentration in the study was  $0.377 \,\mu$ g/ml (IC50). The cells were then incubated with MTT for 4 h at 37 °C. In the viable cells mitochondrial succinic dehydrogenase reduced MTT to an insoluble formazan precipitate. After removal of the media, dimethylsulfoxide (DMSO) was added to each well. After complete solubilization of the purple MTT formazan (approximately 10–15 min), the absorbance was measured at 570 nm with a microplate reader on Infinites F200 PRO (Tecan, Austria). Background readings (blank) were obtained from cell-free wells containing media also incubated with the MTT solution.

**Time dependent cellular entry studies using fluorescence microscopy.** 5000 cells of HCT116, were seeded in each well of 96 well plate. After 24 h, cells were treated with free DOX, CNT-DOX-Fe<sub>3</sub>O<sub>4</sub> and CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots in a time dependent manner (1 h, 4 h, 24 h and 48 h). The concentration of DOX was 0.377  $\mu$ g/ml (IC50). The free DOX and all the nanobots were added according to the IC50 value of DOX and the DOX loading (60  $\mu$ g/mg) in the nanobots. The media were removed and cells were washed with phosphate buffered saline (PBS) after consecutive time points and processed for fluorescence microscopy. Cells were fixed with 4.0% (w/v) paraformaldehyde for 15 min at room temperature, then washed with PBS and maintained in PBS. Cells were stained with 4,6-diamidino-2-phenylindole (DAPI) (Sigma) and examined under a fluorescence microscope (Carl Zeiss, AxioObserver A3, USA).

Additionally, the co-localization of DOX in acidic lysosomal compartments with LysoTracker green as a fluorescent probe was studied using confocal laser scanning microscopy (CLSM), Leica Microsystems.

*Time dependent cellular entry studies using zeta potential.* HCT116 cells were incubated with CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf nanobots at pH 7.4 and 6.5 in presence or absence of  $H_2O_2$  (4.98 mM). The 5000 cell were re-suspended in1 mL of 40 mM HEPES buffer pH 7.4 and 6.5. The zeta potential values of HCT116 cells and cells incubated with CNT-DOX-Fe<sub>3</sub>O<sub>4</sub>-Tf for different time duration *viz.* 0 min and 24 h, were measured using Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). All the Zeta ( $\xi$ ) potential measurements were carried out at room temperature using phase analysis light scattering mode.

**Culture of HCT116 cell 3D spheroidal tumor.** 3D tumor spheroids were formed by a modified method of the hanging drop technique<sup>49</sup>. In brief, the lid of sterile 12 well plates were coated with poly(dimethoxysilox-ane) (PDMS) and Sylgard 184 in a 10:1 ratio and cured at 80 °C for around 45 min. The lids were then placed under UV for 30 min to ensure sterility of the PDMS coated surface. HCT116 cell suspension was prepared in complete McCoy's 5A medium.  $20\,\mu$ L drops of the cell suspension with a density of 2,500 cells/drop were placed at regular intervals on the PDMS coated lid. The wells were filled with sterile MilliQ water to ensure hydration of drops upon incubation. Thereafter, the cells were incubated at 37 °C in presence of 5% CO<sub>2</sub> for three days. Finally, the coherent mass of 3D tumor spheroids formed was selected for further studies.

**Antitumor efficacy of drug loaded nanobots.** Tumors generated by hanging drop method were transferred to 96 well plate for treatment with DOX and nanobots. The 3D tumor spheroids upon transfer to 96 well

plate were immediately treated with free DOX ( $5\mu g/mL$ ) and nanobots containing equivalent DOX for 72 h. The images of tumors were captured using Carl Zeiss, AxioObserver A3, USA, USA inverted fluorescence microscope. The exposure time while capturing bright field images was fixed at 100 ms and the exposure time while capturing fluorescence images was fixed at 400 ms.

Furthermore, the viability of tumors after 72 h was analyzed by MTT assay following similar protocol mentioned earlier. Similarly, for CLSM the 3D tumor spheroids were transferred to a glass bottom well plate before capturing z-stack images. The z-stack images were captured at intervals of 0.75 µm.

Received: 20 December 2019; Accepted: 24 February 2020; Published online: 13 March 2020

#### References

- 1. Tu, Y., Peng, F., White, P. B. & Wilson, D. A. Redox-Sensitive Stomatocyte Nanomotors: Destruction and Drug Release in the Presence of Glutathione. *Angew. Chemie Int. Ed.* 56, 7620–7624 (2017).
- Li, J. et al. Micromotors Spontaneously Neutralize Gastric Acid for pH-Responsive Payload Release. Angew. Chemie Int. Ed. 56, 2156–2161 (2017).
- 3. de Ávila, B. E.-F. *et al.* Micromotor-enabled active drug delivery for *in vivo* treatment of stomach infection. *Nat. Commun.* **8**, 272 (2017).
- Hortelão, A. C., Patiño, T., Perez-Jiménez, A., Blanco, À. & Sánchez, S. Enzyme-Powered Nanobots Enhance Anticancer Drug Delivery. Adv. Funct. Mater. 28, 1705086 (2018).
- 5. Tu, Y. et al. Biodegradable Hybrid Stomatocyte Nanomotors for Drug Delivery. ACS Nano 11, 1957–1963 (2017).
- Li, J., Esteban-Fernández de Ávila, B., Gao, W., Zhang, L. & Wang, J. Micro/nanorobots for biomedicine: Delivery, surgery, sensing, and detoxification. Sci. Robot. 2, eaam6431 (2017).
- 7. Yan, X. et al. Multifunctional biohybrid magnetite microrobots for imaging-guided therapy. Sci. Robot. 2, eaaq1155 (2017).
- Nelson, B. J., Kaliakatsos, I. K. & Abbott, J. J. Microrobots for Minimally Invasive Medicine. Annu. Rev. Biomed. Eng. 12, 55–85 (2010).
- 9. Wang, J. & Gao, W. Nano/Microscale Motors: Biomedical Opportunities and Challenges. ACS Nano 6, 5745–5751 (2012).
- Gao, W. et al. Artificial Micromotors in the Mouse's Stomach: A Step toward in Vivo Use of Synthetic Motors. ACS Nano 9, 117–123 (2015).
- Peng, F., Tu, Y., van Hest, J. C. M. & Wilson, D. A. Self-Guided Supramolecular Cargo-Loaded Nanomotors with Chemotactic Behavior towards. *Cells. Angew. Chemie* 127, 11828–11831 (2015).
- 12. Wang, H. & Pumera, M. Fabrication of Micro/Nanoscale Motors. Chem. Rev. 115, 8704-8735 (2015).
- 13. Sánchez, S., Soler, L. & Katuri, J. Chemically Powered Micro- and Nanomotors. Angew. Chemie Int. Ed. 54, 1414–1444 (2015).
- 14. Wang, H. & Pumera, M. Emerging materials for the fabrication of micro/nanomotors. *Nanoscale* 9, 2109–2116 (2017).
- Zhang, Q., Wang, N., Ma, M., Luo, Y. & Chen, H. Transferrin Receptor-Mediated Sequential Intercellular Nanoparticles Relay for Tumor Deep Penetration and Sonodynamic Therapy. Adv. Ther. 2, 1800152 (2019).
- Zhang, Q. et al. Inlaying radiosensitizer onto the polypeptide shell of drug-loaded ferritin for imaging and combinational chemoradiotherapy. Theranostics 9, 2779–2790 (2019).
- 17. Luo, M., Feng, Y., Wang, T. & Guan, J. Micro-/Nanorobots at Work in Active Drug Delivery. Adv. Funct. Mater. 28, 1706100 (2018).
- Wu, Y., Wu, Z., Lin, X., He, Q. & Li, J. Autonomous Movement of Controllable Assembled Janus Capsule Motors. ACS Nano 6, 10910–10916 (2012).
- 19. Peng, F., Tu, Y. & Wilson, D. A. Micro/nanomotors towards *in vivo* application: cell, tissue and biofluid. *Chem. Soc. Rev.* 46, 5289–5310 (2017).
- 20. Sitti, M. et al. Biomedical Applications of Untethered Mobile Milli/Microrobots. Proc. IEEE 103, 205-224 (2015).
- Szatrowski, T. P. & Nathan, C. F. Production of Large Amounts of Hydrogen Peroxide by Human Tumor Cells. Cancer Res. 51, 794–798 (1991).
- 22. Sun, Y.-P., Fu, K., Lin, Y. & Huang, W. Functionalized Carbon Nanotubes: Properties and Applications. Acc. Chem. Res. 35, 1096–1104 (2002).
- 23. Kostarelos, K. The long and short of carbon nanotube toxicity. Nat. Biotechnol. 26, 774-776 (2008).
- Banerjee, S. S. et al. Calcium phosphate nanocapsule crowned multiwalled carbon nanotubes for pH triggered intracellular anticancer drug release. J. Mater. Chem. B 3, 3931–3939 (2015).
- Sun, C. et al. PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo. ACS Nano 4, 2402–10 (2010).
- 26. Halliwell, B., Clement, M. V. & Long, L. H. Hydrogen peroxide in the human body. FEBS Lett. 486, 10-3 (2000).
- 27. Veal, E. A., Day, A. M. & Morgan, B. A. Hydrogen Peroxide Sensing and Signaling. Mol. Cell 26, 1–14 (2007).
- Lacy, F., O'Connor, D. T. & Schmid-Schönbein, G. W. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J. Hypertens. 16, 291–303 (1998).
- 29. Lisanti, M. P. et al. Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis. Cell Cycle 10, 2440-2449 (2011).
- Vilema-Enríquez, G., Arroyo, A., Grijalva, M., Amador-Zafra, R. I. & Camacho, J. Molecular and Cellular Effects of Hydrogen Peroxide on Human Lung Cancer Cells. *Potential Therapeutic Implications. Oxid. Med. Cell. Longev.* 2016, 1–12 (2016).
- Liu, S.-L. et al. Reactive oxygen species stimulated human hepatoma cell proliferation via cross-talk between PI3-K/PKB and JNK signaling pathways. Arch. Biochem. Biophys. 406, 173–82 (2002).
- Park, I.-J., Hwang, J.-T., Kim, Y. M., Ha, J. & Park, O. J. Differential Modulation of AMPK Signaling Pathways by Low or High Levels of Exogenous Reactive Oxygen Species in Colon Cancer Cells. Ann. N. Y. Acad. Sci. 1091, 102–109 (2006).
- Dartier, J. et al. ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells. Biochim. Biophys. Acta - Gen. Subj. 1861, 1075–1084 (2017).
- 34. Mirzaei, H. & Regnier, F. Protein:protein aggregation induced by protein oxidation. J. Chromatogr. B 873, 8–14 (2008).
- 35. Sabuncu, A. C. et al. Probing nanoparticle interactions in cell culture media. Colloids Surfaces B Biointerfaces 95, 96-102 (2012).
- Weids, A. J., Ibstedt, S., Tamás, M. J. & Grant, C. M. Distinct stress conditions result in aggregation of proteins with similar properties. Sci. Rep. 6, 24554 (2016).
- Khandare, J. J. et al. PEG-conjugated highly dispersive multifunctional magnetic multi-walled carbon nanotubes for cellular imaging. Nanoscale 4, 837–844 (2012).
- Allen, B. L. et al. Mechanistic Investigations of Horseradish Peroxidase-Catalyzed Degradation of Single-Walled Carbon Nanotubes. J. Am. Chem. Soc. 131, 17194–17205 (2009).
- 39. Ma, X., Hortelão, A. C., Patiño, T. & Sánchez, S. Enzyme Catalysis To Power Micro/Nanomachines. ACS Nano 10, 9111–9122 (2016).
- 40. Orozco, J. et al. Artificial Enzyme-Powered Microfish for Water-Quality Testing. ACS Nano 7, 818–824 (2013).
- Shankar, R. *et al.* Cathepsin B Degradable Star-Shaped Peptidic Macromolecules for Delivery of 2-Methoxyestradiol. *Mol. Pharm.* 10, 3776–3788 (2013).

- Chae, S. et al. Encapsulation and Enhanced Delivery of Topoisomerase I Inhibitors in Functionalized Carbon Nanotubes. ACS Omega 3, 5938–5945 (2018).
- 43. Thorn, C. F. et al. Doxorubicin pathways. Pharmacogenet. Genomics 21, 440-446 (2011).
- 44. Kiyomiya, K., Matsuo, S. & Kurebe, M. Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus. *Life Sci.* 62, 1853–1860 (1998).
- Liu, J., Zheng, H., Tang, M., Ryu, Y.-C. & Wang, X. A therapeutic dose of doxorubicin activates ubiquitin-proteasome systemmediated proteolysis by acting on both the ubiquitination apparatus and proteasome. *Am. J. Physiol. Circ. Physiol.* 295, H2541–H2550 (2008).
- Munoz, M., Henderson, M., Haber, M. & Norris, M. Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer. *IUBMB Life* 59, 752–757 (2007).
- 47. Thorstensen, K. & Romslo, I. The role of transferrin in the mechanism of cellular iron uptake. Biochem. J. 271, 1-9 (1990).
- Lähdesmäki, K., Ollila, O. H. S., Koivuniemi, A., Kovanen, P. T. & Hyvönen, M. T. Membrane simulations mimicking acidic pH reveal increased thickness and negative curvature in a bilayer consisting of lysophosphatidylcholines and free fatty acids. *Biochim. Biophys. Acta - Biomembr.* 1798, 938–946 (2010).
- 49. Kuo, C.-T. *et al.* Three-dimensional spheroid culture targeting versatile tissue bioassays using a PDMS-based hanging drop array. *Sci. Rep.* **7**, 4363 (2017).
- 50. Hillen, F. & Griffioen, A. W. Tumour vascularization: sprouting angiogenesis and beyond. *Cancer Metastasis Rev.* **26**, 489–502 (2007).
- 51. Liao, D. & Johnson, R. S. Hypoxia: A key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 26, 281–290 (2007).
- Zhou, M. et al. Doxorubicin-Loaded Single Wall Nanotube Thermo-Sensitive Hydrogel for Gastric Cancer Chemo-Photothermal Therapy. Adv. Funct. Mater. 25, 4730–4739 (2015).
- Banerjee, S. S. & Chen, D.-H. Magnetic Nanoparticles Grafted with Cyclodextrin for Hydrophobic Drug Delivery. Chem. Mater. 19, 6345–6349 (2007).
- Polshettiwar, V., Baruwati, B. & Varma, R. S. Magnetic nanoparticle-supported glutathione: A conceptually sustainable organocatalyst. Chem. Commun. 14, 1837–1839 (2009).
- Fernando, C. D. & Soysa, P. Optimized enzymatic colorimetric assay for determination of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) scavenging activity of plant extracts. *MethodsX* 2, 283–291 (2015).

#### Acknowledgements

We acknowledge financial support from Department of Biotechnology, Government of India and Department of Science and Technology, Government of India.

#### **Author contributions**

S.S.B. and J.J.K. conceived the idea and designed the research. S.S.B., J.J.K., R.D.W., K.D.D. and Y.N.P co-analyzed the experimental and calculated data. S.S.B., J.J.K., S.S.A., R.D.W., G.P.C. and Y.N.P. contributed to the writing and editing of the manuscript. R.D.W. prepared the nanobots and also performed the motion experiments. K.D.D. performed the *in vitro* cellular entry and cytotoxicity studies. B.V.T. supported the experiments on TEM characterization. S.S.A. supported all *in vitro* tumor experiments. S.S.B. directed the project. All authors reviewed the manuscript.

#### **Competing interests**

The authors declare no competing interests.

#### **Additional information**

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-61586-y.

Correspondence and requests for materials should be addressed to J.J.K. or S.S.B.

Reprints and permissions information is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020



Shashwat Banerjee <shashwatbanerjee@mitmimer.com>

### Lecture on Intellectual Property Rights, Feb 19-20, 2020

 Shashwat Banerjee <shashwatbanerjee@mitmimer.com>
 Wed, Feb 5, 2020 at 3:27 PM

 To: MEDICAL DIRECTOR MIMER <director@mitmimer.com>, Ghaisas Virendra <virendraghaisas@gmail.com>, Suchitra

 Karad <suchitra@mitpune.com>, PRINCIPAL MIMER <principal@mitmimer.com>, "PRINCIPAL, COLLEGE OF

 PHYSIOTHERAPY" <principal\_th@mitmimer.com>, medical Suprintendent <ms@mitmimer.com>, Dr Arun Jamkar

 <jamkar@gmail.com>, Admin Office MIMER <admin@mitmimer.com>, Department <department@mitmimer.com>

Dear Madam/Sir,

It is our pleasure to invite all faculties & residents for lectures on:

Topic: Introduction to Intellectual Property Rights (IPR)

Speaker: Dr. Govind Chate [Ph.D. (Pharmaccutics)], Registered Patent Attorney (IN/PA 3623)

Date: 19 & 20 February 2020

Time: 2.30 - 3.30 pm

Venue: Sushrut hall, OPD Building

Warm regards,

Dr. Shashwat Banerjee Head, Central Research Lab MIMER Medical College Talegaon Dabhade, Dist Pune 410507, India. Phone: +91 2114308312 Email: shashwatbanerjee@mitmimer.com

## MIMER MEDICAL COLLEGE TAEGAON (D) DEPARTMENT OF BIOCHEMISTRY

### Attendance

## Topic: Introduction to Intellectual Property right (IPR)

Date: 19/02/2020

Sr.	Name of faculty	Department	Signature
<u>No.</u>	Dr. Suchitra Magne	Admin	Ser.
2	Dr-sandhja s. Kulkali	Principal 1/c	Krandugs
3	Dr. Prashaut Kanult	Med. supt	QLLE
4	Dr. Jadhan Dhanaji S.	vice principal	Store to With
5.	Dr Derek D'Souza	Dentistry	18 there
6	Do Sudeep Keimor	ronadieni.	such
7.	A hatinichi	Biochemity	Non
B.	Dr. D.V. Gopalghare	only ?	when
4	& Darpan M	orthe	gan
10	Dr. Arita Kalkerons	Comm Med	Ahlesta
41	Dr. Arita Kalleronó	Arnestlesi	· Ari.
'`	dardi charan kaun	Auro	Chy_
13	Smita Anand Watwe	Micro	Sulat
14	Du Janice Jaison	Patho	m
15	pr. Smita Bhide	Patho	Se
16	02 DUBE. S.B	Swigory	Dulas
17	Dr. S.K Chavan	Adnadomy.	Fawer
18	Da Sonali Khake	Anatomy.	Allate

### MIMER MEDICAL COLLEGE TAEGAON (D) DEPARTMENT OF BIOCHEMISTRY

#### Attendance

### Topic: Introduction to Intellectual Property right (IPR)

Date: 19/02/2020

Sr. No.	Name of faculty	Department	Signature
19	br showhank Vedpathak	Anatomy	God
20	Dr. Nivek K. Ninnale	Anatomy	Virel
21	DR. SWAPNIL A. MORE	PATHOLOGY	A.
22	Dr Kavya Iyer (Junior resident-I)	ORTHOPAEDICS	freed
23	Dr Vidye R. Chalker	Physiology	Dedy .
24	DR. SAMEER DESAI	ORTHOPAEDICS	Allea
25	DR. SHRIRANG GOBBOLE	ORTHOPAEDICS	Đ.
26	Dr Sinil Yadar	O Mopulairs	Gent.
27	DK. Vinuj S. Fedwal	Ophthalmology	fortural
28.	Dr Dipti Thakas (JR 2 Skink V.D.)	skind V.D	Anter
29.	Dr. Shulphan Gadkar (JP1)	Skin & V.D	Shubber
30	Ir sonthan Ich	ENT	h
31.	Dr. Pruchi S. Punderker	Dentisty	standay
32		Dentistry	Ø.
38.	De Sway Pawar (SF)	skind w.D	S
34	& Rajsi munde	Ortho	taple
35	Dr. Shivraj Konde Dr. Nitin Kanale	orting.	Sunde
86	Br. Nitin Kanale	Osteo	Dent

### MIMER MEDICAL COLLEGE TAEGAON (D) DEPARTMENT OF BIOCHEMISTRY

### Attendance

### Topic: Introduction to Intellectual Property right (IPR) Date: 19/02/2020

#3	C. C	Department	Signature
Sr.	Name of faculty	Department	
No.	Dr Saybosh Barkar	Aho.	AR
37		reducine	Stadodz
38	Do Tustor S Kanawaade	Otho	Str12
31.	Dr. Sagar Kulthe	Othe	15 hr
40.	Dr. Vijith Hegde	OBGY	martial
41-	Dr. Varsha Kumbhar	*	Nille
42.	Dr. Nikhila Agote	OBGY	Nender
43.	Dr. Nandan Nagaonkor	OBGLY	n hel
44.	Dr. Snehal Saleinkhe	OBGY	brehes
45	D. Mardon Kale	Poelsigences	morder
66	Do Smirang Pafil	medicine	the
47		Pharmacol	
48		Mino	Sherak
43	A. Smile Prover.	offlere.	Saite.
50	DR. MANGALA NAGARC	patho	Anon
51	Dr. Chardrahas Godbole	Patho.	Coffee -
52	Dr. Sandesh Grownele	surgery	Damlen 4.
53	Tor. Ashish Ubhale	AP/pm -	Ast
54	Dr. Repali Munde	Patho .	Pepale .
35	Dr. Shalaka Saraf	Pathology	- inter
66	Dr. Praelie Kate	Patticlety	Yvorber
<del>जि</del> .	Dr. Sayli Dhande	Pathelogy	- 25 - ···
58	Dr. vibhavan Barharte	ophihal	Orber
59	of. Sushma what mor	Obgyn -	ling
60	Dr. Bhoushay	8-8-1	a thought
		AND SOUTH AND INC. IN A SAME AND A	NAME OF A DATA O

and the second		0/2/20	
Topic -	, Introduction to intelled	tual prop	enty orgues.
Br.	Name of touthy	pept	Sign
NO-	DR. MANGALA NAGARG	Patho	Angere .
) 2)	Dr-smith Bhidh	pathe	se.
3)	De Gausi mettar	pothe	Ga
4)	Dr Swabi Belsone	Anotomy	Apres
5)	28. Sadhana Chat	Milo	sochale
San Cartan	Sangeeta. B. Trombatu	Biochem	8152
6) 7)	Hate Chandhai		tet
() 8)	pr Pratiniahi	Bidden	
9)	-Aujum sarried	Riochem	AKS
10)	Dr. P. N. Basavkar	Riochem	GRA
11	Dr Aastha Pandey	PEM	A
12.	R. S.V. dunchoutar	BSM	el
13:	Q. S. J. Kulkann	PSM	Ach .
14	A S.S. Kulkarni	nicro	Krandby-
15	Mrs. Anjali Jaywant	nicro	Ar
16	Mis charan Kaur Dards	mim	curr

Gerep Dept turning ot Norme Sr no pollology pr. cmita Blide PERON 17 DR. SWAPNIL A MORE Patho 18 Do Jane Jaison 19 Rativelyn Munde or Typeli Ca Patho DR. Mangala, Non 21 23 se. CRL Do Shadwat Banerjee 20 DL Orthe. Dor. P.S. Kamelt 23 a KOMISD-P ENT DR 2 4 cum PSUM Dr. Marchuna Aspluster 25 ew wature Miero Smitha 26 shine Mino Dr Sadhana Chate 23 Baburdika 3 13 hypeolog 28 A.J. RyARI FAL T Arring/ both. 29 M-J. Bederor 54 30 Phy sio

### MI,MER MEDICAL COLLEGE, TALEGAON DABHADE

TPR

19/8/20 **Activity Report** Department : Central Research Lab Activity \$ Overview on Intellectual Property Rights : From----- To-----Duration 19th 2019 Participant : No. of Faculty: : 32 No. of Students: Objective of the activity: give DO intener toal property Wentiles on IPP ) Ticht aculties and Students Outcome of the activity: IND participant KADIN get about toTPR 0.00 oxotert their TPRO Submitted by Dr. Shashwat Banerjee Head, Central Research Laboratory MIMER Medical College

Topic -	: Introduction to Intelle	etual prof	conty ing was, (1
Sr. 100-	Nume of transfor	Pept	Sorg
-)	Dr Aparno Chaudhari	Bioche	Ase
-=)	Dr. Rotan Majundar	Con Hed	Phlaquadas
3)	Do Madhuro Ashtuka	com med	und.
47	Ds Junis Release	Rivalong	Bus
5)	Dr. Geets Bhaka	(C)	Al
6)	Sangerto B Tormholia	Biochern	.8752
2)	Mis Holan Chaudhan	Biahem	Hulan_
3)	pr. But michi	Bischam	mp
_9)	Me- Anjum Sarred	Richen	Ars
10)	Dr. P. N. Barnukar	Ricchem	Get .
11	Pr Aastla Pandey	PS M	A
the second se	D.S. S. V Chinch dikas	the second se	
	Dr SJ Kulkarne		1
:4)	DL. S.S. Kulkarni		
15)	Mas. Anjali Jaywant		mr.
and the second se	Mis charan Kalul Davdi		awy

Introj	pluction to Intellectual	propert	y rigi
Sr	Name of faminy	Dept	Sign
No.			
17) 18)	DR. Smith Blide DR. SWAPNIL A. MORE Dr. Tance Jaison	Petrology Petrology Patro	Ser An
19)	28. Reput Munde	Patholyg	A.L
_2i) ·	Dr. Mangala, Non Dr. Shadwat Baserjee	Patho	P
23)	Dog. P. S. Kamilt	ortho	DL-
24)	DR. KOMISD.P	ENT	
25)	Dr. Madhura Ashkuler	PSWM	unz
26)	Smita Wature	Micro	Gli
27)	Dr Sadhana Chate	Mino	she
28)	Dr. R. S. Baburditar	physiolog	
29)	Dr. A.J. Rynn	EMT	Arr
30)	M. Y. Bedekar	Plysio	19

7	Introduction to Intell Norma of formally	Pept	Sign
31)	Do gausi cretkar	Pottere	Qu-
	Dr. Ashnini Gunstawar	Patho	289
	Dr. Walk K. Hismale	Andt	These
	Dr. Swapnil Acus Cradhere	Anat	A

### MIMER MEDICAL COLLEGE, TALEGAON DABHADE

No./MIMER/Cir/ 624/2019

Date: 28.08.2019

1

### **CIRCULAR- Good Clinical Practices (GCP) Workshop**

### To – HOD – Pre/Para/Clinical departments –

A workshop on Good Clinical Practices (GCP) Guidelines will be held on 31<sup>st</sup> August 2019. The workshop will include sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y' Regulations in Clinical trials, Rules & Responsibilities of IEC/IRB members, Sponsor & Investigator & latest Regulatory updates.

Attendance by all participants is compulsory for all sessions for award of certificate.

The workshop will be held at Sushruta Hall, 1<sup>st</sup> floor, OPD complex from 09:30AM to 03:30PM. Working lunch will be provided.

tai Principal Principal

MIMER Medical College Talegaon Dibbhade - 410 507

- Medical Director
- Executive Director (P. & D.)
- Executive Director (H.A.)
- Director P.G. Programme R. & D.
- Medical Supdt.
- Asst. Registrars
- HR Head

#### Copy for necessary arrangement-

- Electric Dept- Sound & mike system
- IT Dept- Projector & screen system
- Artist dept- Photography
- Maintenance dept Table & chairs arrangement

No	Name	Designation	Department	Signature
r. No.	Dr. Vivek K. Nirmale	AssoProf.	Anatomy	Vict
	Dr. Sonali A. Khake	AssoProf.	Anatomy	LAXLoxe
	Dr. Swati Belsare	Prof. & Head	Anatomy	Auce
	Dr. Deepa S. Nair	Prof. & Head	Physiology	per 2
	Dr. Rupali S. Baburdikar	Asso.Prof.	Physiology	Dealer Dealer Shaller Shaller
	Dr. Vidya Ohatk <b>e</b> r	Tutor	Physiology	Shalker .
	Dr. Sadhana S. Chate	Professor	Microbiology	Sunale
-	Dr. Rupali Bagga	Asso. Prof.	Community Medicine	Rupas
1-	Dr. Sudam Khedkar	Asso. Prof.	Medicine	thellow
10	Dr. Meenakshi Surve	Asst. Prof.	Obst. & Gyn	alem
11	Dr. Priya Karmani	Asst. Prof.	Obst. & Gyn	pringe
12	Dr. Jaya Barla	Asst. Prof.	Obst. & Gyn	Jappor
13	Dr. Khushboo singh	SR	Obst. & Gyn	Cale
14	Dr. Prajakta Sambarey	Prof & Head	Ophthalmology	Samplace
15	Dr. Vijay Bhavari	Assoc. Prof	Paediatrics	Kalicium
16	Dr. Ujjwala Keskar	Assoc. Prof.	Paediatrics	how
17	Dr. Vidya Fadnis	Asst. Prof.	Paediatrics	U
8	Dr. Sudjhir Dube	Professor	Surgery	Dappens
19	Dr. Samadhan Kshirsagar	Assit. Prof	Surgery	for
20	Dr. Ajit Jadhav	Assit. Prof	Surgery	Halam
21	Dr. Shantaram Gulve	Assit. Prof.	Surgery	- halw
22	Dr. Atul Gowardhan	Assit Prof	Surgery	KINDUN
23	Dr. Manas Pusalkar	Assit Prof	Orthopedic	Mag
24	Mr. Santosh Chitnis			S.J. CHITHI
25	Mr. Shashank Ogale			State
26	Mr. Jag Mohan Dingra			Denbringer
27	Miss.Sunita Solanki	MSW	Comm. med.	Swith
28	Adv. PAURAVI GAMBHIR			Jamblel
29	or Ravindra Vedpath	al rutos	Anatomy.	Augathick
30	Or Santosh Bork		ortho	182
31	Dr Manas Pu	U	Ortho	Mono
32	or sanden	Councile	sures	Lamo

Asso-prot Psychiaty 8. Dr. Aneesh &- Bhat 3. Dr. Aneesh & Bhad 34. Dr Rupali Verma Bogga Associat Bog community Medicat 35 Dr. Snehal Ghoday Principal/Professor Physiotherapy I 35 Dr. Snehal Ghoday Principal/Professor Physiotherapy I 36. Dr. Superiya Korde Private Practioner Physiotherapy Je 36. Dr. Superiya Korde Private Practioner Physiotherapy Je 36. Dr. Superiya Korde Private Practioner Physiotherapy Je Mi Prand fai Paked- coordinal Mincren 35 Dr. Snehal ghoday 36. Dr. Supriya Korde 37 NS Frank fai



25 April 2019 at 17:02

#### Workshop on Good Clinical Practices (GCP) Guidelines

PRINCIPAL MIMER <principal@mitmimer.com> To: "Dr. Yuvraj Patil" <yuvrajpatil@mitmimer.com>

To.

#### Dr Yuvraj Patil

This is to inform you that you have been nominated to the Institutional Ethics Committee of this Institution.

A workshop on "Good Clinical Practices (GCP) Guidelines" is being organized as part of the mandatory training for IEC members.

The date & timing of the workshop are 29th April 2019 from 10.00AM to 1.00PM at Shushruta Hall on 1st floor of OPD Bldg.

Please ensure that you are attend the workshop. Kindly confirm your attendance.

Please confirm your attendance by replying to this email.

Sd/-

Dr. Rajendra Prasad Gupta Principal, MIMER Medical College Talegaon (D), Pune - 410507



PRINCIPAL MIMER <principal@mitmimer.com>

25 April 2019 at 16:59

#### Workshop on Good Clinical Practices (GCP) Guidelines

PRINCIPAL MIMER <principal@mitmimer.com> To: rupali baburdikar <drrupalibaburdikar@gmail.com>

To,

Dr Rupali Baburdikar

This is to inform you that you have been nominated to the Institutional Ethics Committee of this Institution.

A workshop on "Good Clinical Practices (GCP) Guidelines" is being organized as part of the mandatory training for IEC members.

The date & timing of the workshop are 29th April 2019 from 10.00AM to 1.00PM at Shushruta Hall on 1st floor of OPD Bldg.

Please ensure that you are attend the workshop. Kindly confirm your attendance.

Please confirm your attendance by replying to this email.

Sd/-

Dr. Rajendra Prasad Gupla Principal. MIMER Medical College Talegaon (D), Pune - 410507



PRINCIPAL MIMER <principal@mitmimer.com>

#### Workshop on Good Clinical Practices (GCP) Guidelines

PRINCIPAL MIMER <principal@mitmimer.com> To: santoshborkar197616@gmail.com

To,

Dr Santosh Borkar

This is to inform you that you have been nominated to the Institutional Ethics Committee of this Institution.

A workshop on "Good Clinical Practices (GCP) Guidelines" is being organized as part of the mandatory training for IEC members.

The date & timing of the workshop are 29th April 2019 from 10.00AM to 1.00PM at Shushruta Hall on 1st floor of OPD Bidg.

Please ensure that you are attend the workshop. Kindly confirm your attendance.

Please confirm your attendance by replying to this email.

26 April 2019 at 09:54

## Good clinical Practice (GCP) Workshop Attendance sheet on 29<sup>th</sup> April 2019 MIMER Medical College & B.S.T.R. Hospital

Sr. No.	Name	Designation	Department	Signature
SF. NO.	Dr. Vivek K. Nirmale	Asso Prof.	Anatomy	Vice
1	Dr. Sonali A. Khake	Asso Prof.	Anatomy	LANDAKE
2	Dr. Swati Belsare	Prof. & Head	Anatomy	1 million
3	The state of the s	Prof. & Head	Physiology	pertr2
4	Dr. Deepa S. Nair	Asso.Prof.	Physiology	non.
5	Dr. Rupali S. Baburdikar			ono
5	Dr. Vidya Ohatker	Tutor	Physiology	Dualker
2	Dr. Sadhana S. Chate	Professor	Microbiology	ssual
8	Dr. Rupali Bagga	Asso. Prof.	Community Medicine	Dealter Drother Shaller Repair
9	Dr. Sudam Khedkar	Asso. Prof.	Medicine	toollan
10	Dr. Meenakshi Surve	Asst. Prof.	Obst. & Gyn	of som
11	Dr. Priya Karmani	Asst. Prof.	Obst. & Gyn	my
12	Dr. Jaya Barla	Asst. Prof.	Obst. & Gyn	John
13	Dr. Khushboo singh	SR	Obst. & Gyn	11
14	Dr. Prajakta Sambarey	Prof & Head	Ophthalmology	Langha
15	Dr. Vijay Bhavari	Assoc. Prof	Paediatrics	Alicu
16	Dr. Ujjwala Keskar	Assoc. Prof.	Paediatrics	here
17	Dr. Vidya Fadnis	Asst. Prof.	Paediatrics	U
8	Dr. Sudjhir Dube	Professor	Surgery	Tables
19	Dr. Samadhan Kshirsagar	Assit. Prof	Surgery	. to
20	Dr. Ajit Jadhav	Assit. Prof	Surgery	Hard
21	Dr. Shantaram Gulve	Assit. Prof.	Surgery	~ (42)
22	Dr. Atul Gowardhan	Assit Prof	Surgery	Kinow
23	Dr. Manas Pusalkar	Assit Prof	Orthopedic	Mag



## MIMER Medical College Talegaon (D), Pune

This is to certify that Dr Swati Belsare

ortiticate

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that Dr Usha Khadtare

ortificate

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that Dr Shilpa Pratinidhi

ortificate

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that Dr Sandhya Kulkarni

ortificate

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that Dr Ketaki Pathak

Cortificate

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



## MIMER Medical College Talegaon (D), Pune Certificate This is to certify that

Dr Ashwini Gundewar

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that Dr Aastha Pandey

ortiticate

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that

Cortificate

Dr Ranjit Wagh

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that

ortificate

Dr Ganesh Pentewar

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that Dr Vaishali Korde

ortificate

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



## MIMER Medical College Talegaon (D), Pune

ortiticate

This is to certify that Dr Sushma Sharma

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



## MIMER Medical College Talegaon (D), Pune

This is to certify that Dr Manas Pusalkar

ortiticate

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that

ortiticate

Dr Avinash Pujari

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



MIMER Medical College Talegaon (D), Pune

# Certificate This is to certify that Dr (Col) Derek SJ DSouza has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

Cortificate

This is to certify that Dr Ramchandra Bhardwaj

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that Dr Aparna Chincholkar

Cortificate

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that Dr Santosh Borkar

ortiticate

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

Cortificate

This is to certify that

Dr Dattatreya V Gopalghare has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

This is to certify that Dr Ujjwala Keskar

ortificate

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai



# MIMER Medical College Talegaon (D), Pune

ortificate

This is to certify that Dr Sandesh Gawade

has successfully completed the training programme on "Good Clinical Practice (GCP) Guidelines" held on 29<sup>th</sup> April 2019 at this institution. The programme included sessions on GCP Guidelines (ICMR & ICH), Schedule 'Y', Regulations in Clinical Trials, Roles and responsibilities of IEC/IRB members, Sponsor & Investigator, and Regulatory Updates.

Dr Khokan Debnath GCP Trainer Mumbai Dr Deepak Langade Prof & Head, Dept of Pharmacology DY Patil University School of Medicine, Navi Mumbai

## MIMER Medical College, Talegaon Dabhade

### Value Added Courses

Year	Name of Course	No of Participants
2020-2021	Haemorrhoids	11
2020-2021	Mucormycosis workshop	25
2020-21	Orientation to Methods in Clinical Research	23
2020-21	Basic Life Support	151
2019-20	Workshop on wheels (Johnsons and Johnsons)	27
2019-20	Basic Life Support	151
2018-2019	Spine Cadaveric Hands on Workshop	7
2018-2019	Basic Life Support	150
2017-2018	Orientation to Trauma life suppotrt	38
2017-2018	Suturing, Knotting & Staplers	34
2016-2017	SURGICAL KNOTTING & SUTURING Workshop	7

## MIMER MEDICAL COLLEGE, TALEGAON DABHADE

I

## Value-Added Courses During The Last Five Years

Sr. No	Name of the value-added courses	Year of offering	Name of students enrolled		
	(with 15 or more contact hours)		in the year		
	offered during the last five years				
	Year 1				
1	Life Skill Training	2020-21	as per list attached (150)		
2	Meditation and pranayam sessions	2020-21	as per list attached (150)		
3	Basic Life Support	2020-21	as per list attached (150)		
	Year 2				
4	Meditation and pranayam sessions	2019-20	as per list attached (150)		
5	ISSH Basic Hand Surgery Course and Cadaveric Hand Workshop	2019-20	as per list attached (13)		
6	Workshop on Wheels (Laproscopy)	2019-20	as per list attached (26)		
7	Live Endoscopic Surgical Skills Enhancement Workshop	2019-20	as per list attached (15)		
8	Basic Life Support	2019-20	as per list attached (150)		
		Year 3			
9	Certificate Course in Clinical Research	2018-19	as per the list attached (60)		
10	Suturing,knotting & Staplers	2018-19	as per the list attached (27)		
11	Basic Life Support	2018-19	as per list attached (150)		
	Year 4				
12	Certificate Course in Clinical Research	2017-18	as per the list attached (29)		
		Year 5			

# <u>MIMER MEDICAL COLLEGE, TALEGAON DABHADE</u> Policy & SOP for quality of care and patient safety procedures.

Policy for maintaining quality of care in hospital

Patient Input - Classified as

- 1. New patient
- 2. Already registered patient
- 3. Referred patient
- 4. Pick up by ambulance
- 5. Walk in/ brought in patient
- 6. Sent from OPD

Service given	Control point
OPD	OPD paper, OPD register, speciality
	register
Admission in ward/ ICU	Case file- history and findings, progress
	notes, referral sheets, consent and preanaesthetic check-up notes, OT list,
	blood transfusion forms, OT register,
	patient clinical register, police
	intimation register
Transfer/ Discharge	Transfer letter, referral form, discharge
	card, ambulance register
DAMA/ Death	DAMA consent form, discharge card
Death	Death certificate, postmortem referral
	letter

Patient Output -

- 1. Treated and sent as outpatient OPD paper.
- 2. Admission in ward/ICU.
- 3.Transfer, discharge at request

4.Discharge against medical advice

5.Death

# Policy for uniform care of patients

- All patients are to be treated alike irrespective of religion, caste, social status, financial ability.
- Similar care is given in different settings which are guided by applicable laws and regulations. Setting may include right from admission to discharge for IPD services, in OPD services and emergency services. All protocols are uniformly given in the same manner to all patients irrespective of the category status.
- Clinical practice and SOP's are adopted whenever possible.

# SOP for reception of patients in emergency room (casualty)

- Emergency staff shall ensure availability of wheelchairs and stretcher trolleys at the emergency room main door.
- After examining the patient and immediate resuscitative and stabilization care the chief medical officer (CMO) shall contact the consultant on call in the relevant specialty by means of the telephone and inform the registrar on call (who is sitting in the casualty) in the relevant specialty.
- Registrars/ CMO shall inform the consultant of the patient's condition and take instructions regarding investigations and treatment.
- Registrar/ CMO shall write admit in the casualty paper if the patient requires admission after consultant advice
- Patient shall be transferred to the allocated bed at the earliest after screening diagnostic test or if the patient's condition so requires it.
- Entry to be made in the casualty register about patients name, diagnosis and treatment given.
- CMO shall inform concerned police station if it is a medicolegal case.
- If a patient is to be transferred to a higher facility adequate details about treatment given. If necessary ambulance facility will be provided after informing the medical superintendent who will also decide the staff(doctor/nurse) to accompany patient to higher center.
- If there are economic issues in treatment CMO/ registrar will inform the medical superintendent to waive off emergency charges for few patients investigations and/or treatment.
- Custody of medicolegal case records shall be under the CMO on duty. MLC records shall be kept under lock and key.
- In case of dying patient a senior staff of the hospital remains with the patients' relatives and permits them to complete the formalities. Death certificate and death summary will be handed over to the police. Body to be handed over to the police to be/ shifted for post mortem in case of death of patient.
- If patient is posted for emergency surgery registrar of concerned specialty follows instructions for surgery. Patient should be shifted to minor OT/ major OT depending on the complexity of the case.
- Arrange for blood if necessary instructions from blood bank.

# SOP for triaging in casualty

# Policy of prioritizing patients based on their individual need for medical care

Under normal working conditions patients shall be triaged and allotted beds in the emergency room as per the urgency of their medical needs using ESI scores.

During external disasters (code red) patients shall be triaged as red, yellow and black.

## **Red**- First priority, most urgent

Life threatening shock or hypoxia is present or imminent but patient can be stabilized and if given immediate care shall probably survive.

Examples of red: -

- Compromised airway
- Respiratory arrest or survive respiratory distress or SpO2 < 90
- Trauma patient who is unresponsive or requires immediate fluid resuscitation
- Overdose with a respiratory rate of 6
- Severe bradycardia or tachycardia with signs of hypo-perfusion, chest pain, pale, diaphoretic, blood pressure < 70 mmHg (palpatory method)
- Anaphylactic reaction
- Baby that is flaccid
- Hypoglycemia

## Yellow- Second priority, urgent

Injuries have systemic implications or effects but patient is not yet in life threating shock or hypoxia although systemic decline shall ensue and given appropriate care patient seems able to withstand a 45-60 min wait without immediate risk.

Examples of yellow: -

Following diagnosis with stable blood pressure

- Acute abdominal pain
- Gastrointestinal bleeding
- Acute arterial occlusion
- Fever in immunocompromised patients
- Testicular torsion
- Acute renal failure
- Ectopic pregnancy
- Spontaneous abortion
- Meningitis
- Acute cerebrovascular accident
- Vomiting/diarrhea in children.
- Acute asthmatic attack
- Pleural effusion
- Spontaneous pneumothorax
- Road traffic accident with transient loss of consciousness.

## Green -Third priority, non-urgent

Injuries are localized and without systemic implications, with a minimum of care.

# Black- Dead

The above color coded ID bands shall be used during a code red.

# **SOP for ICU**

- 1. Each patient shall be under the care of one nurse, always maintaining the patient to nurse ratio of 1:1 for patients on ventilator and 1:2 for their patients in ICU
- 2. Intensive care areas shall follow infection control practices
- 3. Visitors shall not be allowed in ICU except in special situations during visiting hours- one relative only
- 4. One empty bed shall be reserved at all times for emergency patients
- 5. Patients requiring emergency care only are to be admitted or shifted to the ICU. After substantial resolution of the problems responsible for admission patient may be transferred to the ward- after order by the treating specialist
- 6. Specialized life support equipment like ventilators, infusion pumps, defibrillators, central oxygen supply and suction must be readily available in the ICU. Biomedical engineer shall check this equipment on weekly basis
- 7. Staff on duty should be trained to handle specialized equipment

Infectious cases need isolation from other patients in ICU

# **Surgical Safety Checklist**

Sign in- Before induction and anesthesia

- 1. Patient has confirmed (identity, site, procedure and consent)
- 2. Site marked/ not applicable
- 3. Pulse oximeter placed n patient and is functioning
- 4. Check for any known allergies that the patient has
- 5. Difficult airway/ aspiration risk Yes/No
- 6. Equipment/ Assistance/ IV Access available- Yes/ No
- 7. NBM status- Yes/ No
- 8. Blood Availability- Yes/ No

Time out- Before skin incision

- 1. Confirm whether all team members have introduced themselves
- 2. Surgeon, anesthetist and nurse confirm patient, site and procedure
- 3. Surgeon reviews critical step, operative duration, anticipated blood loss
- 4. Anesthetist reviews patient specific concerns
- 5. Nursing team reviews sterility of the OT and equipment
- 6. Antibiotic prophylaxis given- Yes/No
- 7. Essential imaging displayed- Yes/ No

Sign out- After operation

- 1. Nurse confirms procedure name, specimen, instruments used, sponge count
- 2. Surgeon/ Anesthetist/ Nurse reviews key concerns for postoperative recovery

# Patient safety in ward protocol

1. Identification band with patient's name and other important details around wrist or ankle.

2. All hospital staff members have to wear identity cards at all times on duty.

3. All hospital staff must maintain privacy and security of patient's health information at all times.

4. Washing hands properly by patient after using toilet is compulsory. Also, washing hands by staff after coming in contact with a patient is compulsory.

5. Dressings must be done by only resident doctor on duty with autoclaved dressing material only with the help of trained staff in ward. Dressing trolley to be checked for infection before dressing.

6. Patient must do deep breathing exercises during their ward stay to prevent chest inflation.

7. Sister in charge to see that patient's skin is clean and dry. All patients must change their position in bed every one hour to prevent development of bed sore/ water bed to be provided to patients at risk of bed sore.

8. Medical superintendent and nursing in charge to ensure proper cleaning of wards daily by concerned staff.

9. To prevent fall related injuries patient to keep personal items within reach to get them. Patient must ask for help when patient needs to get out of bed for toilet if patient is feeling unsteady. Patient's slippers or other footwear should be checked so that they are proper and no slippery. For some patient in need proper walking aid should be provided. Appropriate railings may be provided to bed of patient at risk of falling.

10. Personal and hospital owned electrical appliances should be checked by electrician regularly (at least once weekly)

11. It is not allowed to bring food from outside hospital for patients without informing the nursing staff on duty for food safety.

12. Patients are not allowed to consume any medicine without consent of medical team/ if it is not prescribed by doctor.

13. Patient should not keep jewelry, lot of money or valuable personal items to ward.

14. Visitor's access to ward is limited to two visitors per day during visiting hours only. However for pediatric patients and those patients in need, one or two relatives can stay with the patient.

# SOP FOR OPD

- 1. The registration desk is arranged at the entrance lobby.
- 2. Opd paper dispencing is available near the entrance lobby.
- 3. Waiting area with efficient spacing is available near the opd registration desk.
- 4. Patients are directed to specialized opd based on their symptoms.
- 5. Patients with acute symptoms and emergency conditions are directly shifted to emergency department.
- 6. Ramps and elevators are available for immediate shifting of such patients.
- The help desk always guides the patient regarding specialized opd, registration counters, cash counters, emergency departments, restrooms etc.
- 8. Restrooms available for males, females and handicapped.
- 9. Doctors, nurses and cleaning staff are checked regularly for symtoms, body temp etc.
- 10. Hand washing facilities in all OPD clinics, wards, emergency, ICU and OT areas. There shall be proper written handwashing protocols
- 11. Sanitization practices are followed before and after checking a patient
- 12.Surface cleaning and disinfection including doors, handles, elevator buttons and frequently touched surfaces.
- 13.Safe clinical practices as per standard protocols to prevent health care associated infections and other harms to patients.
- 14. Restrooms are cleaned and disinfected .
- 15. Wheel chair, trolleys and other transport equipments are available handy and staff to carry the patients are well trained and available at all hours.
- 16. Formation of Infection control team and provision of trained Infection Control nurses.
- 17. Hospital shall develop standard operating procedure for minor opdaseptic procedures, culture surveillance
- 18.Safe Injection administration practices as per prescribed protocols.

- 19. Ensuring Safe disposal of Bio-medical waste as per rules (National Guidelines to be followed)
- 20. Immunization of Health care workers against Tetanus and Hepatitis B.
- 21. Provision of round the clock Post exposure prophylaxis against HIV in cases of needle sticks injuries.
- 22. During opd consultation and minor procedures, female patients are always attended by a female attendant.
- 23. Arrangements made for medicine dispencing in the same premises of opd.
- 24. Medicines once dispenced are crosschecked and schedule of such drugs explained to the patient by the treating consultant.

## Pharmacovigilance Committee Attendance

Dept. of Pharmacology

Date: 13/12/2019

Dr. R. J. Wagh (Secretary)

Name

Sign

#### Copy to:

1)	Dr. Dilip Bhoge (Chair person)
2)	Dr. R. J. Wagh (Secretary)
3)	Dr. P. S. Kamat
4)	Dr. Ashok Ohatkar
5)	Dr. E.P. D'Souza
6)	Dr. Sandesh Gawade
7)	Dr. Vaishali Korde
8)	Dr. Aneesh Bhat
9)	Dr. V. B. Powar
10)	Dr. Mrs. Aditi Deshmukh
11)	Mrs. Jagdale H.

Prof & HOD (Gen. Medicine) Prof & HOD (Pharmacology) Medical Superintendent Prof & HOD (Orthopedics) Associate Professor (Paediatrics) Asso. Prof (Gen. Surgery) Professor (OBGY) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD)

Please note that a meeting of the Institutional Pharmacovigilance Committee will be held on Friday, 13/10/2019, at 12.00 pm in the cabin of the Medical Superintendent Dr. Kamat Sir. All the members are requested to attend the same.

Circular

Date: 13/12/2019

Dr. R. J. Wagh (Secretary)

#### Copy to:

- 1) Dr. Dilip Bhoge (Chair person)
- 2) Dr. R. J. Wagh (Secretary)
- 3) Dr. More Vinayak
- 4) Dr. P. S. Kamat
- 5) Dr. Maya Borle
- 6) Dr. Sandesh Gawade
- 7) Dr. Vaishali Korde
- 8) Dr. Aneesh Bhat
- 9) Dr. V. B. Powar
- 10) Dr. Mrs. Aditi Deshmukh
- 11) Mrs. Jagdale H.

Prof & HOD (Gen. Medicine) Prof & HOD (Pharmacology) Medical Superintendent Prof & HOD (Orthopedics) Prof & HOD (Orthopedics) Asso. Prof (Gen. Surgery) Professor (OBGY) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD)

# MIMER MEDICAL College, Talegaon, (D)

# Dept of Pharmacology

# Minutes of the IPvC meeting held on 21/06/2019

- 1. Minutes of the last meeting were read and approved by members present.
- 2. Since last 3 months, 8 ADR cases were reported from Depts. of Ortho, OBGY, MEDICINE, Psychiatry, Surgery, ICU as per the information gained during the weekly visits by the staff of Dept. of Pharmacology.
- 3. Some of the members have now been reappointed, as follows Dr. Ashok Ohatkar, Prof. HOD, Ortho.
- 4. P'V Seminar for the newly admitted PG students will have to be conducted.
- 5. If was decided that next meeting will be held on 27<sup>th</sup> September, 2019, in the office of Med Superintendent.

## Institutional Pharmacovigilance Committee Meeting

Prof & HOD (Gen. Medicine)

Prof & HOD ( Pharmacology )

Medical Superintendent PLt

Associate Professor (Paediatrics)

Asso. Prof (Gen. Surgery)

Professor (OBGY)

Prof. (Psychiatry)

Incharge, Blood Bank

Senior Resident (Skin VD)

 $\ell \times \text{Prof & HOD (Orthopedics)} OL L^{-1}$ 

Venue: Dept. Ortho Library

Date: 21/06/2019

#### Attendance:

#### Name

- 1) Dr. Dilip Bhoge (Chair person)
- 2) Dr. R. J. Wagh (Secretary)
- 3) Dr. P. S. Kamat
- 4) Dr. P. S. Kamat
- 5) Dr. E. P. D'Souza
- 6) Dr. Sandesh Gawade

7) Dr. Vaishali Korde

8) Dr. Aneesh Bhat

9) Dr. V. B. Powar

10) Dr. Mrs. Aditi Deshmukh

11) Mrs. Helen Jagdale

12) Dr. Ashok Ohatkar

HOD, Prof. Orthopaedics.

Matron In Charge

Sign

## Circular

Please note that a meeting of the Institutional Pharmacovigilance Committee will be held on Friday, 21/06/2019, at 2.00 pm in the Dept. of Ortho Library. All the members are requested to attend the same.

#### Date: 18/06/2019

Dr. R. J. Wagh (Secretary)

#### Copy to:

- 1) Dr. Dilip Bhoge (Chair person)
- 2) Dr. R. J. Wagh (Secretary)
- 3) Dr. P. S. Kamat
- 4) Dr. P. S. Kamat
- 5) Dr. E.P. D'Souza
- 6) Dr. Sandesh Gawade
- 7) Dr. Vaishali Korde
- 8) Dr. Aneesh Bhat
- 9) Dr. V. B. Powar
- 10) Dr. Mrs. Aditi Deshmukh
- 11) Mrs. Jagdale H.

Prof & HOD (Gen. Medicine) Prof & HOD (Pharmacology) Medical Superintendent Prof & HOD (Orthopedics) Associate Professor (Paediatrics) Asso. Prof (Gen. Surgery) Professor (OBGY) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD)

# MIMER Medical College, Talegaon (D.) Minutes of the IPvC Meeting held on 13/03/19

# Dept of Pharmacology

- Dr. Dilip Bhoge (Chair person) welcomed all the members in the Dept. of Gen. medicine. Other teaching staff viz. Dr. Madhu Bansode, Dr. Usha Khadtare also were also present who were also apprised of various IPvC activities
- 2) Last meeting minutes were discussed.

-

- 3) Causes of less reporting of Adverse Drug Reactions were disused in detail-
  - Number of Patients ignore the adverse events associated with drug usage thinking them as trivial e.g. Fever, any other symptoms of patients
    - Good nursing care, scrupulous exclusion of patient related contraindications
- 4) Skin dept. staff will be told to report all adverse events related to cosmetic procedures and topical drugs application.
- 5) Blood transfusion reactions need to be reported by the particular department to the BTO and Dept. of Pharmacology/ ADR reporting centre as soon as possible. A circular to be issued to each ward to send patients blood bag (remaining) along with the tubings, IV set, urine and blood samples of patient to BTO.
- 6) Cardboard boxes with ADR forms are fixed at the nursing stations in wards; Gen. Medicine wards have been provided first and other wards shortly.
- 7) Talegaon D IMA to be addressed with IPvP and members to be motivated for reporting ADR. Dr. Sudam Khedkar would be contacted for arranging for such a briefing during April meeting (1st Friday, 9 pm -11 pm, attending members no. 30-55); a circular to be issued to IMA members.
- 8) The meeting was concluded by Dr. R. J. Wagh, Secretary, paying a vote of thanks.

PROFESSOR & HOD PHARMACOLOGY DEPARTMENT M 1ER MER AL COLLEGE TAL MOA, OE - 420507

## Pharmacovigilance Committee Attendance

#### Dept. of Pharmacology

#### Date: 13/03/2019

#### Name

- 1) Dr. Dilip Bhoge (Chair person) 2) Dr. R. J. Wagh (Secretary)
- 3) Dr. More Vinayak
- 4) Dr. P. S. Kamat
- Dr. E.P. D'Souza 5)
- 6) Dr. Sandesh Gawade
- 7) Dr. Vaishali Korde
- 8) Dr. Aneesh Bhat
- 9) Dr. V. B. Powar
- 10) Dr. Mrs. Aditi Deshmukh
- 11) Mrs. Jagdale H.

Prof & HOD (Gen. Medicine) Prof & HOD ( Pharmacology ) Medical Superintendent Prof & HOD (Orthopedics) Associate Professor (Paediatrics) Asso. Prof (Gen. Surgery) Professor (OBGY) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD) Matron In Charge





### Circular

Please note that a meeting of the Institutional Pharmacovigilance Committee will be held on Wednesday, 13/03/2019, at 2.00 pm in the Dept. of Medicine. All the members are requested to attend the same.

Date: 13/03/2019

Dr. R. J. Wagh (Secretary)

Copy to:

1)	Dr. Dilip Bhoge (Chair person)
2)	Dr. R. J. Wagh (Secretary)
3)	Dr. More Vinayak
4)	Dr. P. S. Kamat
5)	Dr. E.P. D'Souza
6)	Dr. Sandesh Gawade
7)	Dr. Vaishali Korde
8)	Dr. Aneesh Bhat
9)	Dr. V. B. Powar
10)	Dr. Mrs. Aditi Deshmukh
11)	Mrs. Jagdale H.

Prof & HOD (Gen. Medicine) Prof & HOD (Pharmacology) Medical Superintendent Prof & HOD (Orthopedics) Associate Professor (Paediatrics) Asso. Prof (Gen. Surgery) Professor (OBGY) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD) Matron In Charge

### Minutes of the IPvC meeting held on 28/09/18

- 1. All the members were welcomed by Dr. Wagh.
- 2. He briefed the members about the ADR reported in the last 6 months. Dept of Gen. Medicine 2, Skin-3, Gen Surgery-1, Ortho-1, OBGY- 1 ADR were reported respectively. Out of these none were serious. All patients recovered on stopping the medication. The possible causality and preventability of these ADR were discussed.
- 3. He further reiterated that the weekly visits by the staff of Dept. of Pharmacology to various wards and guiding the concerned clinical personnel there, resulted in more reporting of ADR.
- 4. He also informed that they were in process in arranging and fixing for ADR form boxes at the nursing stations at various wards.
- 5. The meeting was concluded with a vote of thanks.

PROFESSOR & HOD PHARMACOLOGY DEPARTMENT MIMER MEDICAL COLLEGE TALEGAON DABHADE - 410507

Chairman / Secretary / Member 1. Chairman / Secretary / Secre

# Pharmacovigilance Committee Attendance

# Dept. of Pharmacology

Date: 28/09/2018

Dr. R. J. Wagh (Secretary)

Sign

Vyore

Char

#### Name

Dr. Dilip Bhoge (Chair person)	
Dr. More Vinayak	
Dr. P. S. Kamat	
Dr. Maya Borle	
Dr. Sandesh Gawade	
Dr. Vaishali Korde	
Dr. Aneesh Bhat	
Dr. V. B. Powar	
Dr. Mrs. Aditi Deshmukh	
Mrs. Jagdale H.	
Dr. Col. R. P. Gupta	
	Dr. P. S. Kamat Dr. Maya Borle Dr. Sandesh Gawade Dr. Vaishali Korde Dr. Aneesh Bhat Dr. V. B. Powar Dr. Mrs. Aditi Deshmukh Mrs. Jagdale H.

Prof & HOD ( Gen. Medicine ) Prof & HOD ( Pharmacology ) Medical Superintendent Prof & HOD ( Orthopedics ) (1) Prof & HOD (Paediatrics) faul in G Asso. Prof (Gen. Surgery) Professor (OBGY) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD) Matron In Charge Principal

> Dr. R P GUPTA PRINCIPAL MIMER Medical College Talegaon Dabhade, Pune - 410507.

#### Circular

Please note that a meeting of the Institutional Pharmacovigilance Committee will be held on Wednesday, 28/09/2018, at 12.00 pm in the Dept. of Pharmacology. All the members are requested to attend the same.

#### Date: 29/09/2018

Copy to:

- 1) Dr. Dilip Bhoge (Chair person)
- 2) Dr. R. J. Wagh (Secretary)
- 3) Dr. More Vinayak
- 4) Dr. P. S. Kamat
- 5) Dr. Maya Borle
- 6) Dr. Sandesh Gawade
- 7) Dr. Vaishali Korde
- 8) Dr. Aneesh Bhat
- 9) Dr. V. B. Powar
- 10) Dr. Mrs. Aditi Deshmukh
- 11) Mrs. Jagdale H.

Prof & HOD (Gen. Medicine) Prof & HOD (Pharmacology) Medical Superintendent Prof & HOD (Orthopedics) Prof & HOD (Orthopedics) Asso. Prof (Gen. Surgery) Professor (OBGY) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD)

Dr. R. J. Wagh (Secretary)

## Minutes of the IPvC meeting held on 29/06/2018.

1)The honorable Principal, Dr. Col. R. P. Gupta Sir, had presided over this meeting. Dr. Wagh welcomed all the members and briefed about the meeting's agenda.

2) It was noted that no ADR reporting in the prescribed format was done about two serious ADR events had taken place during the last month. Dr. More brief the members about a serious ADR case of a child following vaccination, was admitted in the NICU ward of our hospital for a stay of about a week. The DHO was informed about this incidence and the necessary steps to control the ADR was vigorously followed. Dr. More also informed about a case of anaphylaxis following ASV that was managed with ICU care. It was decided that these cases need to be duly followed and reported as per the ADR reporting format to a Pv Centre by the resident in Dept. of Pharmacology.

3) Dr. Madhu Bansode, also briefed about 2 cases of ADR viz. fever and chills following IV 3% NS plus Inj. Optoneuron, in Gen. Medicine ward that had occurred on 29/06/2018. The !V administration was stopped in both the cases and the ADR were controlled. These cases would also be reported in proper format to the IPv centre.

4) Dr. Col. Gupta Sir, pointed out that all the Incharge of the various clinical units at our hospital and the clinical staff working there should be informed about the urgency of reporting and consequences of not reporting of any serious ADR occurring in the hospital during the following Bed Occupancy Meeting.

5) Dr. More also suggested to maintain an ADR reporting register clinical unit wise and to make it compulsory for the Incharge of such clinical units to report the number of ADR whether serious or not, occurring in a week by every Friday.

6) Dr. Wagh further told that a brief seminar about ADR reporting will be arranged for the newly admitted post-graduate residents tentatively on Friday, 06/07/2018.

7) Dr. Wagh concluded the meeting with a vote of thanks.

PROFESSOR & HOD PHARMAPOLICIC END

## **Pharmacovigilance Committee Attendance**

## Dept. of Pharmacology

## Date: 29/06/2018


Dr. R. J. Wagh (Secretary)

#### Name

1)	Dr. Dilip Bhoge (Chair person)	d
<u>2)</u>	Dr. R. J. Wagh (Secretary)	
3)	Dr. More Vinayak	
4)	Dr. P. S. Kamat	
5)	Dr. Maya Borle	
6)	Dr. Sandesh Gawade	
7)	Dr. Vaishali Korde	
8)	Dr. Aneesh Bhat	
9)	Dr. V. B. Powar	
10)	Dr. Mrs. Aditi Deshmukh	
11)	Mrs. Jagdale H.	
12	Dr. Col. R.P. Gupta	P

Prof & HOD (Gen. Medicine)
Prof & HOD (Pharmacology)
Medical Superintendent
Prof & HOD (Orthopedics)
Prof & HOD (Paediatrics)
Asso. Prof (Gen. Surgery)
Professor (OBGY)
Asso. Prof. (Psychiatry)
incharge, Blood Bank
Senior Resident (Skin VD)
Matron In Charge
Matron In Charge





6/19/2018

MAEER's MIMER Medical College Mail - Institutional Pharmacovigilance Committee meeting



Pharmacology Department <pharmac@mitmime

### Institutional Pharmacovigilance Committee meeting 1 message

## Pharmacology Department <pharmac@mitmimer.com>

Pharmacology Department <pharmac@mitmimer.com</p>
To: Medicine Department <medicine@mitmimer.com</p>
PAEDIATRICS DEPARTMENT <paediatrics@mitmimer.com</p>
SURGERY DEPARTMENT <surgery@mitmimer.com</p> To: Medicine Department <medicine@mitmimer.com>, PAEDIALINGS DEL AN MELL Providence@mitmimer.com ORTHOPAEDICS DEPARTMENT <ortho@mitmimer.com>, SURGERY DEPARTMENT <surgery@mitmimer.com> medical Suprintendent <ms@mitmimer.com>, "Mrs.H.D. Jandela & VD DEPARTMENT <skin@mitmimer.com>, medical Suprintendent <ms@mitmimer.com>, "Mrs.H.D. Jagdale" chdjagdale@mitmimer.com>, PSYCHIATRY DEPARTMENT psychiatry@mitmimer.com>, OBST & GYNAE DEPARTMENT <gynaec@mitmimer.com>, Blood Bank MIMER <bloodbank@mitmimer.com>

#### Circular

Please note that a meeting of the Institutional Pharmacovigilance Committee will be held on Friday, 29/06/2018, at 12.00 pm in the Dept. of Pharmacology. All the members are requested to atter

Date: 19/06/2018

Copy to:

- Dr. Dilip Bhoge (Chair person) 1)
- Dr. R. J. Wagh (Secretary) 2)
- 3) Dr. More Vinayak
- 4) Dr. P. S. Kamat
- 5) Dr. Maya Borle
- Dr. Sandesh Gawade 6)
- 7) Dr. Vaishali Korde
- 8) Dr. Aneesh Bhat
- 9) Dr. V. B. Powar
- Dr. Mrs. Aditi Deshmukh 10)
- 11) Mrs. Jagdale H.

Prof & HOD ( Gen. Medicine )

Dr. R. J. Wagh (Secretary)

Prof & HOD ( Pharmacology)

Medical Superintendent

Prof & HOD (Orthopedics)

Prof & HOD (Paediatrics)

Asso. Prof (Gen. Surgery)

Professor (OBGY)

Asso. Prof. (Psychiatry)

Incharge, Blood Bank

Senior Resident (Skin VD)

Matron In Charge

283 Rein.

## Minutes of the IPvC meeting held on 28/03/18

- 1) Dr. Wagh welcomed all the members and briefed about the meeting's agenda.
- 2) As, Dr. Deepali Ambike has resigned from her post, so in her place, Dr. Vijay Bhavari, Asso. Prof., Dept. of Paeds has consented to be an IPvC member to represent vanious Paediatric ADR issues.
- 3) Similarly, Dr. Ninad Khaladkar from Dept. of Skin, VD would be the IPvC member representing the ADR issues among their patients in place of Dr. Aditi Deshmukh.
- 4) There was reporting of 2 ADR from Dept. of Pharmacology during last three months it was reported to ADR reporting centre at AFMC by e-mail.
- 5) Dr. Mrs. A. S.Chincholkar, Prof., Dept. of Pharmacology, has planned a study titled "the knowledge, attitude and practice of ADR reporting amongst (our institutional) PG students in a tertiary are hospital - a questionnaire based study". The study questionnaire was discussed and was suggested with some changes.
- 6) Dr. Mrs. Jayashree Nikose, Tutor, Dept. of Pharmacology, is regularly visiting the wards and OPDs to collect ADR forms. She has noticed that the ADR forms have not been kept at a proper visible and accessible place there. It was mooted to bring this to the notice of concerned HODs, Unit heads and matron and make due provision accordingly.
- 7) Tentative date for the next IPvC meeting would be 29/06/2018, Friday.

Dr. R. J. Wagh,

Scanned by CamScanner

# Pharmacovigilance Committee Attendance

# Dept. of Pharmacology

Date: 28/03/18

# Dr. R. J. Wagh (Secretary)

Sign

#### Name

- 1) Dr. Dilip Bhoge (Chair person)
- 2) Dr. R. J. Wagh (Secretary)
- 3) Dr. More Vinayak
- 4) Dr. P. S. Kamat
- 5) Dr. Maya Borle
- 6) Dr. Sandesh Gawade
- 7) Dr. Vaishali Korde
- 8) Dr. Aneesh Bhat
- 9) Dr. V. B. Powar
- 10) Dr. Mrs. Aditi Deshmukh
- 11) Mrs. Jagdale H.

Prof & HOD ( Gen. Medicine ) Prof & HOD ( Pharmacology ) Medical Superintendent Prof & HOD (Orthopedics) OLL Prof & HOD (Paediatrics) Asso. Prof (Gen. Surgery) Asso. Prof ( Gen. Surgery ) Professor ( OBGY ) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD)

Matron In Charge

# <u>Circular</u>

Please note that a meeting of the Institutional Pharmacovigilance Committee will be held on Wednesday, 28/03/2018, at 12.00 pm in the Dept. of Pharmacology. All the members are requested to attend the same.

Date: 26/03/2018

Dr. R. J. Wagh (Secretary)

Copy to:

1)	Dr. Dilip Bhoge (Chair person)	
2)	Dr. R. J. Wagh (Secretary)	
3)	Dr. More Vinayak	
4)	Dr. P. S. Kamat	
5)	Dr. Maya Borle	
6)	Dr. Sandesh Gawade	
7)	Dr. Vaishali Korde	
8)	Dr. Aneesh Bhat	
9)	Dr. V. B. Powar	
10)	Dr. Mrs. Aditi Deshmukh	
11)	Mrs. Jagdale H.	

Prof & HOD (Gen. Medicine) Prof & HOD (Pharmacology) Medical Superintendent Prof & HOD (Orthopedics) Prof & HOD (Paediatrics) Asso. Prof (Gen. Surgery) Professor (OBGY) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD) Matron In Charge

# Minutes of the IPVC meeting held on 29/12/17

- 1. It was proposed that the information of newly introduced drugs in the clinical practice to be distributed to the clinicians working in the college hospital.
- 2. It was also proposed to find out the incidence of ADR with i.v. Iron sucrose (compared to of patients who received it ) to be studied retrospectively.
- 3. The Blood Transfusion Officer, found that wrong blood groups were reported during the sampling process, and stressed the need of the group reporting to be checked strictly.
- 4. Display of ADR reporting forms in wards has to be regularly checked.
- 5. It was also mooted to seek information from ADR reporting centre, regarding the causality analysis and the incidence etc., of the reported ADR.

6. We should also try to establish an ADR reporting center in our College

# Pharmacovigilance Committee Attendance

# Dept. of Pharmacology

Date: 29/12/2017

## Dr. R. J. Wagh (Secretary)

Sign

#### Name

1) Dr. Dilip Bhoge (Chair person)

Dr. R. J. Wagh (Secretary)

Dr. More Vinayak 3)

2)

- 4) Dr. P. S. Kamat
- 5) Dr. Deepali Ambike
- 6) Dr. Sandesh Gawade
- 7) Dr. Vaishali Korde
- 8) Dr. Aneesh Bhat
- 9) Dr. V. B. Powar
- 10) Dr. Mrs. Aditi Deshmukh
- Mrs. Jagdale H. 11)

Prof & HOD (Gen. Medicine) Prof & HOD ( Pharmacology ) Umn De ti Medical Superintendent Prof & HOD (Orthopedics) Prof & HOD (Paediatrics) Asso. Prof (Gen. Surgery) Professor (OBGY) Asso. Prof. (Psychiatry)

Senior Resident (Skin VD)

Matron In Charge

Incharge, Blood Bank

Please note that a meeting of the Institutional Pharmacovigilance Committee will be held on Friday, 29/12/2017, at 12.00 pm in the Dept. of Pharmacology. All the members are requested to attend the same.

JMG

Date: 09/12/2017

#### Copy to:

- 1) Dr. Dilip Bhoge (Chair person)
- 2) Dr. R. J. Wagh (Secretary)
- 3) Dr. More Vinayak
- 4) Dr. P. S. Kamat
- 5) Dr. Deepali Ambike
- 6) Dr. Sandesh Gawade
- 7) Dr. Vaishali Korde
- 8) Dr. Aneesh Bhat
- 9) Dr. V. B. Powar
- 10) Dr. Mrs. Aditi Deshmukh
- 11) Mrs. Jagdale H.

Prof & HOD (Gen. Medicine) Prof & HOD (Pharmacology) Medical Superintendent Prof & HOD (Orthopedics) Prof & HOD (Orthopedics) Prof & HOD (Paediatrics) Asso. Prof (Gen. Surger) Professor (OBGY) Asso. Prof. (Psychiatry)For Incharge, Blood Bank Senior Resident (Skin VD) for Matron In Charge

Dr. R. J. Wagh (Secretary)

# -

# Institutional Pharmacovigilance Committee Meeting

An emergency meeting of IPvC was called upon on 25.09.17 in the Dept. of Pharmacology to discuss a serious ADR case (Ref no. Pv 11/03/17) of an IUD that followed after a pregnant mother received i.v. Inj Iron sucrose for treatment of anemia.

- 1. The detailed case study (attached herewith) was presented by Dr. Jaya Barla of OBGY Dept. The case was discussed by the various IPvC members present and a possible cause of such on ADR was sought. Since the case was scrupulously followed by the attending doctors, any obvious preventable primary cause of such an ADR could not be derived at. It was concluded that this could be due to the secondary effect on foetal heart following maternal hypotension due to an anaphylactic like reaction to the i.v. Iron sucrose. It is further noted that intradermal skin testing of Iron sucrose should be routinely performed while keeping all the resuscitative measures ready and possibility of such an unfortunate incidence must be mentioned in the consent form before administration i.v. iron sucrose.
- 2. Dept. of Pharmacology has organized a seminar on Indian Pharmacovigilance Programme for the newly admitted PG residents is arranged on 27.09.17. All the concerned clinical departmental Heads were urged to bring it to notice of these students to have a good attendance.
- 3. Apart from this discussion it was noted that ADR forms in the wards were not kept at visible and accessible place, so all the nursing staff of the various hospital wards were provided new ADR forms to be kept at a right place and do the needful.

Next meeting of IPVC has been scheduled for 29/12/17, Friday.

# Pharmacovigilance Committee Attendance

# Dept. of Pharmacology

Date: 25/09/2017

Dr. R. J. Wagh (Secretary)

Sign

### Name

- 1) Dr. Dilip Bhoge (Chair person)
- 2) Dr. R. J. Wagh (Secretary)
- 3) Dr. More Vinayak
- 4) Dr. P. S. Kamat
- 5) Dr. Deepali Ambike
- 6) Dr. Sandesh Gawade
- 7) Dr. Vaishali Korde
- 8) Dr. Aneesh Bhat
- 9) Dr. V. B. Powar
- 10) Dr. Mrs. Aditi Deshmukh

11) Mrs. Jagdale H.

Prof & HOD ( Gen. Medicine ) For aket shinde . Prof & HOD ( Pharmacology ) Medical Superintendent Prof & HOD (Orthopedics) Prof & HOD (Paediatrics) Asso. Prof (Gen. Surgery) Professor (OBGY) Dr Jaye Barlefup Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD) Matron In Charge

Minutes: Agenda: A serious ADR (Ref no. 11-03/17). Agenda: A serious following IV Iron Subose in of IVFD following IV Iron Subose in

Please note that a meeting of the Institutional Pharmacovigilance Committee will be held on Monday, 25/09/2017, at 12.00 pm in the Dept. of Pharmacology. All the members are requested to attend the same.

Dr. R. J. Wagh (Secretary)

# Date: 22/09/2017

Copy t	o:	
J822046935- 1)	Dr. Dilip Bhoge (Chair person) 9822046935	Prof & HOD ( Gen. Medicine )
2)	Dr. R. J. Wagh (Secretary)	Prof & HOD ( Pharmacology )
3)	Dr. More Vinayak - 3822423331	Medical Superintendent
942235841	Dr. P. S. Kamat 942235847 9890761303	Prof & HOD ( Orthopedics )
_5)	Dr. Deepali Ambike 9373002072	Prof & HOD (Paediatrics)
6)	Dr. Sandesh Gawade 38 90 95-00 97	Asso. Prof (Gen. Surgery)
7)	Dr. Vaishali Korde 937 247 8118	Professor ( OBGY )
8)	Dr. Aneesh Bhat 7558311855-	Asso. Prof. ( Psychiatry )
9)	Dr. V. B. Powar - 9604871471	Incharge, Blood Bank
10)	Dr. Mrs. Aditi Deshmukh - 94229 872	Senior Resident (Skin VD)
11)	Mrs. Jagdale H. 81494797148	Matron In Charge
5) Dr. Deen	ali Ambike	

# Minutes of the IPvC meeting held on 30/06/2017.

- It was noted that the response of the residents to Sensitization of Indian Pharmacovigilance Program, ADR Reporting seminars arranged in 19<sup>th</sup> & 21<sup>st</sup> April 2017, was bleak. However such it was well received by the nursing fraternity with active interaction. So, it was decided that another such seminar needs to be arranged for the new as well as the old residents in the month of September 2017.
- 2. It was mooted of an urgent need of spreading the awareness about the reporting of ADE, amongst the General Practitioners in and around Talegaon, by organizing a CME.
- It was also deliberated on how to encourage the reporting of ADE by the general public visiting the BSRTH.
- 4. A Drug Information Centre has been set up at the Drug Store at the OPD complex and is managed by the Dept. of Pharmacology.

Dr. R. J. Wayh (Secretary, IPVC)

Please note that a meeting of the Institutional Pharmacovigilance Committee will be held on Friday, 30/06/2017, at 02.30 pm in the Dept. of Pharmacology. All the members are requested to attend the same and brief about any ADR reporting.

Date: 27/06/2017

## Copy to:

- 1) Dr. Dilip Bhoge (Chair person)
- 2) Dr. R. J. Wagh (Secretary)
- 3) Dr. More Vinayak
- 4) Dr. P. S. Kamat
- 5) Dr. Deepali Ambike
- Dr. Sandesh Gawade
- 7) Dr. Vaishali Korde
- 8) Dr. Aneesh Bhat
- 9) Dr. V. B. Powar
- 10) Dr. Mrs. Aditi Deshmukh
- 11) Mrs. Jagdale H.

Prof & HOD (Gen. Medicine)

Dr. R. J. Wagh (Secretary)

The Institutional Pharmacovigilance Committee was held on 30/06/2017 was attended by:

Dr. Dilip Bhoge (Chair person)
Dr. R. J. Wagh (Secretary)
Dr. More Vinayak
Dr. P. S. Kamat
Dr. Deepali Ambike
Dr. Sandesh Gawade
Dr. Vaishali Korde
Dr. Aneesh Bhat
Dr. V. B. Powar
Dr. Mrs. Aditi Deshmukh
Mrs. Jagdale H.

Prof & HOD (Gen. Medicine) Prof & HOD ( Pharmacology ) **Medical Superintendent** Prof & HOD (Orthopedics) Prof & HOD (Paediatrics) Asso. Prof (Gen. Surgery) Professor (OBGY) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD) Matron In Charge

Matron In Charge

Scanned by CamScanner

# Minutes of the IPvC meeting held on 07/04/2017.

- The Committee welcomed new members Dr. P. S. Kamat, Dr. Sandesh Gawade (in place of Dr. J. B. Pardeshi), Dr. Aneesh Bhat, Dr. V. B Powar, Dr. Mrs. Aditi Deshmukh (in place of Dr. Rohini Gaikwad, who resigned) and Mrs. H. Jagdale to strengthen ADR reporting system.
- 2. It was decided to conduct seminars for the hospital clinical staff, viz. the residents and the nursing staff about the **Pharmacovigilance Program of India** and the procedure of **ADR reporting**.
- 3. The staff from the Dept. of Pharmacology viz. Dr. R. J. Wagh (Prof. HOD), Dr. A. S. Chincholkar (Prof.) and Mr. Rahul Kedare (Asst. Prof.) have attended the National Conference in Pharmacovigilance held by Dept. of Pharmacology, LTMMC, GH, Sion, Mumbai, on 17/03/2017. It was decided to avail their expertise for the training of the clinical and nursing staff at BSRTH, Talegaon, in future.

Dr. R.J. Wagh. (Dr. R. Secretary, IPVC)

PROFESSOR & HOD PHARMACOLOGY DEPARTMENT MIMER MEDICAL COLLEGE TALEGAON DASHADE - 410507

Scanned by CamScanner

Report submitted to MCI inspectors on 28:08.17

Please note that a meeting of the Institutional Pharmacovigilance Committee will be held on Friday, 07/04/2017, at 02.30 pm in the Dept. of Pharmacology. All the members are requested to attend the same and brief about any ADR reporting.

Date: 03/04/2017

Dr. R. J. Wagh (Secretary)

#### Copy to:

- 1) Dr. Dilip Bhoge (Chair person)
- 2) Dr. R. J. Wagh (Secretary)
- 3) Dr. More Vinayak
- 4) Dr. P. S. Kamat
- 5) Dr. Deepali Ambike
- 6) Dr. Sandesh Gawade
- Dr. Vaishali Korde
- 8) Dr. Aneesh Bhat
- 9) Dr. V. B. Powar
- 10) Dr. Mrs. Aditi Deshmukh
- 11) Mrs. Jagdale H.

Prof & HOD (Gen. Medicine) Prof & HOD (Pharmacology) Medical Superintendent Prof & HOD (Orthopedics) Prof & HOD (Orthopedics) Prof & HOD (Paediatrics) Asso. Prof (Gen. Surger Professor (OBGY) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD) Matron In Charge

The Institutional Pharmacovigilance Committee was held on 07/04/2017 was attended by:

- Dr. Dilip Bhoge (Chair person) 1) Dr. R. J. Wagh (Secretary) 2) Dr. More Vinayak 3) Dr. P. S. Kamat 4) Dr. Deepali Ambike 5) Dr. Sandesh Gawade 6) Dr. Vaishali Korde 7) Dr. Aneesh Bhat 8) Dr. V. B. Powar 9) Dr. Mrs. Aditi Deshmukh 10) Mrs. Jagdale H. 11)
- Prof & HOD (Gen. Medicine) Prof & HOD (Pharmacology) Medical Superintendent Prof & HOD (Orthopedics) Prof & HOD (Paediatrics) Asso. Prof (Gen. Surgery) Professor (OBGY) Asso. Prof. (Psychiatry) Incharge, Blood Bank Senior Resident (Skin VD)

MIMER Medical College, Talegaon (D)

# Link for

# Clinico Pathological Correlation Meet Mortality & Morbidity meeting Tumor Board Meeting

https://mimer.edu.in/02-pdf/naac/2.3.5-cpc-morbiditytumor-board.pdf